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Abstract 
 
 Although general anti-proliferative agents that induce death in all rapidly dividing cell 
types remain the backbone of many chemotherapeutic regimens, recent advances have suggested 
that “personalized” anticancer strategies hold considerable promise.  In personalized medicine, a 
detailed understanding of the molecular aberrations in the cell is utilized to select a drug with an 
appropriate mechanism of action.  The potential for such strategies has been powerfully 
demonstrated for cancers that have translocations, mutations, or aberrant expression levels of key 
proteins.  The apoptotic protein procaspase-3 has been shown to be upregulated in a variety of 
cancer cell types and plays a pivotal role in the execution of apoptosis.  As such, the reactivation 
of the apoptotic cascade through small molecule activators of procaspase-3 is an attractive 
anticancer strategy.  In 2006, the discovery of the first small molecule activator of procaspase-3 
(PAC-1) was reported by the Hergenrother laboratory.  The studies described herein build on that 
discovery to expand our understanding of the potential and promise of small molecule activators 
of procaspase-3 in the treatment of cancer.  Characterization of the mechanism of action of PAC-
1 in vitro and in cell culture reveals that PAC-1 activates procaspase-3 through the relief of zinc-
mediated inhibition of procaspase-3 resulting in the induction of apoptosis.  In vivo studies in 
mice and dogs further demonstrate the feasibility and tolerability of procaspase-3 activators in 
the treatment of cancer.  Canine clinical studies show that small molecules in the PAC-1 class 
are capable of inducing tumor regression in dogs with lymphoma.  These results highlight the 
importance that zinc plays in the regulation of caspase activity and the induction of apoptosis.  
Studies that characterize the interaction between procaspase-3 and zinc are presented.
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Chapter 1: Caspase Activity in Apoptosis 
 
Some of the text of this chapter was taken with permission from: 
 Peterson, Q.P., Goode D.R., West, D.C., Lee, J.J.,  Ramsey, K.N., Hergenrother, P.J. 
PAC-1 activates procaspase-3 in vitro through relief of zinc-mediated inhibition. J. Mol. 
Biol.  2009, 388 (1), 144-158. 
Peterson, Q.P., Hsu, D.C., Goode, D.R., Novotny, C.J., Totten, R.K., Hergenrother, P.J. 
Procaspase-3 Activation as an Anti-Cancer Strategy:  Structure-activity relationship of 
PAC-1, and its cellular co-localization with caspase-3. J. Med. Chem.  2009, 52 (18), 
5721-5731. 
Peterson, Q. P., Hsu, D.C., Novotny, C.J., West, D.C., Kim D., Schmit, J.M., Dirikolu, 
L., Hergenrother, P.J., Fan, T.M.  Discovery and canine preclinical assessment of a non-
toxic procaspase-3-activating compound.  Cancer Res.  2010, 70 (18), 7232-7241. 
1.1 Apoptosis 
One of the hallmarks of cancer is its resistance to apoptosis,1 a programmed form 
of cell death important in both the development and maintenance of higher organisms.  
This resistance enables cancerous cells to survive and divide even in the presence of 
endogenous pro-apoptotic stimuli.  Morphologically, apoptosis is characterized by 
nuclear pyknosis, chromatin condensation, membrane blebbing, cytoskeletal collapse, 
and formation of apoptotic bodies2 that facilitate the engulfment and recycling of cellular 
components without provoking the inflammatory response.3  Mechanistically, 
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programmed cell death is a coordinated and linear process that requires the controlled and 
serial activation of key proteases characterized as cysteine aspartases, called caspases.  
Apoptotic caspases can be segregated based upon their protein structure into either 
initiator caspases (caspase-2, -8, -9, -10, -12) or executioner caspases (caspase-3, -6, -7).2  
The caspases are produced as low activity zymogens (proenzymes),4,5 with proteolytic 
activities that are tightly regulated, and only induced following key cellular signals 
mediated by extrinsic and intrinsic events.6  
Biochemical events leading to apoptosis occur through two major pathways.7 The 
extrinsic apoptotic pathway begins with a signal to death receptors on the extracellular 
surface, leading to the activation of procaspase-8 to caspase-8.  In the intrinsic apoptotic 
pathway cytochrome c is released from the mitochondria,8 leading to the formation of the 
apoptosome and the activation of procaspase-9 to caspase-9.9  For example, procaspase-9 
is converted to caspase-9 through formation of a multimeric protein complex called the 
apoptosome,9 while procaspase-8 is converted to caspase-8 through a proximity 
model.10,11  Active caspase-9 and caspase-8 can in turn directly proteolyze procaspase-3 
and procaspase-7, forming active caspase-3 and caspase-7.12,13  Caspase-3 is the key 
“executioner” caspase in the apoptotic cascade, and once activated this enzyme cleaves 
scores of cellular substrates, committing the cell to apoptotic death.14,15  Putatively, the 
activation of procaspase-3 to caspase-3 is a pivotal and committed step for programmed 
cell death, given the multitude of substrates that are cleaved by caspase-3, as well as its 
downstream position in the apoptotic cascade.2 Based on mouse knockout studies and 
other work, procaspase-7/caspase-7 may have a less important function relative to 
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procaspase-3/caspase-3 in the “demolition phase” of apoptosis, although caspase-7 likely 
has some distinct cellular substrates.16,17 
Appropriate programmed cell death is necessary for maintaining cellular 
homeostasis (e.g. lymphocyte apoptosis), and also regulates anatomic development of 
various organs and soft tissues.18,19  The preservation of normal apoptotic signals is 
necessary for maintaining genomic integrity of host organisms, which thwarts the 
successful replication of somatic cells harboring mutated or damaged DNA, so as to 
prevent malignant transformation.20-22   
Given its central role in cellular life and death, it is of no surprise that alterations 
to basal levels of apoptosis lead to an assortment of disease states.  For example, it is now 
well recognized that a hallmark of cancer is a resistance to apoptosis,1 and cancerous 
cells are known to evade apoptosis through a variety of mechanisms involving mutation 
or altered expression levels of key proteins in the apoptotic cascade,23,24 including 
mutation of p53,25 elevated expression of the anti-apoptotic proteins in the Bcl-2 family,26 
and inactivation of Apaf-1.27  The net result of these alterations is a resistance to 
apoptosis, allowing for unchecked cellular proliferation. 
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Figure 1.1.  Schematic of canonical pathways in apoptosis.  In the intrinsic pathway the cell responds to 
internal signals such as oxidative stress or DNA damage.  These signals activate a cascade of upstream 
messengers that results in the dimerization of Bax proteins on the mitochondrial wall.  This results in pore 
formation and mitochondrial depolarization.  Once depolarized, cytochrome c is released from the cell and 
participates in a complex with Apaf1 and procaspase-9.  The formation of this complex called the 
apoptosome results in the activation of procaspase-9 to caspase-9.  Caspase-9 is then able to activate 
procaspase-3 to caspase-3.  Once activated, caspase-3 cleaves a host of cellular substrates to carry out the 
apoptotic program.  In the extrinsic pathway, the cell responds to extracellular death signals such as the 
binding of TRAIL or Fas binding to death receptors.  Once bound, these receptors trigger the formation of a 
death complex that involves the binding and activation of procaspase-8.  Caspase-8 is then released from 
this complex and activates procaspase-3 to caspase-3. 
 
1.2 Regulators of Apoptosis 
 A number of mechanisms are present in the cell to regulate the initiation and 
execution of apoptosis.  For example, spurious low-level activation of caspase-3 is 
mediated by the ubiquitination and degradation of active caspase-3.28  When appropriate 
apoptotic signals are received, caspase activation supersedes this degradation mechanism 
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resulting in apoptosis.28  In addition to this mechanism, a number of proteins regulate the 
activity and automaturation of procaspase-3, including IAPs, BH3 proteins, and zinc.   
1.2.1 IAPs 
 Inhibitor of Apoptosis Proteins (or IAP) are a class of highly conserved proteins 
that act to inhibit the caspase family of proteins.29  These proteins function by binding to 
the active site of active caspases to inhibit their catalytic activity.  Each member of the 
IAP family contains a number of Bir domains that are sequences of high homology that 
participate in binding to target caspases.  Among the IAP family members implicated in 
cancer are CIAP, XIAP and survivin.30-32  Each of these proteins is capable of inhibiting a 
different set of caspase proteins based on the Bir domains present. 
1.2.2 Zinc 
 Zinc is known to exert an antiapoptotic role in cells, treatment of cells with 
exogenous zinc inhibits the induction of apoptosis and promotes cell survival and 
proliferation.33  Additionally chelation of cellular zinc results in increased levels of 
apoptosis.34  Although zinc is known to exert this antiapoptotic role, the mechanism by 
which zinc exerts this effect is unknown.  Zinc is known to inhibit a number of apoptotic 
caspases including caspase-3, -7, -9.35  Further, procaspase-3 has been shown to be co-
localized with zinc in the cell.36  Taken together, these results suggest a key role for zinc 
in the regulation of apoptosis.   
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1.3 Mechanism of Caspase-3 Activity 
Members of the caspase family of cysteine proteases are critical to the apoptotic 
pathway.  These enzymes exist in the cell as low activity zymogens (proenzymes) that are 
proteolytically activated to the mature, highly active enzyme.37,38  Most critical to 
apoptosis is the proteolytic conversion of procaspase-3 to caspase-3.  
Full length procaspase-3 is comprised of a ~4 kDa (28 amino acid) prodomain, a 
17 kDa large subunit, and a 12 kDa small subunit (Figure 1.2).  While caspase-8 and 
caspase-9 activate procaspase-3 in vivo by proteolysis between the p17 and p12 
fragments (at D175), procaspase-3 is also proteolyzed by active caspases between the pro 
and p17 (at D28), and inside the prodomain (at D9); see Figure 1.2.12,39  In vitro, it is 
known that caspase-3 will cleave procaspase-3 at D9, D28 and D175.4,40  Interestingly, 
the procaspase-3 zymogen is itself also catalytically active.40,41  Procaspase-3 will in vitro 
slowly cleave itself to the active caspase-3, and procaspase-3 (either wild-type or the 
caspase-resistant D9A/D28A/D175A triple mutant) will also process synthetic 
chromogenic/fluorogenic peptidic substrates.40  As inferred by studies on the triple 
mutant, the kcat/KM of procaspase-3 is approximately 200-fold lower than that of caspase-
3 on peptidic substrates, with the major effect being a reduction in kcat.40   
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Figure 1.2.  The maturation of procaspase-3 to caspase-3 in vitro and in vivo. 
 
The automaturation of procaspase-3 proceeds in a different manner than the 
activation of procaspase-3 by caspase-8 or -9.  In the standard apoptotic model, 
procaspase-3 is thought to be cleaved at the D175 site (IETD) by caspase-8/-9, forming 
the fully active caspase-3 with the prodomain still intact.  A rapid cleavage at the D9 site 
(NSVD) then occurs, followed by a slow proteolysis at the D28 site (ESMD).12  This is in 
line with studies with synthetic peptides that indicate IETD is the optimal sequence for 
procaspase-8 processing.42   
 In contrast, in the autoactivation event procaspase-3 appears to first process itself 
at D9, followed by D28, then followed by D1754,40.  Although the substrate specificity 
for procaspase-3 proteolysis has never been determined, the substrate specificity of 
caspase-3 is well known.43  Caspase-3 has a strong preference for aspartic acid at the P4 
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and P1 positions;42,44 thus, as none of the three sites within procaspase-3 have an aspartic 
acid at the P4 position, it is important to recognize that none of these sites are optimal 
sites for caspase-3/procaspase-3 proteolysis.  As caspase-3 has a preference for valine at 
the P2 position, the D9 (NSVD) site might be slightly preferred over the other two; 
however, any amino acid discrimination at the P2 and P3 sites is weak and not nearly as 
dramatic as the importance for Asp at P1 and P4. 
 Thus in vitro procaspase-3 is both an enzyme and a substrate; the cellular 
relevance of the procaspase-3 enzymatic activity is unknown.  In the cell it is known that 
procaspase-3 is the endogenous substrate for caspase-8 and caspase-9, and elegant 
methods to obtain kinetic parameters for the processing of procaspase-3 by caspase-9 
have been recently developed.13  These methods involve the observation of caspase-3 
activity after treatment of procaspase-3 with caspase-9,13 and thus serve as a guide for the 
evaluation of artificial activators of procaspase-3.         
1.4 Caspase-3 Activators 
There are several options available for knocking down protein activity/levels in a 
cell: genetic knockouts, RNAi, and small molecule inhibitors function at the DNA, RNA, 
and protein levels, respectively.  In contrast, the “turning on” of protein function is more 
problematic.  PAC-1 was identified during a screen for compounds that would enhance 
the activity of procaspase-3.45  The small molecule-mediated activation of a proenzyme 
protease is without precedent, so we have sought to further characterize this interesting in 
vitro effect. 
A number of endogenous activators of procaspase-3 are present in the cell.  In 
normal functioning of the apoptosis program, procaspase-3 is activated by either caspase-
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8 or caspase-9.  Additionally, autoprocessing by another molecule of caspase-3 is able to 
rapidly participate in a feed-forward cycle of activation.  Other caspases are capable of 
activating procaspase-3 as well.  Although the substrate specificity is not optimized for 
procaspase-3, caspase-7 and -6 have been shown to activate procaspase-3 in vitro. 
In addition to the caspases, granzyme B, a serine protease expressed in cytotoxic 
T lymphocytes and natural killer cells, is known to activate procaspase-3.  Granzyme B is 
a broad-spectrum protease that cleaves a number of pro and anti-apoptotic proteins.  In 
addition to cleavage of caspases (resulting in activation) granzyme B cleaves Bid and 
other key proteins in the apoptotic pathway.  The result is the activation of apoptosis in 
target cells. 
In the hopes of reactivating damaged apoptotic cascades and inducing cell death, 
several proteins in the apoptotic pathway have been targeted by small molecules.46-48  
Indeed, small molecules that disrupt the p53—MDM-2 interaction,49,50 bind to Bcl-2,51 
promote apoptosome formation,52 or inhibit XIAP53,54 have shown potential in cell 
culture and/or pre-clinical models of cancer. It has therefore been suggested that small 
molecule-mediated reactivation of apoptosis could be an effective anticancer strategy.46-48   
1.4.1 PAC-1 
Given the burgeoning interest in activation of apoptosis and the many damaging 
mutations in cancer, we embarked on an effort to bypass the damaged apoptotic cascade 
in cancer cells and directly activate procaspase-3 to caspase-3 with a small molecule.  A 
procaspase-3 activator would be predicted to induce cell death, and, due to the elevation 
of procaspase-3 in certain tumor types,41,55-59 a procaspase-3 activating compound could 
have selectivity for killing cancer cells versus normal cells.   
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In 2006, we reported the discovery of a small molecule, called PAC-1, which 
enhances procaspase-3 activity in vitro, induces death in cancer cells in culture, and has 
efficacy in multiple mouse xenograft models when administered orally as a lipid-based 
formulation or implanted subcutaneously as a cholesterol pellet.45  PAC-1 appears to 
induce death in cancer cells via the direct activation of procaspase-3, as evidenced by 
both the order and timing of apoptotic events, and the correlation of PAC-1 potency with 
procaspase-3 levels in cancer cells isolated from primary colon tumors.45  
1.4.1.1 Screen and discovery 
 PAC-1 was discovered through a high-throughput screen designed to identify 
compounds capable of activating procaspase-3.  Recombinantly expressed procaspse-3 
was arrayed into 384-well plates and incubated with compounds from a 22,000 
compound library.  The activity of the protein was then monitored using a chromogenic 
synthetic substrate, Ac-DEVD-pNA.  Compounds that exhibited an increase in activity 
resulted in enhanced processing of the substrate and a larger signal.  From this screen a 
small molecule was identified that enhanced the activity of procaspase-3.  This small 
molecule was named Procaspase Activating Compound-1 or PAC-1. 
1.4.1.2 Initial characterization data 
 Initial studies showed that PAC-1 activates procaspase-3 in vitro in a dose-
dependent manner.  Additionally, studies in cell culture showed that PAC-1 activates 
procaspase-3 before mitochondrial membrane depolarization suggesting that PAC-1 is 
acting downstream in the apoptotic pathway.  To further demonstrate the selectivity of 
PAC-1 for procaspase-3, a number of cell lines and primary tumor isolates were 
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evaluated for their sensitivity of PAC-1 cytotoxicity.  It was observed that cells that 
contained elevated levels of procaspase-3 were more susceptible to cell death in response 
to PAC-1 treatment.  
As described in detail in this body of work, PAC-1 activates procaspase-3 in vitro 
through the chelation of inhibitory zinc ions,60 and derivative synthesis and evaluation 
reveal that the biological activity of PAC-1 is tied to having an intact ortho-hydroxy N-
acyl hydrazone zinc-chelating motif.61  Evidence suggests that PAC-1 induces apoptotic 
death in cancer cells through the chelation of zinc from procaspase-3, most notably the 
colocalization of a fluorescent PAC-1 derivative with sites of cellular caspase-3 
activity.61 
1.4.2  The small molecule 1541 
 In 2010, the Wells laboratory reported the discovery of another small molecule 
activator of procaspase-3 called 1541.62  This small molecule was shown to make 
procapase-3 more susceptible to proteolytic processing by endogenous proteases.  This 
represents a second class of procaspase activating compound with a secondary 
mechanism of action. 
1.4.3 Limitations of known activators 
 To date, two classes of procaspase activating compounds have been reported in 
the literature.  The PAC-1 class of molecules activates procaspase-3 through the relief of 
zinc mediated inhibition.  Through this mechanism there is no direct change to the 
activity of procaspase-3 but rather a release of the brakes on the natural pathway.  This 
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mechanism relies on endogenous proteases to process procaspase-3 to caspase-3 either by 
upstream caspases or by automaturation. 
 The 1541 class of molecule is proposed to bind to procaspase-3 and induce a 
conformational change that is more susceptible to proteolysis.  As a result procapase-3 is 
more readily processed to active caspase-3.  Although this approach is promising as it 
physically modifies the procaspase-3 properties, other endogenous inhibitors such as zinc 
are likely to limit the efficacy of this molecule.   
 A third class of procaspase activating compound has been envisioned in which a 
small molecule would enhance the activity of the proenzyme (see Figure 1.3).  Through 
this strategy it would be expected that the compound would be able to actively drive 
activation of procaspase-3 to caspase-3 through automaturation and without the reliance 
on other members of the pathway. 
 
Figure 1.3.  Three proposed mechanisms of procaspase-3 activators.   
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1.5 Caspase-3 Activity and Cancer 
The evasion of normal death signals is one of the major changes leading to tumor 
formation.1  Frequently described defects in the apoptotic machinery of cancer cells 
include mutations in tumor suppressor genes, p53 and PTEN, and overexpression of 
antiapoptotic proteins such as bcl-2.63,64  
Given the key role of active caspase-3 for apoptosis, it is not surprising that many 
solid tumors and hematopoietic cancers in people preferentially inhibit the autocatalytic 
conversion of procaspase-3 to caspase-3, and thereby shift the balance towards resistance 
of programmed cell death.56-58,65,66   Interestingly, procaspase-3 is overexpressed in a 
variety of tumor histologies including breast cancer,56 colon cancer,41 lung cancer,57 
lymphoma,65 neuroblastoma,66 melanoma58 and liver cancer,67 suggesting that a small 
molecule that activates procaspase-3 could have selectivity for cancer cells versus normal 
cells. 
1.6 Summary 
 The ability of cancer cells to evade apopotosis is central to their resistance to 
conventional cytotoxins and their sustained proliferation.  Given the central role of 
procaspase-3 activation in the apoptotic pathway, activation of procaspase-3 with a small 
molecule activator is a promising strategy.  A number of mutations and aberrant 
expression levels of proteins upstream in the apoptotic pathway present challenges for 
conventional cytotoxins.  The damaged pathway created by these mutations prevents 
proper signaling and throw up roadblocks to proapoptotic stimuli.  As such small 
molecules that reactivate this pathway may be promising anticancer agents.   
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 Although substantial work has been done to develop and study caspase 
inhibitors, small molecule activators of procaspase-3 specifically (and proteases 
generally) present unique challenges.  A number of exogenous activators of procaspase-3 
are present in the cell that give insight into possible mechanisms of activation.  As shown 
in Figure 1.3, we envision three possible mechanisms for activation:  1) relief of 
endogenous inhibition, 2) generation of procaspase-3 more susceptible to maturation 
(better substrate) and 3) generation of procaspase-3 that possesses enhanced activity 
(better enzyme). 
 Herein, we report the development of a class of small molecules based on PAC-
1 and the discovery of the mechanism of action of this class as zinc chelators capable of 
relieving zinc mediated inhibition of procaspase-3.  In chapter 2, we discuss studies that 
support this mechanism of action and the role that PAC-1 plays in the cellular 
environment.  In chapter 3 we report studies performed in animal models and clinical 
studies that support the promise of this class of molecule and the strategy of procaspase 
activation as an anticancer strategy.  
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Chapter 2:  Procaspase Activating Compounds 
Portions of this chapter were taken with permission from: 
Peterson, Q.P., Goode D.R., West, D.C., Lee, J.J.,  Ramsey, K.N., Hergenrother, P.J. 
PAC-1 activates procaspase-3 in vitro through relief of zinc-mediated inhibition. J. Mol. 
Biol.  2009, 388 (1), 144-158. 
Peterson, Q.P., Hsu, D.C., Goode, D.R., Novotny, C.J., Totten, R.K., Hergenrother, P.J. 
Procaspase-3 Activation as an Anti-Cancer Strategy:  Structure-activity relationship of 
PAC-1, and its cellular co-localization with caspase-3. J. Med. Chem.  2009, 52 (18), 
5721-5731. 
Lucas, P.W., Schmit, J.M., Peterson, Q.P., West, D.C., Hsu, D.C., Novotny, C.J., 
Dirikolu, L., Churchwell, M.I., Doerge, D.R., Garrett, L.D., Hergenrother, P.J., Fan, T.M.  
Pharmacokinetics and derivation of an anticancer dosing regimen for PAC-1, a 
preferential small molecule activator of procaspase-3, in healthy dogs.  Invest. New 
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2.1 Introduction 
As described in Chapter 1, in 2006 the Hergenrother laboratory reported the 
identification of a small molecule, called PAC-1 (compound 1 in Figure 2.1), which 
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enhances the activity of procaspase-3 in vitro and induces apoptotic death in cancer cell 
lines and cells from primary tumor isolates.45  PAC-1 also showed efficacy in mouse 
models of lung and renal cancer and thus has promise as an anticancer agent.45  PAC-1 is 
the first small molecule discovered that induces the in vitro autoactivation of a 
proenzyme protease, and as such could serve as a prototype for other protease activating 
compounds.   
 Preliminary studies with PAC-1 indicate that procaspase-3 activation, as well as 
proenzyme activation in general, could be an important anticancer strategy.  However, 
the precise mechanism by which PAC-1 activates procaspase-3 is unknown.  The further 
development of compounds that induce procaspase activation will be greatly aided by a 
detailed mechanistic understanding of the PAC-1-induced activation of procaspase-3, and 
the utility of PAC-1 as a probe in apoptotic research will be significantly enhanced by 
such information.  Described in this chapter are experiments demonstrating that PAC-1 
activates procaspase-3 in vitro via sequestration of inhibitory zinc ions.  Evidence is also 
presented suggesting that zinc binding is critical to the ability of PAC-1 to induce death 
in cancer cells in culture.  The structure-activity relationship of the PAC-1 class is 
elucidated and the effect of PAC-1 and derivatives on cellular processes are evaluated.  
These experiments represent the first detailed look at the mechanism of the PAC-1-
mediated activation of procaspase-3 and have implications for both the discovery of other 
compounds that activate procaspases and for the role of zinc in regulating latent cellular 
procaspase activity. 
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Figure 2.1.  (a) Chemical structures of PAC-1 and PAC-1a.  (b) Procaspase-3 can be proteolyzed by 
caspases or granzymes at D9, D28, or D175.  (c) Progress curves reporting on the procaspase-3 processing 
of the Ac-DEVD-pNA substrate as a function of time.  In Tris buffer, procaspase-3 has very little activity 
on the Ac-DEVD-pNA substrate (open blue diamonds); this activity is dramatically enhanced in the 
presence of 50 µM PAC-1 (closed blue diamonds).  The effect of PAC-1 on procaspase-3 activity is much 
less pronounced in a Hepes buffer (green circles).  (d) Progress curves reporting on the procaspase-3 
processing of the Ac-DEVD-pNA substrate as a function of time.  Treatment of the Tris buffer with a 
Chelex® resin eliminates the activating effect of PAC-1.  In a Chelex®-treated Tris buffer, the sample 
containing PAC-1 (closed red squares) has no greater activity over the vehicle-treated controls (open red 
squares).  Shown for comparison is the data for procaspase-3 in Tris buffer that has not been Chelex® 
treated (blue diamonds), the same data as in Figure 1(c). Taken with permission from J. Mol. Biol.  2009, 
388 (1), 144-158. 
 
2.2 In Vitro Mechanism of Action 
 In an effort to further understand the mechanism by which PAC-1 induces 
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in this section is the first in vitro demonstration that the catalytic activity of procaspase-3 
is inhibited by zinc.  We show that zinc will inhibit the procaspase-3-catalyzed 
processing of peptidic substrates, and the autoactivation of procaspase-3, where the 
enzymatic and the substrate properties of procaspase-3 were bifurcated.  As wild-type 
procaspase-3 can be contaminated with active caspase-3, the D9A/D28A/D175A triple 
mutant of procaspase-3 was created and evaluated; this mutant is known to be fully 
resistant to caspase cleavage.40  Importantly, experiments with this triple mutant of 
procaspase-3 show that zinc is also an inhibitor of this enzyme, and in the presence of 
zinc PAC-1 is able to enhance the activity of this mutant against both peptidic and 
protein substrates.  The mechanism of PAC-1-mediated activation of procaspase-3 in 
vitro that thus emerges from this work is shown in Figure 2.2: PAC-1 binds to zinc, 
allowing procaspase-3 to be enzymatically active and to subsequently activate another 
molecule of procaspase-3 to form caspase-3. 
 
Figure 2.2.  The proposed mechanism for the PAC-1-induced activation of procaspase-3 in vitro.  
Consistent with data showing that zinc inhibits the catalytic activity of procaspase-3, PAC-1 binds tightly 
to zinc, and PAC-1 relieves the zinc-mediated inhibition of procaspase-3, it is proposed that PAC-1 binds 
to inhibitory zinc.  This zinc sequestration enables procaspase-3 to function as an enzyme and 
proteolytically cleave another molecule of procaspase-3, converting it to caspase-3.  Taken with permission 
from J. Mol. Biol.  2009, 388 (1), 144-158. 
Zn2+
Zn2+
Zn2+PAC-1 PAC-1:
XProcaspase-3 Procaspase-3
Caspase-3 Procaspase-3
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A starting point for our mechanistic studies was the observation that the in vitro 
activation of procaspase-3 by PAC-1 varied considerably depending on the buffer 
composition.  Caspases are typically assessed in complex buffers containing multiple 
components, including EDTA and DTT.  In such buffers the in vitro activating effect of 
PAC-1 on procaspase-3 is low on an absolute scale, 3-4 fold over background 
procaspase-3 levels.45  However, when procaspase-3 activation is assessed in simplified 
buffers (50 mM Tris, 300 mM NaCl, pH = 7.2) large activation of procaspase-3 by PAC-
1 is observed as demonstrated by the enzyme’s ability to cleave the Ac-DEVD-pNA 
substrate.  The progress curves for these experiments are displayed in Figure 2.1(c); in 
the Tris/NaCl buffer, procaspase-3 has very little activity, and the activity is greatly 
enhanced by the addition of PAC-1.  Considerably less PAC-1—mediated activation is 
observed in a Hepes buffer, mostly because procaspase-3 is already quite active in this 
buffer (Figure 2.1(c)).  PAC-1a (Figure 2.1(a)) is a derivative of PAC-1 that had 
previously been shown to have no effect on procaspase-3 activation in vitro, and no 
death-inducing effect on cultured cancer cells.45  In accord with this previous data, PAC-
1a had no activating effect in any of the buffer conditions in Figure 2.1(c).  It had been 
previously shown that caspase-3, and certain other caspases, are inhibited by the divalent 
metal ion zinc.33,35,68-70  Given the known ability of ortho-hydroxy N-acyl hydrazones 
(such as contained within PAC-1) to chelate metals,71 we began to suspect that an 
interaction of PAC-1 with a divalent metal in the assay buffer could be part of its 
mechanism of action.  We thus set out to test the hypothesis that PAC-1 activates 
procaspase-3 via sequestration of inhibitory metals. 
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2.2.1 Activation of procaspase-3 through zinc chelation 
Metal removal abolishes the activating effect of PAC-1.  Aqueous buffers can be treated 
with commercial resins that will bind to and remove divalent metal ions.  One such resin 
is Chelex®, polystyrene beads that display imidoacetate functional groups.  Chelex® will 
bind tightly to divalent transition metals, and poorly to smaller cations; treatment of a 
buffer at 5 grams Chelex® per 100 mL for 1 hour quantitatively removes transition 
metals.  The ability of PAC-1 to activate procaspase-3 was thus assessed by collegue Dr. 
David Goode before and after treatment of the Tris/NaCl buffer with the Chelex® resin.  
As shown by the progress curves in Figure 2.1(d), in the Chelex®-treated buffer 
procaspase-3 has considerable activity, and the addition of PAC-1 has no activating 
effect, and is in fact slightly inhibitory.  PAC-1a also had no activating effect in any of 
the buffer conditions in Figure 2.1(d).  
 Caspase-3 and procaspase-3 are inhibited by divalent metals.  To further probe 
the metal-dependence of PAC-1 activity, we examined the effect of various metal ions on 
caspase-3 activity.  As shown by the graph in Figure 2.3, Zn2+ and Co2+ are both potent 
inhibitors of caspase-3 activity.  Sub-stoichiometric levels of Cu2+ appear to inhibit 
caspase-3, perhaps not surprising given the known redox chemistry of this metal and the 
importance of the active site sulfhydryl in caspase-3.  Other metal ions (manganese, iron, 
magnesium) had a lesser effect on caspase-3 inhibition.  The data for caspase-3 and Zn2+ 
is consistent with data in the literature,35,68 while the effect of other metal ions on 
caspase-3 activity has not been previously reported, to our knowledge.  Thus the variable 
activity of PAC-1 in different buffers (Figures 2.1(c), 2.1(d)) can be explained by the 
presence of metal ions in those buffers.  For example, our ICP-MS analysis of the Trizma 
base (minimum 99% titration purity, from Sigma, analyzed as a solid) showed that a 50 
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mM Tris buffer made from this solid contain 100 nM zinc, 0.3 nM copper, 780 nM iron, 
and 250 nM cobalt.  
 
Figure 2.3. The effect of various metal ions on the catalytic activity of caspase-3.  CuSO4, ZnSO4, CoCl2, 
FeCl2, MnCl2, FeCl3, MgCl2 were added to caspase-3 (500 nM) over the given concentration range.  The 
activity of caspase-3 was then assessed by monitoring the cleavage of the Ac-DEVD-pNA substrate.  
Taken with permission from J. Mol. Biol.  2009, 388 (1), 144-158. 
 Although 90% of cellular zinc is believed to be sequestered in tightly-bound 
complexes within proteins (metalloenzymes, zinc fingers, etc), it is believed that 
approximately 10% of zinc exists in labile, loosely-bound pools.36  Given that zinc 
appears to be the most physiologically relevant metal of those inhibitors identified in 
Figure 2.3, we choose to focus on zinc.  The effect of a range of concentrations of zinc on 
caspase-3 and procaspase-3 enzymatic activity was examined.  All buffers were first 
treated with Chelex® resin to remove any trace metal contaminants.  As procaspase-3 will 
slowly autoproteolyze itself to active caspase-3, we also created the triple mutant of 
procaspase-3 in which all three caspase cleavage sites have been removed 
(D9A/D28A/D175A).  Consistent with data in the literature,40 this procaspase-3 triple 
mutant is proteolytically stable and has activity ~200-fold less than caspase-3 (data not 
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shown).  Enzyme assays in the presence of zinc indicate that this metal powerfully 
inhibits caspase-3 (Figure 2.4(a)), procaspase-3 (Figure 2.4(b)), and the procaspase-
3(D9A/D28A/D175A) mutant (Figure 2.4(c)).  Because procaspase-3 is considerably less 
active than caspase-3, a higher concentration of the procaspase-3(D9A/D28A/D175A) 
mutant was used in these experiments.  To the best of our knowledge this is the first 
demonstration that zinc inhibits procaspase-3 activity in vitro. 
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Figure 2.4 (a) As assessed by the cleavage of the Ac-DEVD-pNA substrate, the ability of zinc to inhibit 
caspase-3 (C3, 500 nM) activity in vitro is reduced in the presence of PAC-1 (50 µM).  (b) As assessed by 
the cleavage of the Ac-DEVD-pNA substrate, the ability of zinc to inhibit procaspase-3 (PC-3, 500 nM) 
activity in vitro is reduced in the presence of PAC-1 (50 µM).  (c) As assessed by the cleavage of the Ac-
DEVD-pNA substrate, the ability of zinc to inhibit the procaspase-3(D9A/D28A/D175A) mutant (D3A, 10 
µM) activity in vitro is reduced in the presence of PAC-1 (50 µM).  Taken with permission from J. Mol. 
Biol.  2009, 388 (1), 144-158. 
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 PAC-1 addition reactivates zinc-inhibited caspase-3 and procaspase-3.  
Experiments were also conducted to assess the ability of PAC-1 to relieve the zinc-
mediated inhibition of caspase-3 and procaspase-3 activity.  A concentration of 50 µM 
PAC-1 was used for these experiments.  The results from these experiments are displayed 
in Figures 2.4(a), 2.4(b), and 2.4(c) for caspase-3, procaspase-3, and the procaspase-
3(D9A/D28A/D175A) mutant, respectively.  PAC-1 relieves the zinc-mediated inhibition 
of caspase-3, procaspase-3 and the procaspase-3(D9A/D28A/D175A) mutant, as 
indicated by the shift in the ZnSO4 inhibition curves in the presence of PAC-1 (Fig. 
2.4(a), 2.4(b), 2.4(c)). 
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Figure 2.5 (a) PAC-1 enhances caspase-3 (C3) activity when assayed in a buffer containing 5 µM ZnSO4.  
(b) PAC-1 enhances procaspase-3 (PC-3) activity when assayed in a buffer containing 5 µM ZnSO4.  (c) 
PAC-1 enhances the procaspase-3(D9A/D28A/D175A) (D3A) mutant activity when assayed in a buffer 
containing 5 µM ZnSO4.  As shown in panels (a), (b) and (c), PAC-1 actually inhibits these three enzymes 
at high compound concentrations.  Taken with permission from J. Mol. Biol.  2009, 388 (1), 144-158. 
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 PAC-1 activates procaspase-3 and caspase-3 in a dose-dependant manner.  Next, 
the ability of PAC-1 to activate procaspase-3 and caspase-3 in a dose-dependant manner 
was assessed by Dr. David Goode in the presence and absence of zinc.  For these 
experiments, concentrations of PAC-1 from 0.025 µM to 100 µM were evaluated, and all 
buffers were treated with Chelex® resin prior to addition of PAC-1 or zinc.   The results 
of these experiments are displayed in Figure 2.5(a), 2.5(b), and 2.5(c) for caspase-3, 
procaspase-3, and the procaspase-3(D9A/D28A/D175A) mutant, respectively.  As 
expected, in the presence of zinc and very low concentrations of PAC-1, the procaspase-
3/caspase-3 enzymes are powerfully inhibited.  However, as PAC-1 concentration is 
increased, the activity of the enzymes in the buffer containing zinc is increased to 40-
60% of the maximal rate (that is, the rate of the enzyme in the absence of zinc).  
Interestingly, very high concentrations of PAC-1 actually inhibit the enzymes.  
Analogous experiments to those presented in Figure 2.5(a), 2.5(b) and 2.5(c) show that 
PAC-1a had no activating effect on caspase-3, procaspase-3, and the procaspase-
3(D9A/D28A/D175A) triple mutant (Figure 2.6, 2.7, and 2.8). 
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Figure 2.6.  PAC-1a does not enhance caspase-3 (C3) activity when assayed in a buffer containing 5 µM 
ZnSO4.    PAC-1a actually inhibits this enzyme at high compound concentrations even in the absence of 
ZnSO4.  Taken with permission from J. Mol. Biol.  2009, 388 (1), 144-158. 
 
 
Figure 2.7.  PAC-1a does not enhance procaspase-3 (PC-3) activity when assayed in a buffer containing 5 
µM ZnSO4.  PAC-1a actually inhibits this enzyme at high compound concentrations even in the absence of 
ZnSO4.  Taken with permission from J. Mol. Biol.  2009, 388 (1), 144-158. 
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Figure 2.8.  PAC-1a does not enhance procaspase-3(D9A/D28A/D175A) (D3A) mutant activity when 
assayed in a buffer containing 5 µM ZnSO4.  PAC-1a actually inhibits this enzyme at high compound 
concentrations even in the absence of ZnSO4.  Taken with permission from J. Mol. Biol.  2009, 388 (1), 
144-158. 
 
2.2.2 Maturation as observed by SDS-PAGE analysis 
 Having established the ability of PAC-1 to relieve the inhibitory effect of zinc on 
procaspase-3 activity, we sought to further evaluate the effect of PAC-1 on the 
procaspase-3 maturation process.  As mentioned in Chapter 1, caspase-3 will cleave 
procaspase-3 in vitro, a process that is easily observed by SDS-PAGE.4,40  In addition, the 
automaturation of procaspase-3 has also been observed in vitro by SDS-PAGE.41  Based 
on our above results in the activity assay, we predicted that zinc would inhibit the 
procaspase-3 cleavage by caspase-3, and the procaspase-3 automaturation, and that this 
inhibition would be relieved by PAC-1.  A potential complication in the analysis is that 
wild-type procaspase-3 is both the substrate and the enzyme in these automaturation 
experiments.  In order to separate these two roles, the procaspase-3(D9A/D28A/D175A) 
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triple mutant was utilized as the version that functions solely as the enzyme (that is, it 
cannot be cleaved by caspases), and procaspase-3(C163A) was utilized as the version that 
functions solely as the substrate.  The mutation of the active site cysteine 163 of caspase-
3/procaspase-3 abolishes catalytic activity,10,30,31,72 thus this protein can still be cleaved 
by caspases, but itself has no enzymatic activity. 
 To assess the effect of zinc and PAC-1 on the ability of caspase-3 to cleave 
procaspase-3, procaspase-3(C163A) was incubated with caspase-3 for defined periods of 
time.  As shown in Figure 2.9(a), in the absence of zinc caspase-3 will process 
procaspase-3(C163A) in this in vitro experiment, consistent with the data in the 
literature.4,40  As shown in Figure 2.9(b), this processing is greatly inhibited by the 
addition of zinc.  Finally, as shown in Figure 2.9(c), addition of PAC-1 restores the 
ability of caspase-3 to cleave procaspase-3.  This is shown both by the appearance of the 
p12 and p17 active fragments, and by the processing of procaspase-3 to successively 
shorter forms.  During in vitro activation of procaspase-3 by caspase-3, it is known that 
the cleavage is such that bands are observed corresponding to the full length procaspase-3 
(~34 kDa), the Δ1-9 procaspase-3 (~32 kDa), and the Δ1-28 procaspase-3 (~30 kDa), in 
addition to the active caspase-3 fragments;4,40 this can be observed in the gels in Figure 
2.9.  
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Figure 2.9 Zinc inhibits the ability of caspase-3 to cleave procaspase-3, an effect that is relieved by 
addition of PAC-1.  (a) Procaspase-3 (C163A) (50 µM) was incubated with caspase-3 (10 µM); (b) 
Procaspase-3 (C163A) (50 µM) was incubated with caspase-3 (10 µM) and ZnSO4 (50 µM); (c) 
Procaspase-3 (C163A) (50 µM) was incubated with caspase-3 (10 µM), ZnSO4 (50 µM), and 50 µM PAC-
1 (50 µM).  Samples were analyzed by SDS-PAGE and coomassie staining. Exogenous wild-type caspase-3 
is not observed on the gel.  Taken with permission from J. Mol. Biol.  2009, 388 (1), 144-158. 
   
 PAC-1 induces procaspase-3 automaturation.  To investigate the effect of zinc 
and PAC-1 on the ability of procaspase-3 to autoactivate itself to caspase-3, an 
experiment was devised whereby procaspase-3(C163A) was used as the protein substrate, 
and procaspase-3(D9A/D28A/D175A) was used as the enzyme.  In the event, procaspase-
3(C163A) (50 µM) was incubated with procaspase-3(D9A/D28A/D175A) (10 µM) in the 
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presence/absence of zinc and PAC-1, for 0, 6, and 12 hours.  The lowered catalytic 
activity of procaspase-3 produces only low levels of product in these experiments, thus 
detection was performed by Western blotting.  When procaspase-3(C163A) is incubated 
with procaspase-3(D9A/D28A/D175A), caspase-3 p17 and p12 fragments are observed 
within 12 hours (Figure 2.10, lanes 1-3).  Running this same experiment in the presence 
of zinc significantly inhibits zymogen processing (Figure 2.10, lanes 4-6).  However, 
upon addition of PAC-1, an increase in the levels of the processed fragments is once 
again observed (Figure 2.10, lanes 7-9); PAC-1a has no such effect (Figure 2.10, lanes 
10-12).  This experiment demonstrates that PAC-1 enhances the activity of the 
procaspase-3 zymogen, allowing it to cleave another molecule of procaspase-3.  In the 
cell, of course, active caspase-3 would be generated through this process, and PAC-1 
could then also enhance the activity of caspase-3 as part of a feed-forward cycle.  
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Figure 2.10.  Zinc inhibits the ability of procaspase-3 to cleave another molecule of procaspase-3, an effect 
that is relieved by addition of PAC-1.  Procaspase-3(D9A/D28A/D175A) (10 µM) was incubated with 
procaspase-3 (C163A)(50 µM) (Lanes 1-3) and 50 µM ZnSO4 (Lanes 4-6) or 50 µM ZnSO4 and 50 µM 
PAC-1 (lanes 7-9) for up to 12 hours at 37 °C.  Samples were analyzed by SDS-PAGE and Western 
blotting using antibodies against the p12 and p17 caspase-3 fragments.  In the absence of zinc, procaspase-
3 (D9A/D28A/D175A)  processes the procaspase-3 (C163A) substrate within 12 hours.  In the presence of 
zinc, this automaturation is inhibited (lanes 4-6), an effect that is relieved by the addition of PAC-1 (lanes 
7-9), but not PAC-1a (lanes 10-12).  Taken with permission from J. Mol. Biol.  2009, 388 (1), 144-158. 
 
 PAC-1-mediated processing at different concentrations of procaspase-3 – gel 
assays.  To further evaluate the effect of PAC-1 on the feed-forward cycle of procaspase-
3 automaturation,  the ability of PAC-1 to activate various concentrations of procaspase-
3 was assessed by SDS-PAGE and Western blotting.  Procaspase-3 was expressed in E. 
coli as a C-terminal 6xHis-tag fusion protein, purified on a Ni-NTA resin, and utilized 
immediately.  This C-terminal 6xHis-tag provides a convenient method to monitor the 
maturation of procaspase-3 by immunoblotting with an antibody to the 6xHis epitope.   
 To directly assess the ability of PAC-1 to induce the automaturation of 
procaspase-3, PAC-1 was incubated with procaspase-3 for a range of times, then the 
solutions were boiled in SDS-PAGE loading buffer and run out on a SDS-PAGE gel.  
The Western blot in Figure 2.11 shows the effect of 100 µM PAC-1 on procaspase-3 (at 
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30 µM).  A strong activating effect of PAC-1 is observed in these assays.  In these 
experiments PAC-1 appears to accelerate the automaturation of procaspase-3; the 
activation pattern is essentially the same in the PAC-1-treated and the vehicle-treated 
samples, except the maturation takes place significantly earlier in the PAC-1 treated 
samples.  
 
Figure 2.11.  The in vitro activation of procaspase-3 by PAC-1 as assessed by Western blotting.  
Procaspase-3 with a C-terminal 6xHis-tag (30 µM) was incubated with 100 µM PAC-1 for a range of 
times, and the resulting proteins were analyzed by Western blotting with an antibody specific for the 6xHis-
tag.  Controls where procaspase-3 was incubated with vehicle were performed and analyzed in parallel.   
 
 In these experiments, various intermediates of procaspase-3 activation can be 
observed.  Based on similar banding pattern that has been seen in the caspase-3-mediated 
activation of procaspase-3,4,40 we assign the bands in Figure 2.11 as (top to bottom):  The 
full length procaspase-3 protein; the procaspase-3 protein in which the first 9 amino acids 
have been removed (Δ1-9 procaspase-3); the procaspase-3 protein in which the first 28 
amino acids (the entire pro domain) have been removed (Δ1-28 procaspase-3); the p12 
fragment (see Figure 2.1) 
 Experiments were also performed in which the procaspase-3-activating effects of 
etoposide (a known pro-apoptotic agent and topoisomerase II inhibitor) and PAC-1a 
(Figure 2.1A, a derivative of PAC-1 that does not induce death of cancer cells in 
0 hr 2 hr 4 hr 6 hr 
PAC-1 - + - + - + - + PC-3 
!1-9 PC-3  
!1-28 PC-3  
p12  
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culture45) were assessed.  As shown in Figure 2.12, neither etoposide nor compound 
PAC-1a has any effect over background in these procaspase-3 activation experiments. 
 
Figure 2.12.  In vitro activation procaspase-3 is not observed upon treatment with vehicle, etoposide or an 
inactive PAC-1 derivative (PAC-1a).  Western blot of recombinantly expressed procaspase-3 (30 µM) that 
had been incubated with vehicle, 100 µM of PAC-1, etoposide, or PAC-1a.  Bands were visualized with an 
antibody to the C-terminal 6xHis-epitope. 
 
2.2.3 Activity Assays 
 
To evaluate the effect of PAC-1 on procaspase-3, two distinct biochemical assays 
were utilized.  First, caspase-3 enzymatic activity was monitored at 405 nm through the 
cleavage of the peptidic Ac-DEVD-pNA substrate.  Second, the maturation of the 
procaspase-3 zymogen was tracked by SDS-PAGE followed by Western blotting.  This 
second method provides a biochemical readout orthogonal to the activity assay and one 
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that allows direct visualization of procaspase-3 maturation. These experiments were 
performed in a buffer that contains trace amounts of zinc. 
 The in vitro auto-activation of procaspase-3 has been previously studied,41 as has 
the in vitro activation of procaspase-3 by caspase-3,4,40 caspase-9,41 and granzyme B.41 
As shown in Figure 2.1B, procaspase-3 has three sites where it is cleaved by 
caspase/granzyme-related enzymes, D9, D28, and D175.  During the in vitro activation of 
procaspase-3 by caspase-3, the cleavage is such that bands are observed corresponding to 
the full length procaspase-3 (~34 kDa), the Δ1-9 procaspase-3 (~32 kDa), and the Δ1-28 
procaspase-3 (~30 kDa), in addition to the active caspase-3 fragments (see Figure 
2.1B).4,40     
 PAC-1-mediated activation of procaspase-3 at different concentrations of PAC-1 
– activity assays.  The procaspase-3-activating effect of PAC-1 was then evaluated in the 
enzymatic activity assay, using PAC-1 concentrations of 10, 50, and 100 µM.  In these 
experiments PAC-1 was incubated with 1 µM procaspase-3 for 4 hours, and then the Ac-
DEVD-pNA substrate was added and the absorbance at 405 nm was followed for 1 hour.  
Controls were performed exactly as above except that vehicle (DMSO) was added instead 
of PAC-1.  Identical triplicate replicates were obtained for all data sets.  When comparing 
the control samples to the PAC-1-treated samples, a clear increase in enzymatic activity 
is observed in all three PAC-1-treated samples (Figure 2.13A-2.13C).  Analogous 
experiments with PAC-1a (100 µM) showed no activating effect of this compound (data 
not shown).   
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Figure 2.13.  A 1 µM solution of procaspase-3 was incubated with three different concentrations of PAC-1 
for 4 hours, and then Ac-DEVD-pNA (1 mM) was added and the absorbance was read at 405 nm for 1 
hour.  The data from identical triplicate replicates is shown.  A) The effect of 100 µM PAC-1.  B) The 
effect of 50 µM PAC-1.  C) The effect of 10 µM PAC-1. 
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 PAC-1-mediated activation of procaspase-3 at different concentrations of 
procaspase-3 – activity assays.  The effect of PAC-1 was then assessed at a range of 
procaspase-3 concentrations.  PAC-1 was incubated with various concentrations of 
freshly isolated procaspase-3 for 6 hours in a 384-well plate, after which time the Ac-
DEVD-pNA substrate was added and the absorbance at 405 nm was monitored over time.  
For each procaspase-3 concentration, controls were performed in which just vehicle was 
added to each well; this allowed for the monitoring of the intrinsic activity of procaspase-
3.  Controls were also performed with PAC-1 only in the wells.  Example raw data for 
this experiment is shown in Figure 2.14A and 2.14B.   
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Figure 2.14.  In vitro activity assays of procaspase-3 in the presence of PAC-1.  A range of concentrations 
of procaspase-3 were incubated with 100 µM PAC-1 for 6 hours.  The Ac-DEVD-pNA substrate was 
added, and absorbance at 405 nm was monitored over a period of 60 minutes.  A) Raw data from these 
experiments with 10 µM procaspase-3 showing the increase in activity that is observed in the presence of 
PAC-1.  B) Raw data from these experiments with 5 µM procaspase-3 showing the increase in activity that 
is observed in the presence of PAC-1.  C) The raw data is then processed by subtracting the activity due to 
vehicle-treated procaspase-3 to give the initial velocity curves.  D) The slopes of these initial velocity 
curves in Figure 5C were then plotted against procaspase-3 concentration.   
 
 After subtracting the absorbance of the control wells (containing procaspase-3 and 
vehicle) from the experimental wells, the initial slope resulting solely from the effect of 
PAC-1 for each procaspase-3 concentration was obtained.  These slopes were converted 
to µmols product formed per minute through a pNA calibration curve, and the initial 
slopes of these initial velocity curves (Figure 2.14C) were then plotted versus procaspase-
3 concentration to provide the graph in Figure 2.14D.  As shown in Figure 2.14D, at high 
procaspase-3 concentrations PAC-1 has a robust activating effect.  Incubation of PAC-1 
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with just the Ac-DEVD-pNA substrate resulted in no significant absorbance change at 
405 nm (Figure 2.14C). 
 The data in Figure 2.14D indicate that PAC-1 activates procaspase-3 in a manner 
proportional to procaspase-3 concentration.  Incubation of procaspase-3 with PAC-1 
provides protein that efficiently cleaves the Ac-DEVD-pNA substrate; procaspase-3 
incubated with vehicle does not produce this level of activity (Figure 2.13A-2.13C, 
2.14A, 2.14B).  The protein catalysts in these assays is likely a mixture of the three 
procaspase-3 forms (Figure 2.1B) and the active caspase-3 itself.  Western blot data 
(Figure 2.11) shows that in the presence of PAC-1 procaspase-3 is converted to the 
shorter procaspase-3 forms and the fully processed caspase-3 more rapidly than 
procaspase-3 automaturation.  It has not been reported if the shorter procaspase-3 forms 
(lacking amino acids 1-9 and 1-28) have altered catalytic activity relative to the parent 
procaspase-3.  It is thus possible that the increase observed in the activity assay with 
PAC-1 is due to the generation of the Δ1−9 and Δ1−28 forms of procaspase-3 that are 
more active.  However, it is more likely that the additional catalytic activity in the PAC-1 
treated samples is due to a higher concentration of caspase-3, generated through the 
PAC-1-mediated enhancement of procaspase-3 autoactivation.  Our data thus support the 
hypothesis that PAC-1 enhances the activity of procaspase-3, allowing procaspase-3 to 
process itself to caspase-3 in a more facile manner.  Experiments show that PAC-1 has 
no effect on the Ac-DEVD-pNA substrate (Figure 2.14C), thus excluding the possibility 
that PAC-1 itself is directly catalyzing the hydrolysis of this substrate.   
 Full length procaspase-3 is comprised of a ~4 kDa (28 amino acid) prodomain, a 
17 kDa large subunit, and a 12 kDa small subunit (Figure 2.1(b)).  While caspase-8 and 
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caspase-9 activate procaspase-3 in vivo by proteolysis between the p17 and p12 
fragments (at D175), there are two additional sites where procaspase-3 is proteolyzed by 
caspase/granzyme-related enzymes: between the pro and p17 domains (at D28), and 
inside the prodomain (at D9) (see Figure 2.1(b)).12,39  In vitro, it is known that caspase-3 
will cleave procaspase-3 at D9, D28 and D175.4,40  Interestingly, the procaspase-3 
zymogen is itself also catalytically active.40,41  In vitro procaspase-3 will cleave itself to 
the active caspase-3,41 and procaspase-3 (either wild-type or the caspase-resistant 
D9A/D28A/D175A triple mutant) will also process synthetic chromogenic/fluorogenic 
peptidic caspase-3 substrates.40  As inferred by studies on the triple mutant, the kcat/KM of 
procaspase-3 is approximately 200-fold lower than caspase-3 on peptidic substrates, with 
the major effect being a reduction in kcat.40  Thus, in vitro procaspase-3 is both an enzyme 
and a substrate; the cellular relevance of the procaspase-3 enzymatic activity is unknown.     
2.3 Structure Activity Relationship of Procaspase Activating Compounds 
In an effort to understand the structural motifs responsible for the activity of PAC-1 we 
sought to define the structure-activity relationship of PAC-1.  Based on our previous 
results with PAC-1a, PAC-1 derivatives lacking the phenolic hydroxyl do not activate 
procaspase-3 in vitro and do not induce death of cancer cells in culture.45  This 
information, combined with the known tendency of ortho-hydroxy N-acyl hydrazones to 
bind metal ions,73 led us to suspect metal ion binding as part of the mechanism of action 
of PAC-1.  As caspase-335 and procaspase-360 are known to be inhibited by zinc, we 
focused on zinc and recently determined that PAC-1 binds to zinc in a 1:1 stoichiometry 
with a dissociation constant of 52 nM.60  In addition, we discovered that PAC-1 enhances 
the activity of procaspase-3, caspase-3, procaspase-7, and caspase-7 in vitro through the 
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sequestration of inhibitory zinc ions.60  Described in this section is the use of derivative 
synthesis and biochemical analysis to determine the exact PAC-1 functional groups 
responsible for caspase activation, zinc chelation, and cell death.  Importantly, the results 
of these experiments show a strong correlation between the ability of a compound to bind 
zinc, activate caspase-3 in vitro, and induce death in cancer cells in culture. Overall, the 
results described herein support the hypothesis that PAC-1 induces death in cancer cells 
through direct activation of procaspase-3 via sequestration of inhibitory zinc ions, 
implicate zinc as an endogenous anti-apoptotic agent, and suggest a shared mode of 
action for certain zinc-chelating anticancer compounds. 
2.3.1 Design of PAC-1 derivatives  
In an effort to fully define the structural requirements of PAC-1 for procaspase-
3/caspase-3 activation and cell death induction, we designed a series of derivatives with 
systematically altered functional groups that would allow a detailed structure-activity 
relationship (SAR) for PAC-1 to be constructed.  This SAR would in turn allow the 
design of a fluorescent version of PAC-1 that could be used to determine the subcellular 
localization of this compound and its ability to co-localize with sites of caspase-3 activity 
in the cell.  Thus, the twin goals of the SAR study were the determination of functional 
groups important for the biological activity of PAC-1, and the discovery of regions on 
the PAC-1 scaffold that could be altered with minimal loss in activity. 
 Four classes of PAC-1 derivatives were envisioned (Figure 2.15): alterations on 
the phenolic ring (Class I, 1a-k), on the benzyl ring (Class II, 2a-g), simultaneous 
modification of both the benzyl and phenolic rings (Class III, 3), and alterations to the 
PAC-1 core (Class IV, 4a-g, with modifications of the indicated atoms and bonds made 
 42 
in red).  In total, 26 derivatives from these classes were synthesized by collegues Joe 
Sandhorst and Dr. Danny Hsu. 
 
Figure 2.15.  PAC-1, and four classes of PAC-1 derivatives.  Class I compounds (1a-k) have 
modifications on the phenolic ring, Class II compounds(2a-g) have modification on the benzyl ring, Class 
III compounds (3) have modifications on both the phenolic and benzyl rings, and Class IV compounds (4a-
g) have modifications to the key heteroatoms and bonds indicated in red.  Taken with permission from J. 
Med. Chem.  2009, 52 (18), 5721-5731. 
 
 
2.3.2 Evaluation in biochemical assays 
 
With 26 derivatives of PAC-1 in hand, all compounds were evaluated for their 
ability to induce death in cancer cells, to relieve zinc-mediated inhibition of caspase-3 in 
vitro, and to bind zinc.  Assessment of all compounds in these three assays provides a 
comprehensive data set (Table 2.1) used to formulate a structure-activity relationship for 
PAC-1; brief descriptions of these assays are provided below.   
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Table 2.1.  Evaluation of PAC-1 and its derivatives  
All errors represent standard error of the mean, n=3.  aThese compounds exhibit a significant inhibitory effect at 10 μM, 
masking any activation (see text).  Taken with permission from J. Med. Chem.  2009, 52 (18), 5721-5731. 
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2.3.2.1 Zinc binding 
Although compounds containing the ortho-hydroxy N-acyl hydrozone motif have been 
previously shown to bind to metals,73 some of these compounds do not bind Zn2+ tightly 
and instead have Kd values in the micromolar range.74  Dr. David Good thus set out to 
determine the affinity of PAC-1 for zinc.  As shown in Figure 2.16(a), titration of PAC-1 
with increasing amounts of ZnSO4 results in a change in the UV-visible spectrum of this 
compound.  This shift in molar absorptivity upon Zn2+ binding provides a convenient 
method to determine both the stoichiometry of PAC-1—Zn2+ binding and the 
dissociation constant of this interaction.   
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Figure 2.16.  (a) Titration of ZnSO4 into a solution of PAC-1 (50 µM in 50 mM Hepes, 100 mM KNO3, 
pH 7.2 buffer) causes a change in the UV-visible spectra of PAC-1.  Shown are ZnSO4 concentrations of 0 
to 75 µM in 5 µM increments.  (b) Analysis of the PAC-1—Zn2+ binding interaction and stoichiometry by 
the continuous variations method.  Based on the location of the peak value, the stoichiometry was 
determined to be 1:1, and the Kd was determined to be 42 nM.  Error bars are standard deviation from the 
mean.  Taken with permission from J. Mol. Biol.  2009, 388 (1), 144-158. 
 
A modified version of the method of continuous variations was used by Dr. David 
Goode for this determination.75  The absorbance at 410 nm was acquired for various mole 
fractions of ZnSO4 and PAC-1 with a total concentration of 50 µM.  These values were 
then normalized versus the maximal absorbance possible at the stoichiometric point (i.e. 
when all of the Zn2+ is bound by excess PAC-1), which was set as 1.  Application of the 
-0.2
0
0.2
0.4
0.6
0.8
1
1.2
0 0.2 0.4 0.6 0.8 1
Mole Fraction of PAC-1
N
or
m
al
iz
ed
 A
bs
or
ba
nc
e
(a)
(b)
0
0.2
0.4
0.6
0.8
1
1.2
250 300 350 400 450 500
Wavelength (nm)
Ab
so
rb
an
ce
0 µM ZnSO4
75 µM ZnSO4
75 µM ZnSO 4
0 µM ZnSO4
N
or
m
al
iz
ed
 A
bs
or
ba
nc
e
N
or
m
al
iz
ed
 A
bs
or
ba
nc
e
Ab
so
rb
an
ce
Ab
so
rb
an
ce
 46 
continuous variations method revealed that PAC-1 binds Zn2+ in a 1:1 stoichiometry, as 
evidenced by the peak at 0.5 mole fraction in the graph in Figure 2.16(b).  Also apparent 
from Figure 2.16(b) is the very strong nature of this small molecule—metal interaction.  
At the 1:1 stoichiometry PAC-1 has almost entirely shifted its absorption to the zinc-
bound state (96% of PAC-1 is Zn2+-bound at a 1:1 ratio of PAC-1— Zn2+).  Using this 
96% value and the equation: log Ka = 0.3010 – log M + log ymax – 2 log (1 - ymax), we 
obtain a Kd = 42 nM for the PAC-1— Zn2+ interaction.  While the Kd for the PAC-1—
Zn2+ interaction is 42 nM, as shown in Figure 2.16(a) an absorbance change is still 
observed with micromolar concentrations of zinc.  This is due to the high concentration 
of total ligand (50 µM) in this experiment relative to the Kd.  Based on the concentrations 
of zinc and PAC-1 utilized in this experiment, the Adair equation76 predicts a half 
maximal population average site occupancy for the PAC-1—Zn2+ complex at ~30 µM 
zinc, consistent with the data obtained (Figure 2.16(a)).  Titration of ZnSO4 into PAC-1a 
gave no spectral change as monitored by UV/vis spectroscopy, consistent with the notion 
that PAC-1a does not bind Zn2+ (Figure 2.17).  
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Figure 2.17.  Titration of ZnSO4 into a solution of PAC-1a (50 µM in 50 mM Hepes, 100 mM KNO3, pH 
7.2 buffer) does not cause a change in the UV-visible spectra of PAC-1a.  Shown are ZnSO4 concentrations 
of 0 to 70 µM in 5 µM increments.  Taken with permission from J. Mol. Biol.  2009, 388 (1), 144-158. 
 
 To confirm this result, a second method was used by Dr. David Goode to 
determine the PAC-1—Zn2+ dissociation constant.  In this experiment, a preformed 
complex of PAC-1 and Zn2+ was titrated with EGTA (a metal binder with a known 
affinity for Zn2+), and the absorbance at 410 nm was monitored (Figure 2.18).  Using the 
literature value for the EGTA—Zn2+ association constant,77 the PAC-1—Zn2+ 
dissociation constant was calculated as 55 nM, in general agreement with Kd of 42 nM 
calculated through the method of continuous variations. 
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Figure 2.18.  EGTA competition with prebound ZnSO4:PAC-1.  Titration of EGTA (2.9 mM) into a solution of PAC-1 
(32 μM PAC-1, 9.5 μM ZnSO4, 50 mM Hepes, 100 mM KNO3, pH 7.4) causes a decrease in absorbance at 410 nm.  
Shown are EGTA concentrations of 0 to 66.1 μM in 4.8 μM increments.  Taken with permission from J. Mol. Biol.  
2009, 388 (1), 144-158. 
 
The affinity of each of the 26 PAC-1 derivatives for zinc was determined by Dr. Danny 
Hsu through the use of the EGTA titration described above and according to the method 
of Zhu and co-workers.78  For these experiments, PAC-1 or derivatives were added in a 
Hepes buffer containing a large excess of EGTA, followed by incremental addition of 
zinc, and the fluorescence of the small molecule—zinc complex was read (excitation at 
410 nm, emission at 475 nm). The resulting increase of fluorescence intensity was plotted 
against the calculated free zinc concentration in accord with similar protocols.78  This plot 
constitutes a formation curve from which binding constants were calculated.   
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2.3.2.2 Relief of zinc mediated inhibition 
We had previously shown that zinc inhibits both active caspase-3 and procaspase-3, 
and that PAC-1 is able to enhance the activity of both of these enzymes.60  Because of the 
low catalytic activity of procaspase-3 (~200-fold less active than caspase-3),40,60 we used 
the activation of caspase-3 as the method to evaluate and compare PAC-1 and its 
derivatives.  Therefore, all 27 compounds (PAC-1 and its 26 derivatives) were tested at 
multiple concentrations with caspase-3 and zinc to determine their ability to relieve zinc-
mediated inhibition of caspase-3 in vitro.  The percent activation of caspase-3 at a 
compound concentration of 10 µM, the concentration at which most compounds showed 
maximal activity, is reported in Table 2.1.  For these enzyme activation assays, all buffers 
were first treated with Chelex resin to remove divalent metal cations. 
 
2.3.2.3 Cytotoxicity 
 The induction of cell death was determined using the U-937 (human lymphoma) 
cell line.  U-937 cells grow in culture as a suspension and previous studies with PAC-1 
have been conducted with these cells,45,60 thus they provide a convenient benchmark for 
assessment of PAC-1 analogues.  For these experiments, cells were exposed to a range of 
compound concentrations for 72 hours, cell death was quantitated via a sulforhodamine B 
assay,79 and IC50 values were calculated from logistical dose-response curves. 
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2.3.2.4 Structure Activity Relationship of PAC-1 
  
The results of these cell death, caspase-3 activation, and zinc binding experiments are 
shown in Table 2.1 (see Figures 2.19-2.20 for individual data sets).  As shown, there is a 
strong correlation between the ability of compounds to activate caspase-3 in vitro, bind 
zinc, and induce death in cancer cells in culture.  Universally, compounds that do not 
activate caspase-3 in vitro do not bind zinc or induce significant death of the cancer cells 
in culture.  For example, removal or alkylation of the ortho-hydroxyl (compounds 1h and 
1k) results in compounds that do not bind zinc, activate caspase-3, or kill cells to any 
large degree.  Likewise, replacement of this –OH with a thioether (1b), amine (1c), 
carboxylic acid (1d), methyl ester (1e), chloride (1f), or sulfhydryl (1g) results in 
compounds that are basically inactive in all three assays.  However, if the ortho-hydroxyl 
is maintained, a variety of substitution patterns are tolerated on the phenolic ring.   For 
example, (1j) contains allyl groups at two positions on this ring and is a potent caspase-3 
activator, zinc binder, and cell death inducer, while the compound lacking any allyl 
groups (1a) is also reasonably potent in these assays. 
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Figure 2.19.  Cytotoxicity of PAC-1 and derivatives.  Each graph shows the dose response curves used to 
generate the IC50 value for each derivative.  The results of these experiments are summarized in Table 2.1.  
Taken with permission from J. Med. Chem.  2009, 52 (18), 5721-5731. 
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Figure 2.19 (cont.).  Cytotoxicity of PAC-1 and derivatives.  Each graph shows the dose response curves 
used to generate the IC50 value for each derivative.  The results of these experiments are summarized in 
Table 2.1.  Taken with permission from J. Med. Chem.  2009, 52 (18), 5721-5731. 
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Figure 2.20.  Relief of zinc mediated caspase-3 inhibition.  Each graph represents three separate dose 
response experiments.  The error bars represent the standard error of the mean for each data point.  The 
majority of compounds show a maximal activity at 10 µM.  The % activity at 10 µM for each compound 
was included in Table 2.1.  Taken with permission from J. Med. Chem.  2009, 52 (18), 5721-5731. 
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Figure 2.20 (cont.).  Relief of zinc mediated caspase-3 inhibition.  Each graph represents three separate 
dose response experiments.  The error bars represent the standard error of the mean for each data point.  
The majority of compounds show a maximal activity at 10 µM.  The % activity at 10 µM for each 
compound was included in Table 2.1.  Taken with permission from J. Med. Chem.  2009, 52 (18), 5721-
5731. 
 
 The derivatives in which the nature of the benzyl ring was altered (Class II 
derivatives, 2a-g) were also assessed.  As shown in Table 2.1, these compounds 
universally retained the ability to induce death in U-937 cells, to activate caspase-3 in 
vitro, and bind zinc.  The one Class III derivative (3) was also active in all three assays. 
Compounds in Class IV were constructed to systematically probe the importance 
of the ortho-hydroxy N-acylhydrazone motif and the piperazine nitrogens on biological 
activity.  Specifically, compounds were created in which the piperazine nitrogens were 
replaced with CH (compounds 4a-c), that have the C-N double bond reduced (4d), that 
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were inactive.  No zinc binding could be detected for compounds 4d-g; these four 
compounds also have no/low capacity for caspase-3 activation in vitro, and they do not 
strongly induce death in U-937 cells in culture (Table 2.1).  In contrast, compound 4c, in 
which one of the piperazine nitrogens is changed to a CH, showed cell death induction, 
caspase-3 activation, and zinc binding activity almost identical to PAC-1.   
Clear SAR trends are thus apparent from the data in Table 2.1:  1) PAC-1 
derivatives that are unable to bind zinc do not activate caspase-3 in vitro, and do not 
appreciably induce death in U-937 cells in culture.  This information suggests the zinc 
binding capacity of PAC-1 is important for its cell death inducing properties.  2) The 
ortho-hydroxy N-acylhydrazone motif is critical for zinc binding. 3) Virtually all 
compounds that bind zinc activate caspase-3 in vitro and induce death in U-937 cells in 
culture.  Only compounds 4a and 4b, which show no in vitro caspase-3 activation but are 
still cytotoxic to U-937 cells, are exceptions to this trend.  Interestingly, we find that 
these two compounds (at a concentration of 10 µM) are reasonably potent inhibitors of 
caspase-3 enzymatic activity, thus any activating effect of the compound may be masked 
by this inhibition (Figure 2.21).  This inhibition effect is consistent with previous data 
showing that PAC-1 will also inhibit procaspase-3/caspase-3 at high compound 
concentrations.60 
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Figure 2.21.  Inhibition by class IV compounds.  4a and 4b inhibit caspase-3 in the absence of zinc.  This 
potent inhibition masks any activation at 10 µM.  Taken with permission from J. Med. Chem.  2009, 52 
(18), 5721-5731. 
 
2.4 Procaspase Activating Compounds in the cellular environment 
 It is interesting to note that the strong in vitro correlation of PAC-1 activity with 
procaspase-3 concentration is very much aligned with what has been observed in cell 
culture for the cytotoxicity of PAC-1.  In the previous study, primary colon samples were 
obtained whose cells had high levels of procaspase-3, up to ~20-fold greater than the 
adjacent non-cancerous tissue.45  In these samples the pro-apoptotic effect of PAC-1 
tracks strongly with the levels of cellular procaspase-3; cells with 20-fold higher 
procaspase-3 are killed by PAC-1 with an IC50 of ~3 nM (versus 6 mM for non-
cancerous cells from the same patient).45  The in vitro data presented herein provide a 
possible explanation for this selectivity: PAC-1 facilitates the autoactivation of 
procaspase-3 much more efficiently at high procaspase-3 concentrations.  As the typical 
cellular concentration of procaspase-3 is believed to be ~100 nM,80 a cancerous cell with 
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making them especially susceptible to death induced by a procaspase-3-activating 
compound such as PAC-1. 
Interestingly, our recent data show that PAC-1 will activate both procaspase-3 
and caspase-3,60 thus another possibility for the PAC-1 mode of action would be that 
PAC-1 relieves the zinc-mediated inhibition of caspase-3.  As the FAM-DEVD-fmk 
inhibitor only reports on active caspase-3, the experiments described in this chapter do 
not directly rule out this possibility.  However, this scenario seems less likely given that 
cancer cell procaspase-3:caspase-3 ratios are typically strongly weighted in favor of 
procaspase-3,32,41,57 although in some primary cancer cell types and cell lines there does 
appears to be significant levels of caspase-3.55,56,67,81 
The data in this chapter also suggest a prominent role for zinc as an endogenous 
anti-apoptotic agent, and there is much literature to support this notion.33,34,69,82  It is 
estimated that as much as 10% of cellular zinc exists loosely bound to various cellular 
proteins or contained in the “zincosomes”.  Perhaps most provocatively, zinc has been 
shown to co-localize with procaspase-3,36,83 and we have shown that zinc inhibits 
procaspase-3 enzymatic activity in vitro.60   
Based on this structure-activity relationship, a novel fluorescent derivative of 
PAC-1 was designed and synthesized by Dr. Danny Hsu.  Subsequent confocal 
microscopy experiments indicate that fluorescently-labeled PAC-1 co-localizes with sites 
of caspase-3 activity in the cell. 
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Induction of Apoptosis  
 Induction of apoptosis by PAC-1 derivatives.  To assess if PAC-1 derivatives 
induce apoptotic death, the effect of two of the more potent compounds (2d and 4c) was 
evaluated versus U-937 cells.  For these experiments, each compound (at 50 µM) was 
incubated with U-937 cells for 12 hours, at which point cells were co-stained with 
propidium iodide (PI) and FITC-labeled Annexin V.  Cells that are negative for PI 
staining, but positive for Annexin V are considered to be in the early stages of 
apoptosis.84  Such dual staining experiments were previously used to show that PAC-1 
induces apoptotic death in cancer cells in culture.45  The result of this PI/Annexin V 
experiment with the PAC-1 derivatives clearly show that each compound induces 
apoptotic death (Figure 2.22). 
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Figure 2.22.  Assessment of apoptotic induction by PAC-1 derivatives.  U-937 cells were treated with 
PAC-1, 2d, and 4c (50 µM each) or vehicle control for 12 hours, then stained with propidium iodide (PI) 
and FITC-labeled Annexin V.  All three compounds induce apoptosis as assessed by the Annexin V 
positive/PI negative populations.  Results shown are representative of three replicate experiments with each 
compound.  Taken with permission from J. Med. Chem.  2009, 52 (18), 5721-5731. 
 
2.4.1 Exogenous zinc relief of cytotoxicity 
Induction of apoptotic cell death by PAC-1 is inhibited by Zn.  Although earlier 
work was focused on the determination of the mechanism by which PAC-1 activates 
procaspase-3 in vitro, we have also conducted preliminary experiments investigating the 
relevance of this mechanism to the death-inducing effect of PAC-1 in cell culture.  Thus, 
the effect of exogenous zinc on the ability of PAC-1 to induce apoptotic death in cancer 
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cells in culture was assessed.  For this experiment, U-937 cells (human lymphoma cell 
line) were incubated with vehicle, ZnSO4 (100 µM), etoposide (10 µM), etoposide plus 
ZnSO4, PAC-1 (50 µM), and PAC-1 plus ZnSO4; after 24 hours apoptotic cell death was 
assessed by FITC-Annexin V and propidium iodide staining and flow cytometry.  
Apoptotic cells are those that stain positive for FITC-Annexin V, but negative for 
propidium iodide.  The results of this experiment are displayed in Figure 2.23.  Treatment 
of cells with vehicle or with ZnSO4 induces little apoptosis, whereas treatment with 
etoposide induces apoptosis in almost 70% of the cells, a value that is not significantly 
reduced by the presence of ZnSO4.  In contrast, the apoptotic death induced by PAC-1 is 
significantly reduced by the addition of ZnSO4.  Comparison of the etoposide and PAC-1 
data suggests that the ZnSO4-mediated inhibition of the PAC-1 cytotoxicity is not merely 
a consequence of a general anti-apoptotic effect of ZnSO4.  It is of course possible that 
exogenous zinc is simply binding to PAC-1 and preventing it from entering the cell.  
Minimally, the data in Figure 2.23 suggests that PAC-1 is capable of binding zinc in cell 
culture media.   
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Figure 2.23.  PAC-1 induces death in U-937 cells, an effect that is reduced in the presence of ZnSO4.  U-
937 cells were treated with the indicated concentrations of PAC-1 and/or ZnSO4 for 24 hours, at which 
point cell death was assessed by propidium iodide staining and flow cytometry.  As also shown, ZnSO4 has 
little effect on the toxicity of etoposide in the same assay.  Error bars represent standard error.  Taken with 
permission from J. Mol. Biol.  2009, 388 (1), 144-158. 
 
2.4.2  Cell permeability 
 In an effort to determine whether the rescue of PAC-1 cytotoxicity is due to 
chelation of cellular zinc, we sought to evaluate the ability of PAC-1 to permeate the cell 
membrane.  To this end, Neuro-2a murine neuroblastoma cells were treated by 
collaborator, Dr. Tim Fan, with PAC-1 (solubilized in HPβCD) at 50 µM for 30 minutes. 
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intracellular compound concentration. PAC-1 was detected in the cell lysates at 
significant concentrations (PAC-1: 29.4 ± 6.5 µM).  These results demonstrate that PAC-
1 is capable of readily and rapidly penetrating neuronal cell membranes.   
2.4.3 Cellular zinc levels upon PAC-1 treatment 
 Given the ability of PAC-1 to rapidly cross cell membranes and the data 
demonstrating that PAC-1 activates procaspase-3 through chelation of inhibitory zinc in 
vitro, we sought to determine if labile pools of zinc in the cell are affected by PAC-1.  
Genetically-encoded Zn2+ sensors have been developed by our collaborator, Dr. Amy 
Palmer, to study changes in intracellular Zn2+ concentrations in live cells 85,86. A 
conformational change in the sensor upon Zn2+-binding leads to increased fluorescence 
resonance energy transfer (FRET), offering an opportunity to visualize the changes in the 
cellular labile zinc pool upon treatment with PAC-1.  Zn2+ levels are proportional to the 
FRET ratio (FRET/CFP signal) which can be measured by fluorescence microscopy 
(Figure 2.24).  Upon treatment of cells, known cell-permeable zinc chelators (such as 
TPEN) induce a significant decrease in the FRET signal of these genetically encoded 
sensors.   
 63 
 
Figure 2.24.  Florescence microscopy evaluating the FRET ratio of HeLa cells transfected with the 
ZapCY2 sensor.  Cells were treated with PAC-1 or the cell permeable zinc chelator TPEN.   
When HeLa cells,  transfected with the ZapCY2 sensor (apparent Kd’ for Zn2+: 
811 pM, 86), were exposed by the Palmer laboratory to PAC-1 at 10 µM for 15 min, the 
FRET ratio decreased, indicating a decrease in intracellular free Zn2+ (Figure 2.25). The 
FRET ratio decreased further upon exposure to 50 µM PAC-1 for 15 min (Figure 2.25). 
To demonstrate that the decrease in FRET was due to chelation of labile zinc, cells were 
washed and exposed to 150 µM TPEN, a cell permeable Zn2+ chelator with a Kd of 2.6 x 
10-16 M 87. The FRET ratio of the sensor decreased further upon treatment with this 
powerful Zn2+ chelator. Finally, cells were permeabilized with digitonin and treated with 
a solution containing 9.5 nM Zn2+, the FRET ratio of the sensor increased. Together, 
these experiments suggest that PAC-1 treatment results in a decrease of labile cellular 
zinc levels.  Given the rapid cellular permeability of PAC-1 (Figure 2.24) and the highly 
regulated nature of cellular zinc levels, it is unlikely that this decrease in labile cellular 
zinc is due to equilibrium redistribution across the cell membrane, but rather represents 
chelation of cellular zinc stores in situ. 
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Figure 2.25 Changes in intracellular labile zinc concentration upon PAC-1 treatment. FRET ratio 
changes in HeLa cells using the genetically-encoded zinc sensor ZapCY2. Graphs of a representative 
individual experiment show a decrease in intracellular free zinc in five cells treated with 10 µM PAC-1 
followed by 50 µM PAC-1.  The decrease in intracellular zinc for both PAC-1 is significant over multiple 
experiments (21 cells or n=4 experiments), S-PAC-1 (14 cells or n=3 experiments). 
 
2.4.4 Subcellular localization of PAC-1 
 Given data showing that PAC-1 crosses the cell membrane and reduces labile 
cellular zinc levels, we were sought to understand the functional role of PAC-1 in the 
cellular environment.  Initially we sought to understand the cellular localization of PAC-
1 in the hopes that this information would help us understand the cellular mechanism 
responsible for the cytotoxicity of PAC-1. 
Design, synthesis, and biochemical characterization of a fluorescent version of 
PAC-1.   Based on the information gleaned from the SAR study, above, a fluorescent 
version of PAC-1 was designed that was predicted to retain the ability to bind zinc, 
activate caspase-3, and induce cell death.  Specifically, as the SAR indicates that 
modifications on the benzyl ring are well-tolerated, a modified benzyl ring was used by 
Dr. Danny Hsu to conjugate PAC-1 with a fluorophore.   
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 To ensure orthogonal fluorescent signals in our proposed co-localization 
experiments, we choose a fluorophore that we could excite at 350 nm to conjugate to 
PAC-1, and of the possible dyes in this category, Alexa Fluor 350 was selected.  Dr. 
Danny Hsu synthesized the fluorophore-conjugated PAC-1 starting with the Alexa Fluor 
350 (activated as its N-hydroxysuccinimide (NHS) ester).  Compound 31, was first 
treated with amine 32 to create alkynyl-Alexa Fluor 350 (compound 33, Scheme 2.1).  
The Cu(I)-catalyzed variant of the Huisgen [3+2] cycloaddition reaction88 was then used 
to link azido-PAC-1 with 33 to form 2h (Alexa Fluor 350-conjugated PAC-1 or AF350-
PAC-1, Scheme 2.1).  Compound 2h was characterized by HRMS and 1H NMR.  Once in 
hand 2h was evaluated for its ability to induce death in U-937 cells in culture, activate 
caspase-3 in vitro, and bind zinc.  2h has activity similar to PAC-1 in these assays (IC50 
versus U-937 cells = 14.8 ± 3.2 μM, caspase-3 activation at 10 μM = 6.3 ± 1.6% and at 
50 μM = 20 ± 3%,  Kd for zinc = 61 ± 9 nM, see figure 2.26) 
 
 
Scheme 2.1.  The synthesis of 2h, a fluorescent version of PAC-1.  Taken with permission from J. Med. 
Chem.  2009, 52 (18), 5721-5731. 
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C 
Zn-AL350-PAC-1(2h): Kd = 62 ± 9 nM                                   
  
 
Figure 2.26.  Biochemical assessment of AF350-PAC-1(2h).  A)  AF350-PAC-1(2h) relieves zinc 
mediated inhibition of procaspase-3.  B)  AF350-PAC-1(2h) induces cell death in U937 human lymphoma 
cells with an IC50 of 14.8 ± 3.2 µM .  C)  AF350-PAC-1(2h) binds zinc with a Kd of 61 ± 9 nM.  Taken 
with permission from J. Med. Chem.  2009, 52 (18), 5721-5731. 
 
Once it was determined that 2h retained similar activity to PAC-1 in these three 
assays, confocal microscopy experiments were conducted.  The goals of these 
experiments were 1) to determine the subcellular localization of 2h; 2) to determine if 2h 
binds zinc in the cell, 3) to determine if 2h can activate procaspase-3/-7 to caspase-3/-7 
inside the cell, and 4) to determine if 2h colocalizes with sites of caspase-3/-7 activity 
inside the cell.   
 Subcellular localization of 2h in fixed cells.  Toward the first and second goals, 
live cell imaging was used with 2h and SK-MEL-5 (human melanoma) cells; these 
adherent cells are a convenient cell line for microscopy studies.  SK-MEL-5 cells were 
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treated with 25 μM 2h for 1 hour, washed with media lacking phenol red, and further 
incubated for 2 hours.  Cells were then imaged using a Leica multiphoton confocal 
microscope.  Cells treated with 2h show clear fluorescence in the cytoplasm, with little 
staining observed in the nucleus (Figure 2.27); the DNA in this experiment was stained 
with the SYBR green nucleic acid dye and pseudo-colored blue in Figure 2.27.  The 
image in Figure 2.27 is representative of wider field images (see Figure 2.28) that show a 
similar staining pattern in ~50% of cells.  The other ~50% of cells are either dead or lack 
staining all together.  Furthermore, a punctate cytoplasmic staining pattern is observed for 
2h (Figure 2.27).  This punctate staining is similar to the localization pattern observed by 
other fluorescent zinc chelators,77,78,89-91 and is hypothesized to be a visualization of the 
“zincosome”.82,92-94  The punctate staining pattern indicates that 2h readily crosses the cell 
membrane in a short period of time (<1 hour) and suggests that 2h chelates zinc in the 
cell. 
 
Figure 2.27.  2h (pseudo-colored green) localizes to the cytoplasm in SK-MEL-5 cells and gives punctate 
staining similar to other fluorescent zinc chelators (see text).  DNA was stained with SYBR green and 
pseudo-colored blue.  Taken with permission from J. Med. Chem.  2009, 52 (18), 5721-5731. 
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Figure 2.28.  Cellular localization of AF350-PAC-1.  Wide field images showing the localization of 
AF350-PAC-1 in SK-MEL-5 cells.  Taken with permission from J. Med. Chem.  2009, 52 (18), 5721-5731. 
 
2.4.5 Subcellular localization of procaspase-3 
 To determine how these localized areas of caspase-3 activity compared to the total 
population of procaspase-3, we utilized a rabbit anti-caspase-3 antibody that recognizes 
both active caspase-3 and procaspase-3.  SK-MEL-5 cells were treated with either DMSO 
or 25 μM PAC-1 for 1 hour.  The cells were then washed with media lacking phenol red 
and allowed to incubate further for 2 hours.  At this point the cells were fixed and stained 
with the anti-caspase-3 primary antibody, followed by an anti-rabbit Alexa Fluor 647 
secondary antibody, and mounted on slides.  All cells were imaged on a Leica multi-
photon confocal microscope.  In the immunofluorescent images, procaspase-3/caspase-3 
localization is confined to the cytoplasm (Figure 2.29, bottom) as is consistent with 
results in the literature.95  Thus, upon short treatments with PAC-1 there is no obvious 
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change in the amounts or localization of procaspase-3/caspase-3.  Analysis of the images 
in Figure 2.29 suggests that a sub-population of the procaspase-3 is being activated to 
caspase-3 in the PAC-1 treated cells.  
 
Figure 2.29.  (Top) Activity of caspase-3 in vehicle-treated and PAC-1 treated SK-MEL-5 cells.  Cells 
were treated with either DMSO or PAC-1 (25 µM), and then treated with FAM-DEVD-fmk (25 µM), a 
caspase-3/-7 inhibitor that will covalently append a fluorophore to enzymes that possess caspase-3/-7 
activity.  (Bottom) Visualization of the entire procaspase-3/caspase-3 population of SK-MEL-5 cells using 
an antibody to caspase-3.  Taken with permission from J. Med. Chem.  2009, 52 (18), 5721-5731. 
 
2.4.6 Activation of cellular procaspase-3 
 Visualization of PAC-1-induced activation of procaspase-3 in live cells.  
Because PAC-1 is known to relieve zinc-mediated inhibition of both procaspase-3/7 and 
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active caspase-3/7 in vitro,60 we sought to investigate this phenomenon in cell culture.   
To determine the effect of PAC-1 treatment on the activity of procaspase-3/-7 and 
caspase-3/-7 in the cell, PAC-1 (not 2h) was utilized in conjunction with a fluorescently-
labeled, irreversible peptidic inhibitor of caspase-3 and -7, known as FAM-DEVD-fmk.  
FAM-DEVD-fmk is a cell permeable carboxyfluorescein conjugated peptide that 
irreversibly alkylates the active site cysteine in active caspase-3 and -7 via its 
fluoromethyl ketone (fmk) warhead,96-98 thus staining with this reagent provides a means 
to visualize caspase-3/-7 activity in the cell.  In the experiment, SK-MEL-5 cells were 
treated with PAC-1 (25 μM) and FAM-DEVD-fmk (25 μM).  After incubation with these 
compounds for 1 hour, the cells were washed with media lacking phenol red and further 
incubated for 2 hours.  Cells were then imaged using a Leica multiphoton confocal 
microscope.  In these live cell images the active caspase-3/-7 population within cells can 
be observed with minimal interference from the inactive procaspase-3/-7.  As shown in 
Figure 2.29 (top), in vehicle treated cells only minimal staining is apparent; however, 
upon treatment with PAC-1, the cells exhibit spots of intense fluorescence, indicative of 
caspase-3 activity.  This result indicates that the procaspase-3 in these areas has been 
activated to caspase-3.   
 
 Cellular co-localization of 2h with sites of caspase-3 activity.  To determine if 
the spots of caspase-3/7 activity observed in the image in Figure 2.29 are due to direct 
induction of procaspase-3/-7 activition by PAC-1, we sought to determine if 2h will co-
localize with caspase-3/-7 activity inside the cell.  SK-MEL-5 cells were treated with 
DMSO or 2h and/or FAM-DEVD-fmk for 1 hour.  Cells were then washed in media 
lacking phenol red and incubated for an additional 2 hours before confocal imaging.  
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Visualization at 400 nm (pseudo colored green) and 520 nm (pseudo colored red) reports 
on the cellular localization of 2h and FAM-DEVD-fmk, respectively, and representative 
images are shown from the red channel, green channel, and a merge of the two (top, 
middle, bottom, respectively in Figure 2.26).  Cells treated with vehicle alone showed 
minimal staining in the green and red channels (Figure 2.30A, B, C). 
    
 
Figure 2.30.  Colocalization of 2h with sites of caspase-3/-7 enzymatic activity.  SK-MEL-5 cells treated 
with DMSO show background levels of staining in both the red and green channels (A-C).  Cells treated 
only with FAM-DEVD-fmk do not show any staining above background levels (D-F).  Cells treated only 
with 2h shows punctate staining in the cytoplasm with no increase in the emission at 400 nm (G-I).  Cells 
treated concurrently with 2h and FAM-DEVD-fmk show spots of intense caspase-3/-7 activity (pseudo-
colored red) and punctate staining of 2h (pseudo-colored green), which exhibit good co-localization in the 
merged image (J-L).  Taken with permission from J. Med. Chem.  2009, 52 (18), 5721-5731. 
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In cells that are stained with the FAM-DEVD-fmk caspase-3/-7 inhibitor, there is 
very little additional staining observed over background (Figure 2.30D, E, F).  Cells that 
were treated with 2h showed punctate cytoplasmic staining in the green channel with no 
bleed-through to the red channel, consistent with data in Figure 2.29 (Figure 2.30G, H, I).  
However, when cells are treated with both 2h and FAM-DEVD-fmk, staining 
corresponding to active caspase-3/-7 is observed in a similar staining pattern to the 2h 
staining (Figure 2.30J, K, L).  In fact, the majority of this staining overlaps in the merged 
image (Figure 2.30L) – this overlap was quantified as 52% using Image J software over 
12 cells (Figure 2.31).99  Combined, the results suggests that there is low/no basal cellular 
caspase-3/-7 activity in these cells, but that procaspase-3/-7 becomes rapidly activated in 
the presence of 2h.  In addition, the sites of intense cellular caspase-3/-7 enzymatic 
activity overlap considerably with the sub-cellular localization of AFC350-PAC-1, 
suggesting that AFC350-PAC-1 is responsible for procaspase-3/-7 activation at these 
sites.  
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Figure 2.31.  Colocalization of AF350-PAC-1 and caspase-3/-7.  Wide field images showing the 
colocalization of AF350-PAC-1 and spots of intense caspase-3/-7 activity as visualized by FAM-DEVD-
fmk.  Taken with permission from J. Med. Chem.  2009, 52 (18), 5721-5731. 
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in the feed forward cycle.  Indeed, there was good association between caspase-3 activity 
elevations and time-dependent cytotoxicity for 10 µM PAC-1 (Figures 2.32a, c, e and 
Figure 2.33a-c).  Incubation times with PAC-1 for 48 hours produced the greatest 
percentage of apoptotic cells (Figures 2.32b,d, and f), which corresponded with the 
relative greatest cell lysate caspase-3 activity in all three B-cell lymphoma lines evaluated 
(Figure 2.33a-c).  Similar trends between caspase-3 activation and induced cytotoxicity 
were also observed with 20 µM PAC-1 (data not shown).  Interestingly, incubation times 
of ≤ 4 hours with PAC-1 (10 or 20 µM), failed to significantly increase cell lysate 
caspase-3 activity above vehicle-treated control cells, suggesting that a minimum 
threshold exists for how long cells must be exposed to PAC-1 before activating sufficient 
quantities of procaspase-3 necessary to irreversibly trigger apoptosis.  
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Figure 2.32. PAC-1 exerts time- and dose-dependent apoptotic effects.  The ability of PAC-1 to induce 
apoptosis is influenced by exposure durations and concentrations.  Treatment conditions which resulted in 
significant increases in the percentage of apoptotic cells (annexin V staining) compared to control cells 
incubated with media (M) alone represented by double asterisks with p < 0.01.  17-71 (a, b) and CA46 (e, f) 
cell lines are more sensitive to the apoptotic effects of PAC-1 in comparison with the GL-1 (c, d) cell line. 
Vehicle control (VC) and all PAC-1 concentrations are in µM.  Error bars represent standard deviation, n = 
5. Taken with permission from Invest. New Drugs.  2010, DOI: 10.1007/s10637-010-9445-z. 
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Figure 2.33. Observed apoptosis correlates with caspase-3 activity in cell lysate.  Time- and dose-
dependent apoptotic death induced by PAC-1 is correlated with increases in caspase-3 activity.  
Concentrations of PAC-1 ranging from 10-20 µM significantly increase caspase-3 activities (as measured 
by mean optical densities) in 17-71 (a), GL-1 (b), and CA46 (c) cell lines, but requires greater than 4 hours 
of drug exposure.  At 10 µM PAC-1 concentrations, treatment conditions which induce significant 
increases in caspase-3 activities above vehicle control treated cells (Hour 0) is represented by double 
asterisk, p < 0.01.  Error bars represent standard deviation, n = 4. Taken with permission from Invest. New 
Drugs.  2010, DOI: 10.1007/s10637-010-9445-z. 
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2.4.8 Gene expression profiling 
 In an effort to further evaluate the cellular response to PAC-1, the expression 
profile of cells treated with PAC-1 was evaluated.  First, mRNA was isolated by 
collegues Dr. Rahul Palchaudhuri and Karen Morrison from HL-60 and U-937 cells that 
were treated with 25 µM PAC-1 for 6 hours, and a transcript profile was generated. At 
this concentration, PAC-1 had a very similar pattern of up- and downregulated transcripts 
in both cell lines. DDIT4, IL8, STC2, JUN, SLC25A24, ATF3, TNF were all among the 
most highly upregulated transcripts in both cell lines compared to DMSO control 
treatment (Figure 2.34).  
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Figure 2.34.  Comparison of the expression profiles of PAC-1 in U937 and HL-60 cells.  Cells were 
treated with PAC-1 at 25 µM for 6 hours. Shown are the most up- or down-regulated transcripts (p < 0.05) 
compared to DMSO control cells.  Fold-change values are shown in white. The ranks of transcripts in 
individual profiles are to the right in black text. Spearman rank correlation value of top 200 up- and 
downregulated genes is 0.701. 
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In a second transcript profile experiment, the expression signature of cells treated 
with high (100 µM) and low (25 µM) concentrations of PAC-1 in U-937 cells were 
compared. The transcript profiles between 25 µM and 100 µM PAC-1 have a Spearman 
rank correlation value of 0.436, indicating that the expression signatures are quite 
different. When compared to vehicle-treated cells, only three genes, DDIT4, ATF3, and 
JUN, are shared in the top 30 most upregulated genes for both high and low PAC-1 
treatments. TNF, which ranks among the top 30 most upregulated genes for 25 µM PAC-
1-treated cells, is among the top 30 most downregulated transcripts in the 100 µM PAC-1 
profile (Figure 2.35). The transcript profiling data also suggest potential pathways 
affected and mechanisms of action at the high concentration of PAC-1. Three of the top 
10 most highly upregulated transcripts (DDIT3, PI3KIP1, and HERPUD1) are associated 
with ER stress and unfolded protein response pathways.100-102  As such, we hypothesized 
that at high concentrations, PAC-1 may induce cell death via the ER stress pathway. 
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Figure 2.35.  U-937 cells were treated with PAC-1 at 100 µM for 6 hours.  Shown are the 30 most up- or 
down-regulated transcripts compared to DMSO control cells.  White text: fold change values, red text: 
common genes with PAC-1 treatments at low (25 µM) concentrations.  TNF (indicated with an *) is 
downregulated at high PAC-1 concentrations but shows upregulation at low PAC-1 concentrations. 
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Further evidence supporting this hypothesis is the similarity of the expression 
signatures of PAC-1 and thapsigargin using the Connectivity Map.  The Connectivity 
Map database contains 7000 gene expression profiles representing about 1300 individual 
compounds.103 In comparison with the expression signature of 100 µM PAC-1, 
thapsigargin was the top permuted compound from the database with the most similar 
gene expression signature (Table 2.2). As a sarco/endoplasmic reticulum calcium ATPase 
(SERCA) inhibitor, thapsigargin induces ER stress as the ER calcium stores are depleted 
by an inhibition of the ability of the ER to pump Ca2+.104  Thus, this similar profile to 
thapsigargin supports ER stress as a possible mechanism for PAC-1 at high 
concentrations. 
 
Table 2.2.  100 µM PAC-1 permuted Connectivity Map results   
 
 
2.5 Second-Generation Libraries 
 The results described in the preceding sections highlight the unique properties of 
PAC-1 and the therapeutic potential of this class of compounds.  Despite the promising 
results from PAC-1, further development of this class of compounds is hampered by low 
aqueous solubility, high hydrophobicity and functional groups that are susceptible to 
metabolic modification.  The specific challenges posed by these properties are discussed 
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in Chapter 3 but here highlight the need for the evaluation of additional PAC-1 
derivatives that may improve on these properties.  Fortunately, the structure-activity 
relationship provides important information on the mechanism of action of this class of 
compound as well as highlighting the structural characteristics necessary for activity.  
Together this data informed our design and investigation of second-generation PAC-1 
compounds. 
2.5.1 Ring Electronics 
 With the intent of investigating the size and electronics of the right and left rings 
of PAC-1, 30 derivatives were synthesized by Dr. Danny Hsu (Figure 2.36) in which the 
core N-acyl hydrazine motif was maintained but modifications to the right and left rings 
were expanded beyond what was evaluated in the initial structure-activity relationship 
study.  Molecular modeling performed by Dr. Danny Hsu of PAC-1 has suggested that 
PAC-1 binds zinc with a wrapped conformation that allows the benzyl ring to participate 
in the coordination through cation-pi interactions (Figure 2.37).  This hypothesis is 
further supported by our SAR where compounds that do modify the position or 
electronics of the benzyl ring exhibit reduced metal binding and activity.  Structurally 
related compound in the literature105,106 that do not possess a benzyl ring bind metals with 
a 2:1 stoichiometry while PAC-1 binds zinc with a 1:1 stoichiometry.  Taken together 
this data supports a binding mode that involves not only the ortho hydroxyl group, but 
also the benzyl group. 
In an effort to further evaluate the role of this benzyl group Dr. Danny Hsu 
synthesized a number of compounds with substituents that would be predicted to modify 
the electronics of the benzyl ring in hopes of identifying derivatives that can more readily 
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chelate zinc. For example, the halide in PAC-1-II-10 is pi donating and should enhance 
the electron density of the benzyl ring.  Conversely, the carboxylic acid on PAC-1-II-8 is 
withdrawing and should reduce the electron density of the benzyl ring. 
We also modified the right ring with the hopes that modification of the electronics 
of this ring might effect the coordination through the hydroxyl position.   For example, 
the methoxy groups on PAC-1-III-3 are donating and should enhance the coordination 
through the hydroxyl, while the nitro groups on PAC-1-III-16 are withdrawing and 
should interfere with the coordination of the hydroxyl. 
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Figure 2.36 PAC-1 derivatives modifying the size and electronics of the right and left rings. 
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Figure 2.37.  Molecular modeling of the PAC-1:Zn2+ interaction.  The model shows metal coordination 
through the carbonyl, hydroxyl and benzyl ring.  The model is the lowest energy conformation from a 
conformational search out of 23 low-energy conformers using MMFF force field.   
2.5.2 Solubility 
 With the intent of producing compounds with greater solubility and polarity than 
PAC-1, a second library of 17 compounds was designed and synthesized by Chris 
Novotny based on the use of a triazole motif (Figure 2.38).  This strategy allowed for the 
generation of compounds with a wide range of polarity while maintaining the same core 
structure.  For example, the hydroxyl group on PAC-1-II-13 provides a polar group on 
this end of the molecule, while the alkyl chanin on PAC-1-II-28 imparts significant non-
polar nature to this compound.  In this manner we able to evaluate the role of polarity on 
the efficacy of PAC-1 compounds. 
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Figure 2.38.  PAC-1 triazole derivatives designed to evaluate the effect of polarity on activity. 
 
 
2.5.3 Biological evaluation of second-generation compounds 
 The compounds designed in Figures 2.36 and 2.38 were evaluated in cell culture 
to determine the effect of these modifications on the cytotoxic activity.  For compounds 
PAC-1-III-7 through PAC-1-III-18, U-937 cells were treated with compound at 10 µM 
for 24 hours.  Cell death was then evaluated by a propidium iodide displacement assay 
using flow cytometry.  The percent cell death is reported in Table 2.3A. 
 For compounds PAC-1-II-8 through PAC-1-II-25 and PAC-1-III-2 through 
PAC-1-III-6, cell death was evaluated by sulforhodamine B assay.  U-937 cells were 
incubated with various concentrations of compound for 72 hours.  Cells were then fixed 
by TCA and the percent cell death was evaluated by SRB staining.  IC50 values were 
calculated and are reported in Table 2.3B. 
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Table 2.3 Biological properties of second-generation compounds. 
 Clear trends are difficult to determine from this data.  This is likely due to the 
complex nature of cell death as an endpoint.  There are many factors that may play a role 
in the cytotoxicity of a compound beyond polarity, electronics and metal chelation.  
Differences in functional groups likely play a role in other critical processes such as cell 
permeability, metabolism and kinetics. 
2.5.4  In vitro evaluation of S-PAC-1 
Of the second-generation compounds synthesized, S-PAC-1 (PAC-1-II-9 in 
Figure 2.36) is particularly promising based on cytotoxicity, solubility, and LogBB 
(described in detail in chapter 3) as a candidate to move forward with in vivo testing.  
Prior to initiating in vivo testing with S-PAC-1 we sought to fully characterize the 
activity of this compound in vitro. 
S-PAC-1 binds zinc in vitro.  The activity of S-PAC-1 was characterized in 
several biochemical assays analogous to previously performed PAC-1 studies60,61.  An 
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EGTA competition titration experiment78 was used by Dr. Danny Hsu to determine the 
binding constant for the S-PAC-1:Zn2+ complex.  In the presence of EGTA, the changes 
in the fluorescence of the S-PAC-1:Zn2+ complex were used to plot a formation curve 
(Figure 2.39B).  Using the known binding constant of EGTA, the free zinc concentration 
can be calculated and used to determine the binding constant of the S-PAC-1:Zn2+ 
complex.  This complex has a Kd of 46 ± 5 nM compared to 52 ± 2 nM for PAC-1:Zn2+61. 
 
Figure 2.39.  In vitro assessment of PAC-1 and S-PAC-1.  A, Structures of PAC-1 and S-PAC-1. B, The 
formation curve of the Zn2+:S-PAC-1 complex as determined by EGTA titration.  S-PAC-1 binds zinc with 
a Kd of 46±5 nM.  Error bars represent SEM (n=3). C, PAC-1 and S-PAC-1 induce rapid relief of zinc-
mediated inhibition of procaspase-3 (D3A).  Using a chromogenic Ac-DEVD-pNA substrate, the activity of 
procaspase-3 (7.5 µM) was assessed in the presence of inhibitory zinc (10 µM) and vehicle, PAC-1 or S-
PAC-1 (50 µM).  Maximal activity is observed after a 5-minute incubation with compound.  Error bars 
represent the SEM (n=3). D, PAC-1 and S-PAC-1 both induce apoptotic cell death in U-937 cells as 
demonstrated by a population of annexin V positive, PI negative cells. Data shown is representative of 
three separate experiments.  Taken with permission from Cancer Res.  2010, 70 (18), 7232-7241. 
 
S-PAC-1 activates procaspase-3 in vitro.  The ability of S-PAC-1 to activate 
recombinantly expressed procaspase-3 in the presence of exogenous zinc was assessed in 
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vitro.  To ensure that the enzymatic activity of the proenzyme was being monitored, a 
proteolytically uncleavable mutant of procaspase-3 was used in which the three aspartic 
acid cleavage site residues are mutated to alanine (D9A/D28A/D175A).40,60  This 
uncleavable form of procaspase-3 in not capable of processing to the mature active 
caspase-3, thus ensuring that any increase in activity observed is due to an increase in the 
activity of the proenzyme rather than autoproteolysis of the proenzyme.  As shown in 
Figure 2.39C, S-PAC-1 rapidly (within 5 minutes) enhances the enzymatic activity of the 
proenzyme by relief of zinc-mediated inhibition, although to a lesser degree than PAC-1. 
  
S-PAC-1 induces death in multiple cancer cell lines in culture.  Having confirmed 
that S-PAC-1 chelates zinc and activates procaspase-3 in vitro, the antineoplastic activity 
of S-PAC-1 was assessed against a panel of human, canine, and murine cancer cell lines 
using the sulforhodamine B assay.79  The 72 hour IC50 values for PAC-1 and S-PAC-1 
are reported in Table 2.4.  Both PAC-1 and S-PAC-1 have micromolar cytotoxic IC50 
values against all lymphoma cell lines tested regardless of the species of origin.  U-937 
cells treated with DMSO, 50 µM PAC-1 or 50 µM S-PAC-1 for 12 hours were assessed 
by annexin V/PI staining and analyzed by flow cytometry Figure 2.39D.  Both PAC-1 
and S-PAC-1 treatment lead to a similar increase in the population of apoptotic cells 
(annexin V positive, PI negative).   
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Table 2.4.  Assessment of PAC-1 and S-PAC-1 cytotoxicity in cancer cell lines.  Cells were exposed to 
compound for the time indicated, compound was washed out, and cell viability/biomass assessment was 
made after 72 hours. Taken with permission from Cancer Res.  2010, 70 (18), 7232-7241. 
Cell line Species Origin Exposure Time (h) 
S-PAC-1 72 
hour IC50  (µM) 
PAC-1 72    
hour IC50  (µM) 
U-937 Human Lymphoma 1 >100 -- 
   3 >100 -- 
   6 >100 -- 
   9 20 ± 12 -- 
   12 9.7 ± 1.1 -- 
   24 5.9 ± 1.0 -- 
   48 5.6 ± 0.8 -- 
   72 6.4 ± 0.8 9.3 ± 0.5 
EL-4 Mouse Lymphoma 72 7.1 ± 1.3 3.8 ± 0.9 
17-71a Dog Lymphoma 72 2.7 ± 0.8 2.5 ± 0.9 
GL-1 Dog Lymphoma 72 7.1 ± 0.3 4.9 ± 0.3 
OSW Dog Lymphoma 72 11.0 ± 0.9 8.6 ± 1.3 
Jurkat Human Leukemia 72 4.5 ± 1.1 5.7 ± 2.8 
SK-Mel-5 Human Melanoma 72 8.6 ± 1.3 11.5 ± 3.6 
HeLa Human Cervical 72 28.4 ± 7.7 15.5 ± 3.8 
MDA-MB-231 Human Breast 72 11.7 ± 5.3 9.9 ± 1.0 
aThis cell line was assessed using the MTS cell viability assay.  All other cell lines were assessed with the 
sulforhodamine B assay. 
Error is SEM, n = 3 
 
In order to confirm that the cytotoxicity of S-PAC-1 is related to the zinc 
chelating ability of the compound, we evaluated two derivatives of S-PAC-1 that are not 
able to chelate zinc for their ability to induce apoptosis.  As shown in Figure 2.40, S-
PAC-1 induces apoptosis in U937 cells treated with 50 µM compound for 24 hours.  The 
two compounds that do not chelate zinc are not able to induce apoptosis under these 
conditions. 
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Figure 2.40.  Evaluation of S-PAC-1 and S-PAC-1 derivatives for their ability to induce apoptosis in U937 
cells.  U937 cells were treated with 50 µM compound for 24 hours after which they were stained with 
Annexin V/PI and evaluated by flow cytometry. 
 
 
In an effort to determine an appropriate treatment strategy for the evaluation of S-
PAC-1 in vivo, the time dependency of S-PAC-1 cytotoxicity was evaluated.  U-937 
cells were treated with S-PAC-1 for various lengths of time.  After treatment with S-
PAC-1, cells were washed to remove compound and were cultured in growth media 
without compound.  Cell death was assessed at 72 hours for all treatment times.  An IC50 
value was determined for each exposure time and reported in Table 2.4.  At times shorter 
than 6 hours, the IC50 value was greater than the highest concentration tested.   Between 
12 and 24 hours the IC50 value rapidly decreased to a minimum and showed little 
variation over the course of the subsequent 48 hours.  These time dependency 
experiments suggest that S-PAC-1 will be most effective in vivo if cancer cells are 
exposed to the compound for at least 24 hours.  
Having confirmed that S-PAC-1 and PAC-1 possesses similar properties, the 
functional response of S-PAC-1 in cells was evaluated.  In analogous experiments to 
those described in preceding sections for PAC-1, the cell permeability of S-PAC-1 was 
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evaluated by collaborator, Dr. Tim Fan.  Neuro-2a murine neuroblastoma cells were 
treated with PAC-1 and S-PAC-1 (solubilized in HPβCD) at 50 µM for 30 minutes. 
Following compound exposure and cell lysis, the lysates were analyzed by HPLC for 
intracellular compound concentration.  Figure 2.41 shows the cellular concentration of 
PAC-1 and S-PAC-1.  Both PAC-1 and S-PAC-1 show similar levels of intracellular 
compound suggesting that both compounds are able to readily cross the cell membrane.  
This is encouraging given the large difference in polarity of these compounds.    
 
 
Figure 2.41. Neuronal cellular membrane and BBB permeabilities of PAC-1 and S-PAC-1.  Mean 
concentrations of intracellular PAC-1 or S-PAC-1 within Neuro-2a cells following incubation with 50 µM 
PAC-1 or S-PAC-1 for 30 minutes. Experiment performed in triplicate, p > 0.5. 
 
 The evaluation of intracellular zinc levels by collaborator, Dr. Amy Palmer and 
coworkers, in response to S-PAC-1 provides further evidence that PAC-1 and S-PAC-1 
demonstrate similar activity.  Indeed, similar to PAC-1, HeLa cells containing the 
ZapCY2 genetically encoded sensor that are treated with S-PAC-1 show a significant 
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decrease in FRET signal (Figure 2.42) suggesting that S-PAC-1 is able to chelate 
intracellular zinc.  The response of labile cellular zinc levels to PAC-1 and S-PAC-1 is 
rapid with a significant reduction in FRET occurring within the first 10 minutes of 
compound exposure.   
 
Figure 2.42. Changes in intracellular zinc concentration upon S-PAC-1 treatment. FRET ratio changes 
in HeLa cells using the genetically-encoded zinc sensor ZapCY2. Graphs of a representative individual 
experiment show a decrease in intracellular free zinc in five cells treated with 10 µM S-PAC-1 followed by 
50 µM S-PAC-1. 
 
 
 Given the similar activity of PAC-1 and S-PAC-1 in the preceding experiments, 
it is perhaps not surprising that these compounds elicit a similar transcriptional response.  
At  25 µM, PAC-1 and S-PAC-1 have a very similar pattern of up- and downregulated 
transcripts (Figure 2.43). The Spearman rank correlation value,107 a measure of similarity, 
is 0.928 for PAC-1 and S-PAC-1 profiles (using the top 200 up- and downregulated 
genes). These results indicate that at 25 µM, PAC-1 and S-PAC-1 act on cancer cells in a 
remarkably similar manner. 
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Figure 2.43.  Expression profiles for PAC-1 and S-PAC-1.  HL-60 cells were treated with PAC-1 or S-
PAC-1 at 25 µM for 6 hours.  Shown are the most up- or down-regulated transcripts (p < 0.05) compared to 
DMSO control cells.  White text: Fold-change values, black text: the ranks of transcripts in individual 
profiles. 
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 The comparison of PAC-1 and S-PAC-1 suggest that these compounds exhibit 
many of the same properties and share a common mechanism of actions, namely, the 
activation of procaspase-3 through relief of zinc-mediated inhibition.  Given the 
similarity of these compounds, it is promising that they will have similar in vivo 
properties.  The in vivo evaluation of these compounds is described in chapter 3. 
2.6 Summary 
The data presented in this chapter demonstrate that PAC-1 activates procaspase-3 
in vitro through the sequestration of inhibitory metals.  While it had been previously 
shown that modest levels of activation of procaspase-3 (and no activation of caspase-3) 
by PAC-1 are observed in complex buffer systems,45 we now show that in buffers 
consisting simply of Tris and NaCl, powerful PAC-1-mediated activation of procaspase-
3 and caspase-3 is observed.  Treatment of these buffers with Chelex® removes inhibitory 
divalent metals, allowing the enzymes to be fully active and thus abolishing the PAC-1-
mediated activation.  Consistent with this hypothesis is the fact that PAC-1 binds quite 
tightly to zinc, with a Kd = 42 nM.  A structurally related compound that does not bind 
zinc, PAC-1a, does not activate procaspase-3 in vitro, and does not induce death of 
cancer cells in culture.  
PAC-1 is a novel experimental therapeutic that has shown efficacy in several 
mouse models of cancer.45  It was recently discovered that PAC-1 enhances the activity 
of procaspase-3, procaspase-7, caspase-3, and caspase-7 in vitro through the chelation of 
inhibitory zinc ions.60  To probe the relevance of this in vitro mechanism to the anticancer 
activity of PAC-1 in cell culture, we determined a full structure-activity relationship for 
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PAC-1 with respect to its ability to induce death in cancer cells in culture, its ability to 
activate caspase-3 in vitro, and its ability to chelate zinc.  We then used this information 
to construct a fluorescent derivative of PAC-1 that could be used to track sub-cellular 
localization.  The information obtained through these experiments not only sheds light on 
the mechanism by which PAC-1 induces death in cancer cells, but also on the role of 
cellular zinc as an endogenous anti-apoptotic agent. 
 Evaluation of 26 PAC-1 derivatives suggests an intimate link between the metal 
chelating properties of the compounds and their ability to induce caspase-3 activation in 
vitro and to induce death in U-937 cells in culture.  Significantly, any alteration to the 
ortho-hydroxy N-acylhydrazone motif results in compounds with no ability to bind zinc 
and low/no activity in the caspase-3 activation and cell death assays.  This data is 
consistent with a large body of literature showing that ortho-hydroxy N-acylhydrazones 
are metal chelators.73,74,105,106,108-111  Conversely, other sites on PAC-1 could be altered 
without losing activity in these three assays.  Minimally, this data suggests that the metal 
chelating moiety of PAC-1 is critical to the anticancer properties of this compound. 
 Procaspase-3 is known to reside in the cytoplasm95,112 where it remains in an 
inactive form until it is cleaved by upstream apoptotic caspases.38  Several studies have 
shown that procaspase-3 is capable of autoactivation in vitro,4,40,60 although the relevance 
of this mode of activation in vivo is unclear.  Our hypothesis for the mode of action of 
PAC-1 induced cell death is that it relieves the zinc-mediated inhibition of procaspase-3, 
allowing procaspase-3 to use its enzymatic activity to cleave another molecule of 
procaspase-3, resulting in the active caspase-3.60  Once this occurs, the process 
accelerates – any caspase-3 generated can then cleave procaspase-3 (this is known to 
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occur in vitro40) in a feed-forward cycle.  We conducted a series of experiments designed 
to investigate if PAC-1 directly induces caspase-3 activity in the cell, and if PAC-1 does 
so through the direct activation of procaspase-3. 
 In an initial experiment, the population of active caspase-3 in PAC-1 treated cells 
was examined relative to vehicle treated controls, and relative to the population of 
cellular procaspase-3.  As might be expected, we found that there is very little caspase-3 
activity in actively growing SK-MEL-5 cells in culture (as assessed by the fluorescent 
caspase-3/-7 substrate).  In contrast, the cytoplasm shows considerable procaspase-3 (as 
assessed with antibody staining).  These results are shown in the left panels of Figure 
2.29.  Treatment of cells with PAC-1 for 1 hr induced strong localized spots of caspase-
3/-7 activity (Figure 2.29, top right), indicating that PAC-1 causes the rapid elevation of 
caspase-3/-7 enzymatic activity.  By employing a fluorescently-labeled version of PAC-1 
(compound 2h) we were then able to determine that 2h co-localizes to the spots of 
intense caspase-3/-7 activity (Figure 2.30).  This co-localization data is perhaps the 
strongest evidence to date supporting the notion that PAC-1 directly induces procaspase-
3 activation inside the cancer cell. 
Notably, the effect of PAC-1 on cellular zinc levels taken together with in vitro 
data for PAC-1a demonstrates a direct correlation between the cytotoxic potential of 
PAC-1 and its ability to bind zinc.  Additionally, zinc has been previously shown to 
colocalize with procaspase-3 inside cells.36,83  Based on the zinc—procaspase-3 co-
localization data and other data, it has been previously suggested that zinc binds to and 
inhibits procaspase-3 inside the cell.36,113  Although alternate mechanisms are possible, 
these data, combined with our in vitro data showing PAC-1-mediated activation of 
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procaspase-3 by metal sequestration, leads us to the following hypothesis:  PAC-1 enters 
cells where, with a Kd of 42 nM, it competes favorably for the labile zinc pool to reduce 
the levels of zinc available to inhibit procaspase-3, thus resulting in procaspase-3 
autoactivation to caspase-3.  Even with an enzymatic rate 200-fold less than caspase-3, 
procaspase-3 is active enough to catalyze the hydrolysis of other molecules of 
procaspase-3, thus activating them to caspase-3.  Once caspase-3 is generated it can 
activate more procaspase-3, caspase-3 substrates are cleaved, and apoptosis occurs.  
This model for the cytotoxicity of PAC-1 is supported by several lines of 
evidence:  Rapid caspase-3/-7 activity is seen in cells treated with PAC-1, both in whole 
cell experiments where caspase-3 activity is measured with chromogenic substrates,45 and 
in microscopy experiments where caspase-3 activity can be assessed with a fluorescent 
inhibitor (Figure 2.29).  In addition, caspase-3 activity is observed before mitochondrial 
membrane depolarization in PAC-1 treated cells.45  Also, exogenous zinc inhibits the 
apoptosis-inducing effect of PAC-1,60 and zinc co-localizes with cellular procaspase-
3.36,83  Finally and perhaps most significantly, a fluorescent version of PAC-1 co-localizes 
with sites of cellular caspase-3 activity. 
Examination of the literature lends ample support to this hypothesis.  There are 
multiple reports that describe the ability of zinc chelators to induce apoptosis.114  Perhaps 
the most detailed and convincing studies have been performed with the zinc chelator 
N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN).  In several different cell 
lines and systems, TPEN has been found to strongly induce apoptosis.90,115-118  Other 
studies have shown that small changes to the labile zinc content of the cell make cells 
more susceptible to apoptosis.91  In light of the data presented herein with PAC-1, and 
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the evidence showing that procaspase-3 is inhibited by zinc, TPEN may be exerting its 
pro-apoptotic effect in a similar manner to PAC-1, through the sequestration of inhibitory 
zinc.  It should be noted that it is also possible that zinc is inhibiting caspase-3 in the 
cancer cell, and that PAC-1, TPEN, and other zinc chelators induce apoptosis by 
relieving this inhibition of caspase-3.  The in vitro data presented in Figures 2.4, 2.5, and 
2.9 indicate that PAC-1 does indeed activate zinc-inhibited caspase-3.  Although in a 
number of cancer types the cellular procaspase-3/caspase-3 ratio is skewed heavily 
toward procaspase-3,32,41,57 there is solid evidence in some cancer cell lines and primary 
isolates for the presence significant levels of caspase-3.55,56,67,81 
 The results described herein have ramifications for the development of zinc 
chelators as anticancer agents and for the regulatory role played by zinc in apoptosis.  As 
shown in Figure 2.5(a) and 2.5(b), PAC-1 actually inhibits caspase-3/procaspase-3 
activity at high concentrations, thus PAC-1 analogues that lack this effect (but still 
strongly chelate zinc) might be more potent proapoptotic agents.  Furthermore, the 
addition of PAC-1 to caspase-3/procaspase-3 in Zn-containing buffer restores enzymatic 
activity to 40-60% of the levels in the absence of Zn (Figures 2.5(a), 2.5(b), 2.5(c)), thus 
it is possible that PAC-1 analogues that more fully activate caspase-3/procaspase-3 may 
be more potent anticancer agents.  Finally, the data presented herein support the notion 
that cellular zinc plays an antiapoptotic role by inhibiting latent procaspase-3 activity.  
The identification of more potent versions of PAC-1, the evaluation of PAC-1 and 
derivatives in multiple animal models of cancer, and the role of zinc in procaspase-3 
inhibition in vivo are all being actively investigated in our laboratory and the results will 
be presented in due course. 
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 Relative to other zinc chelators, PAC-1 appears to have the proper combination of 
moderate affinity for zinc while still retaining the ability to rapidly penetrate cells – 
modest zinc affinity allowing for chelation of the loosely bound zinc pool, with sufficient 
hydrophilicity to promote cell permeability.  It is unlikely that PAC-1 is special in this 
regard; other cell-permeable, moderate-affinity zinc chelators are likely to induce death 
through a similar mechanism as PAC-1.  It is also unlikely that PAC-1 removes zinc only 
from procaspase-3.  The full effect of chelating the loosely-bound cellular zinc pools 
remains to be uncovered; indeed, the results of PAC-1 may explain the mode of action of 
other known zinc-chelating anticancer agents.114,119 
 In summary, the SAR we have established herein for PAC-1 paves the way for 
the development of even more potent versions of this compound.  The design, synthesis, 
and evaluation of 2h has allowed us to gather further data supporting the hypothesis that 
PAC-1 directly activates cellular procaspase-3 through the chelation of inhibitory zinc 
ions.  As PAC-1 is the first small molecule reported to directly activate procaspase-3, the 
data reported herein is critical for the continued understanding and advancement of 
procaspase-3 activation as an anticancer strategy.   The development and in vivo testing 
of more potent versions of PAC-1 and further investigations into the anti-apoptotic role 
of cellular zinc are underway in our laboratories, and these results will be presented in 
due course. 
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2.7 Materials and Methods 
Materials.  All reagents were obtained from Fisher unless otherwise indicated.  
All buffer solutions were made with Milli-Q purified water.  PAC-1 and PAC-1a (Figure 
2.1(a)) were synthesized as described.45  PAC-1 and derivatives were synthesized as 
previously described and as described herein.  Ac-DEVD-pNA was synthesized as 
described.120  Luria Broth (LB) was obtained from EMD.  Etoposide was obtained from 
Sigma.  Caspase Assay Buffer contains 50 mM HEPES pH 7.4, 100 mM NaCl, 10 mM 
DTT, 0.1 mM EDTA Disodium Salt, 0.10% CHAPS, 10% glycerol.  Ni NTA Binding 
Buffer contains 50 mM Tris pH 8.0, 300 mM NaCl, 10 mM imidazole.  Ni NTA Wash 
Buffer contains 50 mM Tris pH 8.0, 300 mM NaCl, 20 mM imidazole.  Ni NTA Elution 
Buffer contains 50 mM Tris pH 8.0, 300 mM NaCl, 500 mM imidazole.  Annexin V 
Binding Buffer contains 10 mM HEPES pH 7.4, 140 mM NaCl, 2.5 mM CaCl2, 0.1% 
BSA.  The C-terminal 6xHis-tagged procaspase-3 proteins were expressed and purified as 
described below.  The 2xSDS sample buffer contains 100 mM Tris-Cl (pH 6.8), 200 mM 
DTT, 4% (w/v) SDS, 0.2% bromophenol blue, 20% (v/v) glycerol.  Towbin Transfer 
Buffer contains 25 mM TRIS (pH 8.3), 192 mM Glycine, 0.1% (w/v) SDS, 20% (v/v) 
MeOH. 
 Strains and Plasmids.  Procaspase-3 and caspase-3 were expressed using the 
pHC332 expression plasmid.  The uncleavable mutant (D9A/D28A/D175A) of 
procaspase-3 was created by successive quick change mutations on pHC332 as 
previously described.40  
Recombinant expression and purification of procaspase-3/-7.  Expression of 
procaspase-3/-7 was preformed in the BL21(DE3) strain of Escherichia coli (Novagen) 
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similar to that previously described.45  Briefly, plasmids encoding for the C-terminally 
6xHis-tagged procaspase-3/-7 protein were transformed into electrocompetent BL21.  
The transformants were selected for by growth in ampicillin.  Individual colonies were 
picked and used to inoculate 10 mL seed cultures of LB with ampicillin (100 µg/mL) for 
expression.  Seed cultures were used to inoculate 2 L cultures of LB which were grown at 
37oC to an OD600 = 0.6.  Protein expression was induced via the addition of IPTG to a 
final concentration of 0.5 mM; after addition of IPTG the culture was incubated at 37oC 
with shaking for 20 additional minutes.  Bacterial cultures were then pelleted by 
centrifugation (at 5000 x g, 5 min, 4oC) and lysed by pulse sonication on ice for five 
minutes in the presence of 30 mL Ni NTA binding Buffer.  Bacterial debris was removed 
by centrifugation (at 35,000 x g, 30 min, 4oC) and the 6xHis-tagged protein was purified 
from the supernatant with 1 mL 50% slurry Ni NTA resin (Qiagen).  Protein was batch 
loaded onto the resin for 1 hr at 4°C.  The bound resin was applied to a disposable 
column and the resin was washed with 15 mL of Ni NTA Wash Buffer.  The protein was 
then eluted from the column with 10 mL of Ni NTA Elution Buffer.  Fractions (~1 mL) 
were collected and the presence of protein was determined by reaction with the Bradford 
reagent (BioRad).  Fractions containing protein were pooled and flash frozen in liquid 
nitrogen.  Protein was stored at -80 °C.  
Zinc-Free Preparation.  Protein was expressed and purified as above until 
fractions were pooled.  Protein was not flash frozen at this point, but fractions containing 
protein were pooled and applied to a PD-10 column (GE Healthcare) charged with 
HEPES buffer that had been treated with Chelex® resin.  The HEPES buffer consisted of 
50 mM HEPES, 300 mM NaCl, pH = 7.4.  The pH was monitored after treatment with 
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the chelex resin and was found to have not changed.  The protein was eluted using an 
additional 3.5 mL of Chelex®-treated HEPES buffer and the concentration was 
determined using the Edelhoch method for protein quantitation by absorbance at 280 nm.  
Protein isolated directly from the column typically had a concentration of ~50 µM; for 
experiments described herein requiring zinc-free conditions, the protein was typically 
diluted to the desired concentration in HEPES Buffer that had been treated with Chelex® 
resin.  Protein was flash frozen in 500 µL aliquots in liquid nitrogen and stored at -80°C.   
Expression of various caspase forms.  Expression of procaspase-3, procaspase-3 
(D9A/D28A/D175A), procaspase-7, and procaspase-7 (D23A/D198A/D206A) were 
performed as described above.  Expression of caspase-3/-7 was performed as above 
except that the induction time with IPTG was for 4 hours rather than 20 minutes.  
Purification and zinc-free preparations were performed the same for all caspase forms. 
Caspase-3 Activity Assays—Zinc-free stocks (2X) of caspase-3 (1 µM) were 
prepared in Caspase Activity Buffer.  Compound stock solutions were made (2X) at 
various concentrations from 200 µM to 200nM in Caspase Activity Buffer.  A stock 
(10X) of ZnSO4 (25 µM) in Caspase Activity Buffer was prepared.  To each well of 384 
well plate was added 20 µL of caspase-3 (500 nM final), 20 µL compound stock, and 5 
µL of ZnSO4 (2.5 µM final) or buffer.  Each plate contained positive control wells (0 µM 
zinc and no compound) and negative control wells (2.5 µM zinc and no compound).   The 
plates were incubated at room temperature for 30 minutes.  Then, to each well of the plate 
was added 5 µL of a 2 mM stock of Ac-DEVD-pNA substrate and the absorbance at 405 
nm was immediately monitored every 1 minute for 30 minutes on a spectramax plate 
reader (Molecular Devices, Sunny Vale, CA).  The slope of each well was used to 
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determine the activity and was normalized to the positive and negative control wells to 
give a percent activity.  The data for each compound concentration (4 wells) was 
averaged and the percent activity was plotted as a function of compound concentration.  
The data was analyzed using Table Curve 2D and fitted to a logistical dose-response 
curve.  The majority of compounds achieved a maximal activity at 10 µM.  The percent 
activity at 10 µM was determined for each compound and reported as an average of the 
three replicate experiments with the corresponding SEM.  
Buffer Analysis.  Aliquots of standard preparation of procaspase-3 were thawed 
and diluted to 500 nM in either HEPES, TRIS buffer or chelex treated TRIS buffer.  A 45 
µL volume of protein was added to each well of a 384 well plate.  Vehicle or compound 
was added to each well to a final concentration of 50 µM.  The plate was incubated at 
37°C for 2 hours.  A 5 µL volume of a 2 mM stock of Ac-DEVD-pNA was added to the 
plates to a final concentration of 200 µM.  The absorbance of each well at 405 nm was 
monitored in a plate reader every minute for 60 minutes and the progress curve was 
plotted. 
  Metal inhibition.  Aliquots of zinc-free procaspase-3 were thawed and diluted to 
500 nM in Chelex®-treated HEPES buffer.  A 45 µL volume of protein was added to each 
well of a 384 well plate.  Various concentrations of different metals were added to each 
well and the plate was incubated for 2 hours at 37°C.  A 5 µL volume of a 2 mM stock of 
Ac-DEVD-pNA was added to the plates to a final concentration of 200 µM.  The 
absorbance of each well at 405 nm was monitored in a plate reader every minute for 60 
minutes.  The initial slope of each well was determined from the linear portion of the 
progress curve.  This typically included all data points collected.  The slopes were 
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converted to a percent of the inhibition in the absence of metal and were plotted vs. 
concentration.  Data was generated in triplicate.   
In vitro activity assay of procaspase-3.  For experiments described in this chapter 
protein samples were diluted to various concentrations in Ni NTA Elution Buffer.  A 45 
µL solution of the appropriate concentration of procaspase-3 was added to the wells of a 
384 well plate.  A 0.5 µL volume of DMSO or PAC-1 stock solution was added to each 
well to provide the appropriate PAC-1 concentration.  The plate was incubated at 37oC 
for various times.  Activity was assessed by the addition of 5 µL of the chromogenic Ac-
DEVD-pNA substrate (to a final concentration of 1 mM) in Caspase Assay Buffer; this 
concentration was used to ensure that the Ac-DEVD-pNA substrate would be in large 
excess even relative to the highest concentrations of procaspase-3.  The change in 
absorbance at 405 nm was monitored over time and the rate of hydrolysis was determined 
from the linear portion of the initial slopes.   
 Analysis of procaspase-3 activation by PAC-1.  The rate of substrate hydrolysis 
for PAC-1 treated samples was compared to the rate of vehicle-treated controls 
(procaspase-3 without PAC-1).    The initial slopes for the PAC-1 treated and vehicle 
treated wells were determined from the graphs of absorbance versus time; these graphs 
are in the text (Figures 2.13A-C, 2.14A, 2.14B).  Slopes from the raw data (in A405 per 
minute) were converted to µmols of pNA generated per minute via a p-nitroaniline 
calibration curve.  To generate the data in Figure 2.14C, for each protein concentration 
the slope of the vehicle-treated control was subtracted from the slopes of the PAC-1-
treated samples.  The resulting slopes were then plotted versus protein concentration to 
generate the graph in 5D.  Controls were also performed in which PAC-1 was added to 
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the wells, but no procaspase-3 was added; these showed no significant increase in 
absorbance after the addition of Ac-DEVD-pNA. 
 Assay of Procaspase-3/-7 and Caspase-3/-7 Activity.  Stocks of zinc-free enzyme 
were prepared with or without the appropriate amount of zinc and were incubated at room 
temperature for at least 30 minutes prior to addition to compound.  Compound dilutions 
were made from the 10 mM DMSO stock to the appropriate concentration in the 
specified assay buffer and DMSO to maintain a constant amount of DMSO in every well 
(never above 5%).  These were placed into wells of a 384 well plate (20 µL), and then 25 
µL of an appropriately diluted enzyme stock in assay buffer was added to the compound 
wells (1 µM procaspase-3, 1 µM caspase-3, or 5 µM D9A/D28A/D175A procaspase-3, 2 
µM procaspase-7, 2 µM caspase-7, or 10 µM D23A/D198A/D206A procaspase-7).  
Controls containing DMSO and assay buffer without compound or without both 
compound and enzyme were included for each experiment.  For experiments in the 
presence of zinc, a control containing no zinc was also included.  The plates were then 
incubated for 2 hours at 37 ºC.  Then, to each well of the plate was added 5 µL of a 2 mM 
stock of Ac-DEVD-pNA in assay buffer and the absorbance at 405 nm was read every 
minute for one hour using a Spectra Max Plus 384 plate reader (Molecular Devices, 
Sunny Vale, CA).  The slope of each well was used to determine the activity as compared 
to the controls.  The data was plotted as percent activity versus compound concentration, 
and fitted to a logistic dose response curve using OriginPro (OriginLab Software, 
Northampton, MA) or Table Curve (SYSTAT Software, Richmond, CA) if appropriate.  
Data was generated in triplicate and repeated at least three times.  The data presented is 
the average of the triplicate data points and is representative of the replicate experiments.  
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 Assay of zinc inhibition of procaspase-3/-7 and caspase-3/-7 activity.  Aliquots of 
frozen zinc-free protein were thawed and diluted in HEPES buffer (that had been treated 
with Chelex® resin) to the appropriate concentration.   A 40 µL solution of protein was 
added to each well of 384 well plate and 5 µL of various concentrations of zinc were 
added.  Appropriate wells also received PAC-1 to a final concentration of 50 µM.  The 
plate was incubated at 37 °C for 2 hours .  A 5 µL solution of a 2 mM stock of Ac-
DEVD-pNA was added to each well to a final concentration of 200 µM.  The absorbance 
at 405 nm was monitored every minute for 60 minutes and the initial slope determined 
from the linear portion of the progress curve.  The slopes were converted to percent of 
maximal activity (the slope in the absence of zinc) and the data was fitted with a 
logistical dose response curve.  Data was generated in triplicate and repeated at least 
three times.  The data presented is the average of the triplicate data points and is 
representative of the replicate experiments. 
SDS-PAGE analysis of caspase-3 activation.  Aliquots of zinc-free caspase-3 and 
zinc-free procaspase-3 (C163A) were thawed and diluted to the appropriate 
concentration.  A 22.5 µL solution of each protein was added to each of fifteen 0.5 mL 
tubes.  A 5 µL solution of 500 µM ZnSO4 in HEPES Buffer was added to ten tubes to 
obtain a final ZnSO4 concentration of 50 µM.  The remaining five tubes received 5 µL of 
buffer.  The appropriate compound was added (0.5 µL of a 5 mM DMSO stock solution) 
to each tube and the final concentrations were: 10 µM caspase-3, 50 µM procaspase-3 
(C163A), 50 µM ZnSO4 and 50 µM compound.  The tubes were incubated at 37 °C for up 
to 3 hours.  The reaction was stopped by the addition of 2x SDS loading dye and boiling 
for 5 minutes.  A 15 µL volume of each sample was loaded on a 4-20% 15-well pre-cast 
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polyacrylamide gel (BioRad).  The gel was run at 150 V for 45 minutes and stained with 
coomassie brilliant blue. The experiment was run three times each on two different 
batches of protein. 
Western blot analysis of procaspase-3 activation.  Aliquots of zinc-free 
procaspase-3 (D9A/D28A/D175A) and zinc-free procaspase-3 (C163A) were thawed and 
diluted to the appropriate concentration.  A 22.5 µL solution of each protein was added to 
each of twelve 0.5 mL tubes.  A 5 µL solution of 1 mM ZnSO4 in HEPES Buffer was 
added to nine tubes to obtain a final ZnSO4 concentration of 100 µM.  The remaining 
three tubes received 5 µL of buffer.  The appropriate compound was added (0.5 µL of a 5 
mM DMSO stock solution) to each tube and the final concentrations were: 10 µM 
procaspase-3(D9A/D28A/D175A) and 50 µM procaspase-3 (C163A); 100 µM ZnSO4 
and 50 µM compound were added to certain experiments as indicated in Figure 2.10.  The 
tubes were incubated at 37 °C for up to 12 hours.  The reaction was stopped by the 
addition of 2x SDS loading dye and boiling for 5 minutes.  A 15 µL volume of each 
sample was loaded on a 4-20% 15-well pre-cast polyacrylamide gel (BioRad).  The gel 
was run at 150 V for 45 minutes and transferred to a PVDF membrane (Millipore) using a 
wet transfer method (40V for 1 hour). The blot was blocked in 10% milk in PBST for 4 
hours at 4 °C.  The blot was then washed three times for 3 minutes with PBST to remove 
excess milk.  The primary antibody (rabbit polyclonal) against the active fragments of 
caspase-3 (calbiochem) was added at a dilution of 1:2000 and incubated at 4°C for 4 
hours.  The blot was then washed 2 times with PBST and a 1:2000 dilution of a goat-
antirabbit alexa fluor 647 conjugated antibody was applied to the blot and allowed to 
incubate at 4 °C overnight.  The blot was then washed 3 times with PBST and imaged on 
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a Typhoon fluorescence scanner (Molecular Devices, Sunnyvale, CA).  The experiment 
was repeated four times on two different batches of protein and the blot shown is 
representative of the results. 
 Zinc Titration.  Compounds were diluted from their 10 mM DMSO stocks into 3 
mL of buffer A (50 mM Hepes, 100 mM KNO3, pH 7.4) to give a final concentration of 
50 µM in a quartz cuvette.  The absorbance spectrum between 260 and 500 nm was then 
acquired using a Varian Carey 4000 Spectrophotometer (Palo Alto, CA).  Then 5 µL of a 
3 mM ZnSO4 solution in buffer A was added.  The solution was mixed and allowed to 
equilibrate for 30 minutes.  The absorbance spectrum was acquired again.  This process 
was continued until the ZnSO4 concentration had reached 75 µM (addition of 75 µL).   
 Continuous Variations Method.  A series of buffer A solutions of PAC-1 and 
ZnSO4 were prepared such that the sum of metal and ligand concentration was constant 
(50 µM).  The mole fraction of PAC-1 was varied between 0.1 and 1.0.  A series of 
buffer A solutions of PAC-1 alone at the same concentrations was also prepared.  A final 
set of solutions was prepared for maximal absorbance readings using 250 µM PAC-1 
with or without 25 µM ZnSO4.  In a 96-well plate, 200 µL of each solution was added to 
different wells in triplicate.  The absorbance at 410 nm was then acquired using a 
SpectraMax 384 plate reader (Molecular Devices, Sunnyvale, CA).  The maximal 
absorbance was calculated by subtraction of the absorbance of 250 µM PAC-1 alone 
from the absorbance of 250 µM PAC-1 with 25 µM ZnSO4.  The normalized absorbance 
for each mole fraction was then calculated by subtracting the absorbance of PAC-1 at the 
appropriate concentration from the corresponding PAC-1/Zn mixed sample and dividing 
by the corrected maximal absorbance value.  The normalized absorbance was then plotted 
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versus mole fraction.  The peak of the plot gives the stoichiometry of the interaction 
(based on the mole fraction) and was used to calculate the binding constant from the 
following equation (as ymax):75  
logKA = 0.3010 – log[T] + log ymax – 2log(1-ymax) 
EGTA Competition Titration.  In a quartz cuvette, a solution containing of 32 µM 
PAC-1 and 9.5 µM ZnSO4 in buffer A was titrated with 5 µL aliquots of a 2.9 mM 
solution of EGTA in buffer A.  Upon each addition of EGTA aliquot, the solution was 
allowed to equilibrate for 30 minutes prior to reading the absorbance spectrum between 
260 and 500 nm on a Varian Carey 4000 Spectrophotometer.  The absorbance at 410 nm 
was used to calculate the [EGTA·Zn].  The absorbance data was first converted to the 
concentration of [PAC-1·Zn] using a calibration curve, then this value was subtracted by 
the total [Zn].  The plot of [EGTA·Zn] versus total [EGTA] was fit to the Hill equation 
using OriginPro (OriginLab Software, Northampton, MA).  The KD for PAC-1 was found 
by dividing the K from the fit by the KD of EGTA (3.78x108 M-1).  
EGTA Fluorescence Titration Assay—This titration assay is based on a published 
protocol. Before titration, cuvette was filled with EDTA (10 mM) for 10 min, followed 
by sterile deionized water and acetone washing for removing any residue metal ions. 
PAC-1 or derivative (60 µM) was added to a cuvette containing buffer (Hepes: 50 mM, 
KNO3: 100 mM, pH 7.2) with EGTA (7.3 mM) to achieve a 10-fold dilution (final PAC-
1 concentration: 6 µM). Zn(OTf)2 (0 - 10 mM) was added incrementally. The formation 
of Zn-PAC-1 (or derivative) complex was monitored by the increase in fluorescence 
intensity (ex/em: 410 nm/475nm). Fluorescence intensity at 475 nm was plotted against 
free Zn concentration ([Zn]f/M) calculated using MaxChelator program. The data was 
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analyzed using KaleidaGraph and fitted to a formation curve based on Eq 1 derived by 
published protocol. 
 
I = (IminKD + Imax[Zn]f)/(KD + [Zn]f)                Eq 1 
 
where Imin and Imax were defined as the fluorescence intensity of the free probe (PAC-1 
or derivative in this case) and that of the Zn-probe complex respectively.   
Cell Culture—U937 human lymphoma cells and SK-Mel-5 human melanoma 
cells were obtained from ATCC.  Cells were cultured in RPMI 1640 growth media 
supplemented with 10% FBS and 1% pen-strep.  Cells were incubated at 37 °C and 5 % 
CO2.  Subculture of SK-Mel-5 cells was achieved through trypsinization of the cell 
monolayer using 0.05% Trysin-EDTA (Gibco) dilution and further culture in RPMI 1640 
growth media supplemented with FBS and pen-strep as above. 
Apoptosis Induction Assays.  U-937 cells were cultured in RPMI 1640 growth 
media with 10% FBS and 1% Penn-Strep.  One million cells were added to each well of a 
12 well plate.  Compound stocks in DMSO were added directly to the growth medium 
maintaining a constant amount of DMSO (< 1%) in each well.  Cells were incubated with 
compound at 37°C and 5% CO2 for 24 hours.  After incubation with compound, cells 
were pelleted and the media was removed by aspiration.  The cells were washed once in 
PBS.  The cells were again pelleted and resuspended in 100 µL of Annexin V binding 
buffer (10 mM HEPES pH 7.4, 140 mM NaCl, 2.5 mM CaCl2, 0.1% BSA).  A 10 µL 
solution of FITC conjugated Annexin V was added to the cells and incubated on ice for 
15 minutes.  An additional 380 µL of Annexin V binding buffer and a 10 µL solution of a 
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1mg/mL stock of propidium iodide was added to each sample.  The cells were analyzed 
by flow cytometry and percent apoptosis was determined.  The experiment was 
performed three times and the data presented is the average of each experiment. 
Cell Death Assay—U937 human lymphoma cells were plated into the wells of 96 
well plate at a density of 5000 cells per well in 200 µL of RPMI 1640 growth media with 
10% FBS and 1% pen-strep.  To each well was added 2 µL of 100X compound stock 
solutions in DMSO at varying concentrations so that the cells were treated with 
concentrations between 0 µM and 100 µM compound.  Each concentration was tested in 
quintuplicate.  In each plate 5 wells received 10 µM etoposide as a positive control and 5 
wells received 2 µL of DMSO as a negative control.   The plates were then incubated at 
37 °C and 5% CO2 for 72 hours.  After the 72 hour incubation period, the plates were 
analyzed using a Sulforhodamine B assay as previously described.79  Specifically, to each 
well of the plate was added 50 µL of an 80% (w/v) solution of TCA in H2O and the plates 
were allowed to rest at 4 °C overnight.  The plates were then washed gently with a steam 
of H2O five times to remove the excess TCA and precipitated serum proteins.  The plates 
were then allowed to air dry after which 100 µL of a 0.057% (w/v) Sulforhodamine B in 
a 1% (v/v) acetic acid solution was added to each well and allowed to stain for 30 
minutes at room temperature.  After staining, the wells were gently washed 5 times with 
100 µL of 1% (v/v) acetic acid to remove the unbound dye.  The plates were then allowed 
to air dry.  200 µL of 10 mM Tris base (pH 10.5) was then added to each well and the 
plates were placed on an orbital shaker for five minutes.  The OD was then read at 510 
nm in a Molecular Dynamics plate reader and the percent cell death calculated and 
normalized to the positive control (100% cell death) and the negative control (0% cell 
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death).  The percent cell death was averaged for each compound concentration and 
plotted as a function of compound concentration.  The data were fit to a logistical dose 
response curve using Table curve 2D and the IC50 value was calculated.  The experiment 
was repeated three times and the average of the calculated IC50 values was reported.  The 
standard error of the mean (SEM) was determined and reported for the triplicate 
experiments. 
 
Immunofluorescent Staining—Round 18 mm no. 1 borosillicate coverglass 
(VWR) were coated with poly-lysine by shaking the coverglass in a poly-lysine solution 
(Sigma) for 1 hour and then washing with MilliQ.  SK-Mel-5 human melanoma cells 
were grown on the poly-lysine coated coverglass in the bottom of a 12 well plate.  When 
Cells achieved ~80% confluency, the cells were treated with either DMSO or 100 µM 
PAC-1 in DMSO (total DMSO <1%) for 1 hour.  The cells were then washed two times 
with 1 mL of PBS and fixed in 3.7% formaldehyde in PBS for 10-15 minutes at room 
temperature.  The cells were then washed again two times with PBS and then 
permeabilized with 0.1% Triton X-100 in PBS for 5 minutes.  The cells were then 
blocked in 3% BSA in PBS for 10 minutes and incubated with a 1:500 rabbit anti-
procaspase-3 antibody for 1 hour.  The coverglass was then washed 5 times with PBS and 
incubated with a 1:1000 dilution of the secondary anti-rabbit Alexafluor 647 conjugated 
antibody for 20 minutes protected from light.  The coverglass was again washed 5 times 
with PBS and once with MilliQ H2O.  The coverglass were then mounted on glass slides 
using Fluorosave (Calbiochem) and stored in the dark until imaging.  Cells were imaged 
on a Leica SP2 Multiphoton Confocal microscope. 
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Live Cell Imaging—SK-Mel-5 cells were grown on the bottom of no. 1 
borosillicate growth chambers (Nunc) to a confluency of ~80%.  Cells were then treated 
with DMSO, 25 µM FAM-DEVD-fmk in DMSO, 25 µM AF350-PAC-1 in DMSO, or 
both 25 µM FAM-DEVD-fmk and 25 µM AF350-PAC-1 concurrently for 1 hour at 37 
°C and 5 % CO2.  Cells were then washed 5 times with RPMI 1640 growth media lacking 
phenol red.  The cells were then allowed to further incubate at 37 °C for 2 hours before 
imaging.  For cells stained with SYBR green for nuclear staining, a 1:100,000 dilution of 
SYBR green in media was added immediately prior to imaging.  Cells were imaged on a 
Leica SP2 Multiphoton Confocal microscope.   
Image Analysis—Images were adjusted in brightness and contrast to allow for 
clarity.  For all images in Figure 2.30 and 2.31, the red channel was adjusted using Image 
J to reflect a linear intensity gradient between 10 and 28.  For the green channel, the 
images were adjusted to a linear intensity gradient between 0 and 44.  To account for the 
offset of the microscope optics, the red channel was manually offset by 5 pixels in the x 
direction and the green channel was manually offset by 6 pixels in the y direction.  The 
images were filtered with a gausian blur with a radius of 1 pixel to improve the signal to 
noise ratio.  Using the Image J plugin, JACoP, the % overlap was determined using the 
Manders overlap coefficient.  
Induction of Apoptosis by PAC-1 derivatives—U937 Cells (1 mL of 1 x 10
6 
cells/mL) were treated with 5 µL ethanol stocks of the various compounds to achieve a 
final concentration of 50 µM. The cells were incubated at 37 ºC for 12 hours. The cells 
were centrifuged (200g for 5 min), washed with PBS (2 mL), resuspended in 500 µL 
Annexin V Binding Buffer.  To each sample was added 10 µL of FITC conjugated 
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Annexin V stain (Southern Biotech) and 10 µL of propidium iodide (Sigma) to a final 
concentration of of 50 µg/mL.  Cell populations were analyzed on a Benton Dickinson 
LSR II cell flow cytometer. 
Western blot analysis.  Protein samples were incubated at 37oC in the presence of 
DMSO or varying concentrations of PAC-1 in DMSO.  Samples were boiled in 2x SDS 
sample buffer for five minutes to denature the proteins and stop the reaction.  The protein 
was analyzed by Western blot.  Procaspase-3 fragments were then separated by SDS-
PAGE using a 4-20% gel gradient (Bio Rad).  A 15 µL volume of sample was loaded into 
each well.  Proteins were transferred to Immoblilon-P PVDF membrane (Millipore) at 40 
volts for 2 hours in Towbin Transfer Buffer.  The Penta-His alexafluor 647 conjugate 
antibody (Qiagen) was used to visualize the protein fragments. Blots were incubated with 
a 1:1000 dilution (in PBS + 0.1% Triton-X100) of antibody for two hours.  The blots 
were imaged using a Typhoon imager (Amersham). 
 Cellular Zn2+ measurements. The following genetically encoded FRET sensors 
were used in this study: ZapCY2  was used to study cytosolic Zn2+,86 D3cpv for cytosolic 
Ca2+,121 and D1ER for ER Ca2+ levels 122. HeLa cells were transfected with sensor 
constructs in 3.5 cm glass bottom imaging dishes using TransIt (Mirus), 1 µg DNA: 5 µl 
TransIt, and imaged 48h post-transfection with an Axiovert 200M inverted fluorescence 
microscope (Zeiss) with a 1.3NA 40X oil immersion objective, and a Cascade 512B CCD 
camera (Roper scientific), equipped with a Xenon arc lamp (XBO75). All experiments 
were conducted at least three times. Statistical analysis was performed using ANOVA 
with a post-hoc test or Student’s t-test using KaleidaGraph.  
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Gene expression profiling and Connectivity Map analysis. U-937 or HL-60 cells 
(3,000,000 cells/sample) were incubated in the presence of 25 µM PAC-1 or S-PAC-1, 
100 µM PAC-1, or DMSO vehicle (0.2% final  DMSO v/v) for 6 hours in a 12-well plate 
in culture media for the respective cell lines as described above. RNA isolation, whole 
genome transcript profiling was performed on the Illumina HumanHT-12 bead array for 
seven compounds and DMSO control from three independent experiments. Data 
processing and comparison to the Connectivity Map database were all performed exactly 
as previously reported 123 and is described in more detail in the Supplementary Data. 
 
In vitro procaspase-3 analysis 
To demonstrate the cellular target of PAC-1, endogenous procaspase-3 was 
assessed in all three B-cell lymphoma lines.  One million cells each of 17-71, GL-1, and 
CA46 cells were harvested, washed in phosphate buffered saline (PBS), resuspended in 1 
ml of fixation/permeabilization working solution (eBioscience, San Diego, CA),  and 
incubated on ice for 2 hours. Following fixation and permeabilization, cells were washed 
twice with permeabilization buffer, and then incubated either with rabbit anti-mouse 
procaspase-3 antibody (1:25, Epitomics, Burlingame, CA) or rabbit IgG isotype control 
antibody (1:25, SCB, Santa Cruz, CA), incubated at 4 oC overnight, and then washed 
once with permeabilization buffer.  Cells were incubated with secondary sheep anti-rabbit 
IgG:RPE (1:10, AbD Serotec, Raleigh, NC) at 4 oC in the dark for 60 minutes, washed 
twice in permeabilization buffer and analyzed by flow cytometry (Beckman Coulter 
Epics XL). 
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In vitro PAC-1 cytotoxicity studies  
Fresh media containing varying concentrations of PAC-1 (0, 5, 10, and 20 µM) 
were added to a 6-well plate containing 100,000 cells/well for either 24 or 48 hours at 37 
oC in 5% CO2.  All lymphoma cell lines, 17-71, GL-1, and CA46, were evaluated and all 
experiments were performed in triplicate.  For analysis of cytotoxicity, an Annexin V-
FITC/PI apoptosis detection kit (BD Pharmingen, San Diego, CA) was used according to 
the manufacturer’s directions and analyzed by flow cytometry (Beckman Coulter Epics 
XL). 
In vitro caspase-3 activation  
Caspase-3 activation was assessed by exposing lymphoma cells to 10 or 20 µM of 
PAC-1 for 0, 1, 2, 4, 24, and 48 hours at 37 oC in 5% CO2.  Caspase-3 activity produced 
by 2 million cells per time point were analyzed and experiments were performed in 
duplicate.  Caspase-3 activity was quantified in cell lysate using a commercially-available 
caspase-3 colorimetric assay (R & D Systems, Minneapolis, Minnesota), and reactions 
were read on a Bio-Tek EL-800 microplate reader using a 405nm wavelength.  Relative 
caspase-3 activities were expressed and compared as optical density (OD) measurements.  
Procaspase-3 Activation.  Recombinantly expressed, zinc-free procaspase-3 D3A 
(7.5 µM) in Chelex® treated Hepes-NaCl was incubated in the presence of  ZnSO4 (10 
µM) and the basal activity was assessed by addition of Ac-DEVD-pNA substrate (200 
µM) and monitored at 405 nm with a Spectramax plate reader (Molecular Devices, Sunny 
Vale, CA).  After the basal activity was determined, DMSO, PAC-1 or S-PAC-1 was 
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added to each sample to a final concentration of 50 µM.  Activity of each stock was 
assessed as described above every 20 minutes.  The slope of each data set was used to 
determine the activity of the protein.  Protein activity was normalized to a percent activity 
at each time point using a zinc-free sample as 100% activity and the DMSO control as 
0% activity controls. 
 
Neuronal cell permeability assay and Blood-brain barrier (BBB) penetration 
study. Neuro-2a cells were treated with 50 µM PAC-1 for 30 minutes, lysed, and PAC-1 
and S-PAC-1 concentrations were determined by HPLC. Details from this experiment are 
found in the Supplementary Data. BBB penetration study was performed as follows: 12 
week old, female, C57/BL6 mice were administered PAC-1 or S-PAC-1 in HPβCD at 
75mg/kg via lateral tail vein injection. Five minutes post lateral tail vein injection, mice 
were sacrificed, blood was collected by lacerating the right auricle with iris scissors.  
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Chapter 3:  Evaluation of Procaspase Activating 
Compounds In Vivo 
Portions of this chapter were taken with permission from: 
Lucas, P.W., Schmit, J.M., Peterson, Q.P., West, D.C., Hsu, D.C., Novotny, C.J., 
Dirikolu, L., Churchwell, M.I., Doerge, D.R., Garrett, L.D., Hergenrother, P.J., Fan, T.M.  
Pharmacokinetics and derivation of an anticancer dosing regimen for PAC-1, a 
preferential small molecule activator of procaspase-3, in healthy dogs.  Invest. New 
Drugs.  2010, DOI: 10.1007/s10637-010-9445-z. 
Peterson, Q. P., Hsu, D.C., Novotny, C.J., West, D.C., Kim D., Schmit, J.M., Dirikolu, 
L., Hergenrother, P.J., Fan, T.M.  Discovery and canine preclinical assessment of a non-
toxic procaspase-3-activating compound.  Cancer Res.  2010, 70 (18), 7232-7241. 
 
The results described in Chapter 2 suggest that compounds capable of activating 
procaspase-3 in vitro may be effective therapeutic agents in treating cancer in vivo.  To 
that end we sought to evaluate procaspase-activating compounds in more complex 
systems to determine the safety and efficacy of these compounds for their use as 
anticancer agents.  The studies described in this chapter investigate the toxicity, 
pharmacokinetics and efficacy of PAC-1 and a derivative, S-PAC-1, with the goal 
evaluating the potential of these compounds for human clinical trials. 
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Of the various lethal tumor histologies diagnosed in people, non-Hodgkin’s 
lymphoma may be a relevant model for evaluating PAC-1.  Given that variants of non-
Hodgkin’s lymphoma possess high concentrations of procaspase-3 and cure rates for 
specific lymphoma subtypes remains relatively low (40-50%), evaluating PAC-1 as a 
novel therapeutic for lymphoma appears mechanistically and clinically warranted.124-126  
3.1 Drug-Like Properties 
Success in clinical evaluation involves many factors beyond target modulation 
and potency.  The evaluation of drug candidates involves the evaluation of a number of 
properties that influence the ability of a compound to be successful as a drug.  These 
properties influence critical events such as drug formulation, bioavailablility, membrane 
permeability, serum stability, metabolism an toxicity.  These factors are typically referred 
to collectively as ADME/Tox (absorbtion, distribution, metabolism, elimination, toxicity) 
and define many of the challenges to successful translation of a drug candidate to market.  
Any discussion of the development and evaluation of candidate drugs necessitates a 
discussion of these properties.  Indeed significant efforts have been taken to evaluate 
PAC-1 and derivatives to identify the most promising candidate for translation to human 
trials. 
3.1.1 ADME-Tox 
 The ideal dose administration is an oral administration that can be taken one time.  
It is generally accepted that for most drugs this is impractical given current 
pharmaceutical technology.  Additionally, there is some benefit to patient compliance for 
a drug that is taken more regularly.  As such, the once-a-day goal is generally recognized 
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in the pharmaceutical industry.  If a drug candidate has good ADME-Tox properties this 
ideal can be achieved.  Alternatively, a deficiency of the ADME properties requires 
modification of this ideal dosing scheme.  For example, a compound that is readily 
metabolized or eliminated (short half-life) would require more frequent dosing.  
Alternatively, a compound with low bioavailability (distribution) would require higher 
dosing levels and compounds with poor absorption would require administration by a 
different route (such intravenous administration).  As a result, ADME-Tox properties 
play a critical role in the ultimate dosing and efficacy of a drug candidate. 
 Additional parameters that affect the dosing scheme employed are the maximum 
tolerated dose (MTD) and the minimum effective dose (MED).  The MTD is the dose at 
which the drug is reasonably tolerated.  At doses above the MTD, unacceptable toxicity is 
observed that outweigh the drug benefit.  The MED is the minimal dose at which 
biological effect is measured.  At doses above the MED, increased efficacy is expected.  
The appropriate dosing strategy for a given drug depends on the relative values of these 
parameters (Figure 3.1).  The example given in Figure 3.1 (left) is of a drug that has an 
optimal effect at concentrations below the maximum tolerated dose.  In this instance a 
bolus dose is able to achieve the optimal effect and plasma concentrations remain above 
the MED for a significant period of time.  In this instance activity of the drug can be 
achieved without severe adverse effects of the drug.  The difference between the MED 
and MTD is called the therapeutic window.  In this instance therapeutic window is large. 
 Not all drugs show such favorable toxicity profiles.  In some instances, the MTD 
may be much lower causing the therapeutic window to be much smaller (Figure 3.1B).  
When the therapeutic window is small, bolus administration of a drug can result in severe 
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toxicity as the peak plasma levels spike above the MTD.  Administration of lower bolus 
doses of drug meant to prevent plasma levels from achieving MTD concentrations 
ultimately result in plasma concentrations being above the MED for very short periods of 
time.  One solution is to repeatedly administer small doses of the drug.  Over time, the 
plasma concentration of the drug reaches a near equilibrium with small periodic variation 
resulting from each administration.  In this manner drug concentration can be kept below 
the MTD while achieving significant drug exposure above the MED. 
 
Figure 3.1.  Typical dosing schemes for pharmaceuticals.  Bolus administration (left) is used for 
pharmaceuticals that are stable in vivo and have a large therapeutic window.  Continuous Exposure or 
Repeat Dosing (right) is used for pharmaceuticals that are rapidly degraded in vivo or have a narrow 
therapeutic window. 
3.1.2 Solubility/Formulation 
 Prior to in vivo evaluation, a drug candidate must undergo formulation.  One of 
the initial challenges to a successful pharmacological agent is the generation of a 
formulation of the active pharmaceutical ingredient that will allow for the compound to 
be administered to the subject and reach the desired target.  In many instances, 
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compounds that possess drug-like properties also have low solubility due to the 
hydrophobic nature of the compound.   
 Initial studies performed by Dr. Tim Fan with an oral formulation of PAC-1 in 
dogs indicated that PAC-1 has a variable oral bioavailability from 3-30% (Table 3.1).  
This low and variable oral bioavailability is perhaps not surprising given the hydrophobic 
nature of PAC-1 as it would likely have difficulty crossing biological membranes such as 
the intestinal lining. 
Table 3.1.  Pharmacokinetic parameters for oral PAC-1.  PAC-1 was formulated as a capsule with 
excipients and placed in a meatball and fed to 4 dogs. 
Oral PAC-1 data Mean Standard deviation 
Elimination half-life (hours) 3.40 0.54 
Distribution half-life (hours) 0.65 0.29 
Area under the Curve (nMol x hour) 0.27 0.12 
Volume of distribution (L/kg) 1116 610 
Clearance (L/hour x kg) 8.63 7.12 
Bioavailability (%) 23.14 12.94 
 
Given the low oral bioavailability of PAC-1, it was necessary to develop an 
alternate formulation strategy that would allow evaluation of procaspase-3 activators 
when administered intravenously (the most common drug delivery route for conventional 
anticancer agents).  To this end, a formulation procedure that reliably maintained high 
concentrations of PAC-1 (a lipophilic drug) in aqueous solution was first optimized by 
BiolineRX.  The solubilizing agent allowing for the dissolution and maintenance of 
PAC-1 in aqueous solution was 2-hydroxypropyl-β-cyclodextrin (HPβCD).127  PAC-1 is 
soluble at 20 mg/mL in an aqueous 200 mg/mL solution of HPβCD and is stable for at 
least 5 days when stored at 4 °C.   
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For all in vivo experiments, PAC-1 was freshly reconstituted to a stock 
concentration of 15 mg/mL.   Briefly, 200 mg/mL of solublizing agent (2-hydroxypropyl-
β-cyclodextrin) was dissolved in 70% of the final volume of sterile water for injection.  
An appropriate mass of PAC-1 was added to this solution and the pH adjusted to 1.5-2 at 
which PAC-1 is fully soluble.  After complete dissolution of PAC-1 in the 2-
hydroxypropyl-β-cyclodextrin solution, the pH is restored to 5-6.  This solution is then 
sterile filtered and stored at 4 °C until use.  The stability of this stock solution was 
followed by LC-MS over 5 days and exhibited no degradation products during this time. 
For i.p. and IV injections of PAC-1 in mice, the drug was delivered directly from 
this stock concentration or was diluted in sterile water for injection to achieve lower 
doses.  For administration to dogs in a continuous infusion, the drug stock was diluted 1:1 
in a saline solution. 
3.2 Evaluation of PAC-1 in vivo 
In this section we report toxicity studies of intravenously administered PAC-1 in 
mice, and the evaluation of PAC-1 in mice and dogs.  We report results suggesting that 
PAC-1 is well-tolerated in mice and research dogs, and has moderate activity in a 
syngeneic intraperitoneal tumor model in mice.  These results demonstrate the feasibility 
and limitations of PAC-1 administration to pet dogs with lymphoma as a means to 
evaluate the therapeutic potential of this class of compounds as well as suggest possible 
improvements to enhance the ADME-Tox properties of PAC-1. 
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3.2.1  In vivo toxicity of PAC-1 
 
In an effort to characterize the feasibility and tolerability of intravenously 
administered PAC-1, together with collaborators, Dr. Tim Fan and Dr. Diana Thomas, 
cohorts of three C57/BL6 mice were given PAC-1 (dissolved in HPβCD) at dosages of 
10, 20, 30 and 50 mg/kg via lateral tail vein injection, and the animals were observed for 
24 hours.  At 10 mg/kg of PAC-1, no clinical signs of acute toxicity were observed.  
Mice that received 20 mg/kg of PAC-1 exhibited mild neurological symptoms including 
lethargy and mild ataxia; these symptoms persisted for 20 minutes after injection, at 
which point the mice recovered and showed no further signs of toxicity.  Mice that 
received 30 mg/kg of PAC-1 exhibited overt signs of neurotoxicity including muscle 
spasms (1/3), ataxia (3/3) and loss of balance (3/3) with onset occurring within 2 minutes 
after the injection and lasting approximately 15 minutes.  Mice that received 50 mg/kg of 
PAC-1 exhibited acute neurotoxic symptoms with more pronounced ataxia and loss of 
balance immediately following intravenous injection.  At this dosage muscle spasms were 
observed in all mice with resolution occurring within 2 hours.  Mice that received only 
the HPβCD vehicle did not exhibit any clinically observable toxicity.  The observed 
neurotoxicity in mice induced by PAC-1 did not appear to be species specific, as grand 
mal seizure activity in one healthy research dog was elicited when administered 25 mg/kg 
of PAC-1 as a 5-minute intravenous infusion.  Adverse side effects in this dog were 
transient and not life-limiting.   
Maximum Tolerated Dose 
 
 Further evaluation has indicated that the maximum tolerated single dose for 
PAC-1 delivered i.p. in mice is 250 mg/kg.  At this dose, mice exhibit significant 
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neurotoxicity starting 5 minutes after administration with a peak intensity 15 minutes 
after administration and persisting for about 45 minutes total (n=3).  This toxicity is not 
life-limiting and mice exhibit no significant long-term effects after recovery from this 
single dose.  At doses higher than 250 mg/kg, mice exhibit sever neurotoxicity that 
ultimately resulted in death in 3/3 mice (300 mg/kg). 
 
 
Neurological hyperexcitation 
Given the known affinity of PAC-1 for zinc in vitro,60 and the data suggesting 
that PAC-1 binds cellular zinc,61 we initially hypothesized that the neurotoxicity 
observed in mice and dogs administered PAC-1 in HPβCD was caused by the chelation 
of intracellular zinc at NMDA receptors within the central nervous system (CNS).  This 
hypothesis is consistent with data from in vivo studies of other zinc chelators that induce 
a neurological phenotype reminiscent of what we observed with PAC-1.128,129  Indeed, in 
silico analysis of PAC-1 to predict the partitioning across the blood-brain barrier 
(BBB)130 shows that PAC-1 has a calculated logBB of -0.07.  This logBB would 
correlate to a partitioning ratio of 1.0:0.85 between the blood and the brain, suggesting 
that a significant amount of PAC-1 may be entering the CNS.  Several studies have 
indicated that chelation of intracellular zinc stores relieves tonic suppression of NMDA 
receptors, resulting in neuronal hyperexcitation.129,131 
 It is perhaps not surprising that high doses of PAC-1 induce neurotoxicity, 
given its zinc chelation properties and predicted BBB permeability.  Zinc homeostasis is 
important in the CNS,132 and NMDA receptors require bound zinc to provide a tonic 
inhibition.129  NMDA receptors bind to zinc with a low affinity (Kd=5.5 µM),133 which 
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suggests that a zinc chelator with a higher affinity for zinc such as PAC-1 (Kd=52 nM) 
would be able to successfully sequester zinc from these receptors.  Several studies 
indicate that intracellular zinc chelation results in hyperexcitation of these receptors,128 
resulting in symptoms such as uncontrolled muscle movement and seizure.129,134 
 
Repeat Dose Toxicity 
 Mice administered PAC-1 at 200 mg/kg i.p. once daily for 10 days exhibit 
transient neurotoxicity after administration similar to that described previously.  Mice 
administered PAC-1 in this manner exhibited no decrease in weight or other observable 
differences over the course of treatment and exhibited no long term effects from the drug.  
At 300 mg/kg, mice exhibit cumulative toxicity that presents as a decreased ability to 
tolerate PAC-1 treatment over time.  Of the three mice treated at this dose, all tolerated 
the treatment for 2 days.  On the third treatment, one mouse did not survive the treatment 
and the other two did not survive the fourth treatment. 
 
Pharmacokinetics 
 In order to investigate the oral bioavailability of PAC-1 treatment in mice, the 
Helferich laboratory treated mice orally with PAC-1 in a cookie.  They then evaluated 
the plasma levels of PAC-1 at various time points after administration (Figure 3.2).  The 
peak plasma concentration was 12 µM and the half-life is 80 minutes.   
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Figure 3.2.  Pharmacokinetics of PAC-1 administered to mice via oral administration.  PAC-1 was 
incorporated into a cookie which were consumed by the mice.  Peak plasma concentration was 12 µM and 
the half-life of elimination was 80 minutes.  
 
 
Intravenous injection 
 Given the low oral bioavailability, intravenous injection was evaluated as route 
of administration together with collaborators, Dr. Tim Fan and Dr. Diana Thomas.  Mice 
were treated with 20 mg/kg PAC-1 (the dose at which significant neurological symptoms 
first appear) and 50 mg/kg PAC-1 (the dose where acute neurological symptoms are 
present) formulated in 2HPβCD via tail vein injection.  Serum was analyzed by HPLC to 
provide the pharmacokinetic profiles for PAC-1 (Figure 3.3).  At the PAC-1 dosage that 
induced mild neurotoxicity (20 mg/kg), peak plasma concentrations were ~50 µM.  This 
plasma concentration is a significant improvement over the oral formulation. 
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Figure 3.3.  Serum concentrations of PAC-1 in mice.  C57/BL6 mice were treated with 20 and 50 mg/kg 
PAC-1 solubilized in 2HPβCD via tail vein injection.  Mice were sacrificed at the times indicated and 
blood was drawn.  The concentration of drug was determined by HPLC.  For PAC-1 error bars represent 
range, n=2. Taken with permission from Cancer Res.  2010, 70 (18), 7232-7241. 
 
 
3.2.2  PAC-1 efficacy studies in mice 
 
 
Efficacy in EL4 syngeneic subcutaneous tumor model 
 Initial efforts to evaluate the antitumor activity of PAC-1 formulated in 2HPβCD 
in a syngeneic tumor model were performed by Dr. Tim Fan.  In these studies EL4 
murine lymphoma cells derived from C57/BL6 mice were injected into the flank of 
C57/BL6 mice and allowed to establish tumors before treatment with PAC-1 or vehicle 
administered via i.p. injection.  PAC-1 was administered at 350 mg/kg to 15 mice once 
per week on day 1, 8, and 15.  Tumor volume was monitored for 23 days (Figure 3.4).  Of 
the 15 mice that received treatment with PAC-1, 12 died as a result of the first treatment 
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and 2 more were sacrificed due to persistent neurotoxicity.  The remaining mouse 
tolerated all three treatments.  The one surviving mouse treated with PAC-1 in this study 
showed a significant reduction in tumor growth over vehicle treated mice (n = 15).  
Figure 3.5 shows the size of a representative vehicle treated mouse and the one surviving 
PAC-1 treated mouse.  Although not statistically significant due to the small sample size 
of the PAC-1 group (n = 1), these results are promising as they indicate that PAC-1 may 
be effective in inhibiting tumor growth in this model at lower doses. 
 
Figure 3.4  Tumor growth curves for PAC-1 syngeneic subcutaneous tumor model.  EL4 murine 
lymphoma cells were implanted subcutaneously in the right flank of C57BL6. Mice received 350 mg/kg 
PAC-1 daily on days 1, 8 and 15 via i.p. administration. Control mice received an equivalent dose of 
2HPβCD. 
 
PAC-1-II-9 
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Figure 3.5.  Representative images of C57BL6 mice with subcutaneous EL4 tumors after 23 days of 
treatment. 
 
 As a result of the toxicity observed at 350 mg/kg, a second animal study was 
designed looking at a much lower dose of PAC-1.  In this study mice were treated with 
PAC-1 at 150 mg/kg once per week or at 50 mg/kg three times per week.  Each of the 
PAC-1 treated groups in this study received equivalent doses of PAC-1 over the course 
of the week (either all at once or spread out over three doses).  In this experiment 8 mice 
were included in each treatment group.  The results shown in Figure 3.6 indicate that 
PAC-1 did not have any antitumor effect at the doses tested.  In fact, it seems from this 
data that the compound elicits a tumor promoting response.  This result is surprising 
given the cytotoxicity of PAC-1 in cell culture. 
Vehicle           PAC-1                 PAC-1-II-9 
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Figure 3.6.  Tumor growth curves for PAC-1 syngeneic subcutaneous tumor model.  EL4 murine 
lymphoma cells were implanted subcutaneously in the right flank of C57BL6. Mice received 150 mg/kg 
PAC-1 daily on days 1, 8 and 15 or 50 mg/kg three times per week via i.p. administration. Control mice 
received an equivalent dose of 2HPβCD. 
 
 Further analysis of individual mice from this study indicates that several tumors in 
mice that were initially of reasonable size (200 mm3) did not continue to grow after day 5 
even in vehicle treated mice.  Because the mice used in this study are immunocompetent, 
it is thought that these tumors that failed to grow were the result of immune rejection.  It 
is possible that PAC-1 elicits an off-target effect that activates the immune system 
against the tumor cells.  To this end, the spleens of mice were weighed after the end of 
the study to determine if significant immune response was likely.  There was not a 
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significant difference in the weight of spleens between treatment groups suggesting that a 
global immune system activation was not responsible for the tumor rejection.  
 A second possibility is that the health of the cells results in differential growth of 
established tumors.  One common problem with establishing tumors is the presence of 
mycoplasma.  Cells contaminated with mycoplasma exhibit slowed growth in cell culture 
and a reduction in the number of established tumors when inoculated in mice.  Although 
the EL4 stocks used for this study had been tested previously and were shown not to 
contain mycoplasma, we re-tested this cell line to see if contamination had occurred 
subsequent to the last test.  Indeed, this test showed that our EL4 cells were positive for 
mycoplasma contamination.  It is possible that this contamination occurred prior to 
inoculation into our mice and was responsible for the variable growth of tumors in this 
study. 
 In an effort to prevent similar difficulty in future experiments we determined to 
treat EL4 cells with plasmocin for two weeks prior to inoculation and to test cell stocks 
the day prior to inoculation to ensure that cells were free from contamination.  As such 
we undertook a second study looking at the effect of PAC-1 treatment on the EL4 
syngeneic tumor model.  In this study, PAC-1 was administered at 150 mg/kg once a 
week or twice a week for two weeks (Figure 3.7). 
 Tumors inoculated in this experiment grew rapidly compared to previous studies 
with much less variability in tumor growth rate.  This result supports the idea that in 
previous experiments mycoplasma contamination played a role in the tumor growth.  
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Despite the improved tumor growth rate, no response was observed in mice treated with 
PAC-1 as all treatment groups are within error of each other. 
 
Figure 3.7. Tumor growth curves for PAC-1 syngeneic subcutaneous tumor model.  EL4 murine 
lymphoma cells were implanted subcutaneously in the right flank of C57BL6. Mice received 150 mg/kg 
PAC-1 daily on days 1, 8 and 15 or 150 mg/kg PAC-1 2 days per week via i.p. administration. Control 
mice received an equivalent dose of 2HPβCD. 
  
Efficacy in EL4 syngeneic intraperitoneal tumor model  
Although the previous mouse experiments have been conducted at doses near the MTD, 
no efficacy was observed.  It is possible that PAC-1 is being excluded from the tumor 
due to decrease angiogenesis.  In an effort to improve the drug exposure of tumor cells 
collaborator, Dr. Tim Fan, sought to evaluate the effect of PAC-1 in an intraperitoneal 
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tumor model.  In this model, EL4 cells are inoculated into the intraperitoneal cavity.  
Tumors are established in this intraperitoneal space and grow rapidly.  As a consequence 
of the internal growth of these tumors, the growth cannot be monitored over the course of 
the study and survival is monitored as an end-point to evaluate efficacy. 
 In this study six mice were treated in each treatment group.  Mice were inoculated 
with EL4 cells and tumors were allowed to establish for 5 days.  The mice were then 
treated with vehicle or 180 mg/kg of PAC-1 every day for 10 days (day 6 through 15).  
Mice were monitored for signs of distress and mice who progressed to significant tumor 
burden were identified and sacrificed.  The Kaplan-Meier survival curve for this study is 
shown in Figure 3.8.  Mice treated with PAC-1 exhibited a modest but significant 
increase in survival of 4 days.  This study indicates that PAC-1 is able to exhibit a clear 
survival advantage over vehicle and suggests antitumor activity of PAC-1. 
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Figure 3.8.  Kaplan-Meier Curve for PAC-1 in syngeneic intraperitoneal tumor model.  EL4 murine 
lymphoma cells were implanted into the peritoneal cavity of C57BL6 mice on day 1. Mice received 180 
mg/kg PAC-1 daily on days 6 through 15 via i.p. administration. Control mice received an equivalent dose 
of 2HPβCD. 
 
3.2.3 Canine Preclinical Studies 
Procaspase activating compounds, such as PAC-1, hold promise as novel 
therapeutics for the treatment of cancer.  However, prior to their clinical translation to 
human patients, the characterization of the apoptotic properties and pharmacokinetics of 
PAC-1 in appropriate model systems is necessary to streamline the drug discovery 
pathway. As described in chapter 2, in vitro conditions conducive for PAC-1 to cause 
programmed cell death were exposure durations ≥ 24 hours with concurrent 
concentrations ≥ 10 µM.  In this section we report pharmacokinetic studies with PAC-1 
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conducted in healthy research dogs and demonstrate the feasibility of achieving and 
maintaining concentrations of PAC-1 predicted to correlate with in vitro cytotoxic 
conditions.  Not only were we able to successfully institute a pharmacokinetically-
derived dosing protocol, but also this treatment regimen was well-tolerated in a large 
mammalian model which closely mimics the body size, physiology, and metabolism of 
humans.  As such, it is likely that our data derived from dogs will be informative for 
expediting the further development of procaspase-3 activating compounds, such as PAC-
1, for translational applications in humans. 
Spontaneously arising cancers in pet dogs share many similarities with human 
cancers including histologic appearance, tumor genetics, molecular targets, biologic and 
clinical behavior, and response to therapy.135  Of these spontaneous canine cancers, 
multicentric lymphoma is the most common, occurring in 13 to 24 of every 100,000 
dogs.136  The clinical progression and treatment of multicentric B-cell or T-cell canine 
lymphoma has many of the same characteristics of non-Hodgkin’s lymphoma in humans, 
specifically diffuse large B-cell variants.137,138  Canine lymphoma and human non-
Hodgkin’s lymphoma both respond clinically to the same cytotoxic drugs such as 
doxorubicin, vincristine and cyclophosphamide.177,178  These drugs are components of the 
CHOP treatment protocol, first line therapy for diffuse large B-cell lymphoma in 
humans.139  When administered to dogs, CHOP will induce complete clinical remission in 
approximately 90% of dogs diagnosed with lymphoma.140,141  Similar to the human 
response, the majority of dogs who achieve remission with CHOP therapy will 
experience disease relapse.142  Given the commonalities between human and canine 
lymphoma, evaluation of PAC-1 in a canine lymphoma clinical trial may provide 
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important translational information for the development of PAC-1 as a novel human 
therapeutic and an effective agents in dogs with lymphoma would have high likelihood of 
exerting similar anticancer effects in humans.143 
 
Intravenous pharmacokinetics 
 
Pharmacokinetics of PAC-1 in healthy dogs. Dogs are frequently used in 
preclinical toxicity studies for investigating experimental therapeutics including 
anticancer agents.  Serving as a large mammalian experimental system, dogs more 
closely mimic the body size, physiology, and metabolism of humans in comparison to 
rodents.  As such, collaborator, Dr. Tim Fan and coworkers, sought to characterize the IV 
and oral pharmacokinetic profiles of PAC-1 in six healthy research dogs through the 
conductance of a crossover design.  Following single-dose, bolus IV PAC-1 at a dosage 
of 1.0 mg/kg, the average peak plasma concentration achieved immediately following the 
completion of drug infusion was 2.8 ± 0.6 µM (Figure 3.9A), with the mean terminal 
elimination half-life of 3.12 ± 0.67 (SD) hours (Table 3.2).  Orally administered PAC-1 
dosed at 1.0 mg/kg produced an average peak plasma concentration of 0.5 ± 0.1 µM 45 
minutes following ingestion (Figure 3.9B), with an elimination half-life of 2.08 ± 0.26 
(SD) hours.  The oral bioavailability of PAC-1 was relatively low and highly variable, 
averaging 17.8 ± 9.5% (Table 3.3). 
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Figure 3.9.  Pharmacokinetics of PAC-1 in healthy dogs.  The pharmacokinetic profiles of (a) intravenous 
and (b) oral PAC-1  at 1 mg/kg were characterized in 6 healthy dogs using a crossover design.  Intravenous 
PAC-1 produces higher and more consistent peak plasma concentrations in comparison with orally 
administered PAC-1.  Error bars represent standard deviation, n = 6.  Taken with permission from Invest. 
New Drugs.  2010, DOI: 10.1007/s10637-010-9445-z. 
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Table 3.2. Pharmacokinetic parameters of PAC-1 following single 1 mg/kg IV injection in dogs 
 
Dog A B C D E F Mean ± SD 
Weight (kg) 37.1 31.3 27.7 30.8 33.3 31.1 31.9 ± 3.1 
A (ng/ml) 1065 2598 908 2199 1119 1014 1483.8 ± 723.0 
B (ng/ml) 288 584 138 176 154 154 249.0 ± 172.9 
t1/2 α (hr) 0.392 0.121 0.636 0.273 0.611 0.412 0.408 ± 0.197 
t1/2 β (hr) 2.71 2.24 3.20 3.08 3.24 4.26 3.12 ± 0.67 
Cls (ml/kg/hr) 578 428 603 608 585 646 574.7 ± 75.7 
Vdc (L/kg) 0.739 0.314 0.957 0.421 0.786 0.856 0.678 ± 0.254 
Vdβ (L/kg) 2.260 1.380 3.145 2.699 2.736 3.968 2.698 ± 0.865 
Vdss (L/kg) 1.587 1.127 1.715 1.405 1.454 2.574 1.643 ± 0.497 
AUC0-inf (ngxhr/ml) 1730 2339 1468 1645 1709 1549 1740 ± 309.6 
AUMC0-inf (ngxhrxhr/ml) 4751 6167 3693 3802 4247 6174 4805 ± 1211 
R2 0.99 0.99 0.99 0.99 0.99 0.99 0.99 ± 0 
 
 
 
 
Table 3.3. Pharmacokinetic parameters of PAC-1 following single 1 mg/kg oral administration in dogs. 
 
Dog A B C D E F Mean ± SD 
Weight (kg) 37.1 31.3 27.7 30.8 33.3 31.1 31.9 ± 3.1 
F (%) 16 17 8 31 8 27 17.8 ± 9.5 
t1/2 K10 (h) 2.02 1.83 1.86 2.40 1.97 2.42 2.08 ± 0.26 
t1/2 K01 (h) 0.36 0.12 0.28 0.32 0.10 0.28 0.24 ± 0.11 
AUC o-inf. (ng/ml/h) 271 408 117 508 145 414 310.5 ± 158.5 
Oral clearance (L/h)  137 77 236 61 230 75 136 ± 79.6 
Tmax (h) 1.09 0.51 0.90 1.07 0.45 0.99 0.84 ± 0.28 
Cmax (ng/ml) 63.9 127 31 108 43 89 77.0 ± 37.5 
R2 0.94 0.87 0.94 0.87 0.98 0.82 0.9 ± 0.06 
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Constant Rate Infusion 
 
Pharmacokinetic-derived dosing regimen and toxicity assessment of constant rate 
infusion PAC-1.  Based upon the in vitro conditions explored in chapter 2, the ability of 
PAC-1 to activate procaspase-3 to caspase-3 appeared both time- and dose-dependent.  
Minimal conditions identified most conducive for the induction of apoptosis in the cell 
lines evaluated were 1) exposure durations ≥ 24 hours and 2) PAC-1 concentrations ≥ 10 
µM.  Given the short half-life of PAC-1 in dogs, administration through the use of bolus 
injections would not provide adequately sustained serum concentrations to meet the 
conditions predicted for efficacy. With the known pharmacokinetics of PAC-1 in dogs 
characterized by our study, collaborator Dr. Levent Dirikolu, was next able to 
pharmacokinetically derive a continuous rate infusion protocol predicted to achieve and 
maintain plasma concentrations of PAC-1 ≥ 10 µM for ≥ 24 hours, which correlates with 
similar in vitro conditions that proved cytotoxic to lymphoma cells in culture.    
 
CRI Pharmacokinetics 
 
Using four of the same research dogs that were utilized to generate the 
pharmacokinetic profile of IV PAC-1; Dr. Tim Fan and coworkers were able to 
“personalize” their IV CRI protocol based upon their individualized volumes of 
distribution, systemic clearance, elimination half-life, and body weights.  The IV CRI 
protocol tested in our investigation included a 10-minute loading dose (LD), followed by 
a CRI maintenance dosage (MD) administered for 48 hours (Figure 3.10).  The 
“personalized” intravenous CRI dosages were calculated to be the following: Dog A, LD 
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6.4 mg/kg and MD 2.3 mg/kg/hour; Dog B, LD 4.5 mg/kg and MD 1.7 mg/kg/hour; Dog 
C, LD 6.9 mg/kg and MD 2.7 mg/kg/hour; and Dog D, LD 5.5 mg/kg and MD 2.4 
mg/kg/hour.  Collectively, the average LD and MD was calculated to be 5.8 mg/kg and 
2.3 mg/kg/hour, respectively.  Using this pharmacokinetically-derived dosing protocol, 
plasma concentrations of PAC-1 after 6 hours of infusion were 10.7 ± 2.0 µM, and 
remained equal to or greater than this concentration for approximately 36 hours (Figure 
3.11).  PAC-1 concentrations appeared to plateau off following completion of the first 24 
hours of the CRI, with plasma concentrations ~18 µM. 
 
Figure 3.10.  Constant Rate Infusion.  (1) Catheters are placed in the front and hind legs of the dog.  (2) A 
loading dose is infused into the front leg over 10 minutes.  (3) The catheter is attached to a syringe pump 
that will provide the constant drug infusion.  (4) Blood samples are collected from the hind leg of the dog. 
1 2 
3 4 
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Figure 3.11.  Continuous rate infusion of PAC-1.  A pharmacokinetically-derived dosing regimen, 
designed to achieve and maintain steady state plasma concentrations of PAC-1 predicted to exert time- and 
dose-dependent cytotoxic effects, was evaluated in healthy dogs.  The achievement of predicted PAC-1 
cytotoxic concentrations ≥ 10 µM, as well as durations of exposure ≥ 24 hours was technically feasible and 
biologically well-tolerated by all dogs.  Error bars represent standard deviation, n = 4.  Taken with 
permission from Invest. New Drugs.  2010, DOI: 10.1007/s10637-010-9445-z. 
 
Tolerability in research dogs 
 
In addition to characterizing the feasibility for instituting a pharmacokinetically-
derived dosing regimen with PAC-1, in the same 4 dogs we determined the associated 
hematologic, non-hematologic, and gastrointestinal toxicity associated with a 48-hour 
exposure to micromolar concentrations of PAC-1.  Following PAC-1 48-hour CRI, dogs 
were re-evaluated weekly for 4 consecutive weeks by clinical care staff.  Weekly serial 
blood tests and physical examinations documented the absence of any clinically 
meaningful hematologic and non-hematologic toxicity (Table 3.4).  In addition, no 
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clinically overt gastrointestinal toxicity was reported by animal caregivers throughout the 
4 week duration of monitoring. 
Table 3.4. Hematologic and Non-hematologic tolerability of 48-hour PAC-1 CRI  
 
Parameter  Reference Day 0 Day 7 Day 14 Day 21 
WBC  6-17.0 x 103 8.2 ± 1.5 7.0 ± 0.4 7.0 ± 0.4 8.4 ± 0.6 
Neutrophil  3-11.5 x 103 5.4 ± 1.0 5.0 ± 0.5 4.3 ± 0.9 5.9 ± 0.3 
Lymphocyte  1-4.8 x 103 1.9 ± 0.3 1.3 ± 0.2 1.9 ± 0.7 1.5 ± 0.2 
Hematocrit  35-52% 53.0 ± 3.8 55.4 ± 1.3 49.3 ± 6.0 50.6 ± 3.4 
Platelet  2-9 x 105 1.9 ± 0.4 1.8 ± 0.3 2.0 ± 0.4 2.2 ± 0.8 
Creatinine  0.5-1.6 mg/dl 0.9 ± 0.2 1.0 ± 0.3 0.9 ± 0.1 1.0 ± 0.2 
Calcium  7.9-11.5 mg/dl 10.3 ± 0.1 10.5 ± 0.3 10.2 ± 0.4 10.4 ± 0.4 
Phosphorous  2.4-6.5 mg/dl 3.7 ± 0.4 2.9 ± 0.9 3.6 ± 0.3 3.4 ± 0.4 
ALT  17-87 U/L 46.7 ± 34.1 57.0 ± 34.6 56.3 ± 46.7 49.7 ± 29.0 
 
Tolerability and efficacy in canine patients 
 Given the tolerability of PAC-1 in low doses in research dogs, we sought to 
evaluate the efficacy of PAC-1 in pet dogs with cancer.  Four pet dogs with lymphoma 
were evaluated in a clinical study by Dr. Tim Fan and coworkers to identify the 
maximum tolerated dose of PAC-1 that can be administered to patient dogs.  These dogs 
are summarized in table 3.5.  Dogs were treated in a rapid dose-escalation strategy.  If 
adverse events were not observed during treatment, the next dog enrolled would receive 
an elevated dose determined by the modified Fibonacci sequence (1x, 2x, 3.3x, 5x, 7x 
10x).  In this study two dogs received a 1x 48-treatment due to complications during the 
administration of drug to Dog1.  Dog1 partially pulled out the catheter during infusion 
and as a result did not receive the entire dose by iv administration.  Consequently, blood 
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samples were not analyzed for this dog and a second dog, Clifford, was enrolled at the 1x 
dose. 
Table 3.5.  Clinical response for dogs with lymphoma receiving PAC-1 in a 48 hour constant rate infusion.  
Treatment at 1x is 5.8 mg/kg loading dose and 2.3 mg/kg/hr maintenance dose. 
Dog Breed Weight Treatment Adverse Events Response 
Dog 1   1x Catheter Pulled Progression 
Clifford   1x None Stable 
Brodie   2x None Stable 
Ares   3.3x Respiratory Death 
   
Both of the 1x dogs were treated with an equivalent dose as the research dogs described 
above (5.8 mg/kg loading dose and 2.3 mg/kg/hr maintenance dose).  Blood was 
collected periodically over the 48-hour infusion and serum concentrations were 
determined.  Figure 3.12A shows the serum concentration for Clifford during his four 
treatments.  Figures 3.12B and 3.12C show serum data for Brodie and Ares. 
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A) 
  
B) 
  
C) 
  
 
Figure 3.12.  Serum concentrations of PAC-1 in canine patients.  Dogs enrolled in the clinical trial were 
administered PAC-1 at (A) 1x, (B) 2x, or (C) 3.3x constant rate infusion for 48 hours.  Blood was drawn at 
the times indicated and the serum concentration of PAC-1 was determined by HPLC analysis. 
 
 
3.2.4  Understanding PAC-1 Neurotoxicity 
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Based on the results from patient dogs treated with PAC-1, it is clear that the 
toxicity observed from PAC-1 is a limiting factor in treatment at higher doses and may 
prevent optimal efficacy from being observed.  We initially hypothesized that the BBB 
permeability of PAC-1 might contribute to the observed neurotoxicity of PAC-1 in 
vivo.144 The calculated logBB is a predictive value based on the ClogP of a compound 
and its total polar surface area 130,145. The PAC-1 calculated logBB value is –0.07 (ratio 
of PAC-1 concentrations in brain:blood of 46:54)144. Collaborators, Dr. Tim Fan and 
coworkers, performed an in vivo study of BBB penetrance in which four C57/BL6 mice 
were injected with 75 mg/kg PAC-1 (formulated in HPβCD) via the lateral tail vein and 
subsequently sacrificed 5 minutes post-injection. Immediately following sacrifice, both 
serum and perfused brain samples were submitted for HPLC analysis of PAC-1 
concentration. PAC-1 serum concentrations was 70.4 ± 20.7 µM and the concentration of 
PAC-1 in the brain 47.3 ± 5.4 ng/mg (Figure 3.13). These results strongly suggest that 
significant amounts of PAC-1 cross the BBB and that BBB penetration likely contributes 
to the observed neurotoxicity of PAC-1 when high concentrations are administered in 
vivo.  
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Figure 3.13. BBB permeability of PAC-1.  C57BL/6 mice received PAC-1 at 75mg/kg dissolved in 
HPβCD via lateral tail vein injection.  Concentrations of PAC-1 within serum and brain tissue 5 minutes 
post-injection. Cohort size per group (n=4). 
 
Having established that PAC-1 is able to cross the BBB, we sought to investigate 
if the toxicity observed from PAC-1 was indeed due (as we hypothesized) to chelation of 
inhibitory zinc in the CNS.  The toxicity of PAC-1 is dose limiting and efforts to limit the 
toxicity of PAC-1 are dependent on if those toxicities are on-target or off-target 
toxicities.  As such Howard Roth synthesized two derivatives of PAC-1 that are not 
capable of chelating zinc (Figure 3.14).  In this way, we hoped to evaluate if the 
neurotoxicity observed with PAC-1 was due to the mechanism of action.  We predicted 
that these compounds would not exhibit neurotoxicity in mice at concentrations where 
significant neurotoxicity is observed with PAC-1.  
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Figure 3.14.  Structures of inactive derivatives evaluated in mice.  PAC-1-I-8 (left) and PAC-1-I-11 
(right). 
 
 
Mice were treated with 180 mg/kg of PAC-1, PAC-1-I-8, and PAC-1-I-11 via i.p. 
administration and mice were observed for toxicity.  As expected, PAC-1 elicited a 
neurotoxic effect similar to that previously described.  Unexpectedly, we also observed 
that PAC-1-I-8 and PAC-1-I-11 showed equally severe neurotoxicity with symptoms 
indistinguishable from the toxicity observed with PAC-1.  This suggest that the 
neurotoxicity observed as a result of PAC-1 is an off-target toxicity that is not related to 
the ability of these compounds to chelate zinc. 
Taken together, these results suggest two strategies toward the development of 
novel PAC-1 derivatives that have reduced toxicity.  Given the neurotoxicity observed, it 
is likely that compounds that do not cross the BBB would be well tolerated and could be 
administered at elevated doses.  Secondly, given the off-target nature of the 
neurotoxicity, it is thought that compounds could be developed that eliminate the 
structural characteristics responsible for the neurotoxicity without effecting the core motif 
required for anticancer activity of the compound. 
3.3 Evaluation of S-PAC-1 in vivo 
In an effort to overcome the undesirable side effect of neurotoxicity, we 
hypothesized that a derivative of PAC-1 that had a lower propensity to cross the BBB 
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would exhibit decreased neurotoxicity and allow for dosing at higher concentrations.  
One strategy for reducing the permeability of a compound through the BBB is to increase 
the polarity of the molecule.130  Addition of the sulfonamide functional group is a good 
candidate for such polarity increase as the aryl sulfonamide motif is common in a number 
of small molecule therapeutics.  Based on the structure-activity relationship previously 
reported,61 it was predicted that a polar functional group installed on the benzyl ring of 
PAC-1 should decrease the predicted logBB while maintaining the activity of the parent 
compound.  As such S-PAC-1, a sulfonamide derivative of PAC-1, was identified from 
the 2nd generation derivatives described in chapter 2 as a compound predicted to have a 
markedly decreased ability to cross the BBB (logBB of -1.26, providing a predicted 
blood:brain ratio of 1.0:0.055).  
3.3.1 Murine Toxicity Studies with S-PAC-1 
Given the properties of S-PAC-1 identified in chapter 2 and described above, we sought 
to evaluate S-PAC-1 in vivo to determine if indeed S-PAC-1 would exhibit diminished 
toxicity and while retaining activity. 
Toxicity and pharmacokinetics 
 
S-PAC-1 has no detectable neurotoxic effect in mice.  Having confirmed the 
activity of S-PAC-1 in vitro and in cell culture in chapter 2, the toxicity of S-PAC-1 
(when administered in HPβCD via tail vein injection) was assessed in C57/BL6 mice 
together with Dr. Tim Fan and Dr. Diana Thomas and is summarized in Table 3.6.  S-
PAC-1 exhibited no observable toxicity at any dose tested.  
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Table 3.6 Observed neurotoxicity of PAC-1 in C57/BL6 mice. Taken with permission from Cancer Res.  
2010, 70 (18), 7232-7241. 
 
Dose (mg/kg) 
Toxicity 
PAC-1 S-PAC-1 
10 - ND 
12.5 ND - 
20 + ND 
25 ND - 
30 ++ ND 
37.5 ND - 
50 +++ ND 
350 ND - 
(-) no observable toxicity 
(+) mild neurological symptoms 
(++) overt neurotoxicity 
(+++) severe neurotoxicity 
ND, Not Determined 
n=3 for each condition 
 
 
The toxicity profile of S-PAC-1 supports our hypothesis that S-PAC-1 has a 
reduced penetrance to the BBB.  In an effort to confirm the predicted difference in BBB 
penetration of PAC-1 and S-PAC-1 we evaluated the ability of S-PAC-1 to cross the 
BBB.  In an experiment analogous to that performed on PAC-1 (Section 3.2.1.4), four 
C57/BL6 mice were injected by Dr. Tim Fan and coworkers with 75 mg/kg S-PAC-1 
(formulated in HPβCD) via the lateral tail vein and sacrificed 5 minutes post-injection. 
Immediately following sacrifice, both serum and perfused brain samples were submitted 
for HPLC analysis of PAC-1 concentration.  Figure 3.15 shows the relative concentration 
of S-PAC-1 in blood and brain samples.  Compared to PAC-1 (Figure 3.13), S-PAC-1 
has a significantly reduced permeability to the BBB.  This data supports the hypothesis 
that PAC-1 derivatives that do not cross the BBB will not exhibit neurotoxicity. 
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Figure 3.15. BBB permeability of S-PAC-1.  C57BL/6 mice received S-PAC-1 at 75mg/kg dissolved in 
HPβCD via lateral tail vein injection.  Concentrations of S-PAC-1 within serum and brain tissue 5 minutes 
post-injection. Cohort size per group (n=4). 
 
Neurosuppression 
 At doses above 350 mg/kg, mild toxicity was observed.  Mice receiving 500 
mg/kg S-PAC-1 i.p. exhibited transient lethargy, decreased responsiveness and depressed 
breathing.  This behavior typically lasted for 6 hours after treatment upon which mice 
returned to normal activity.  Given the nature of these symptoms and the predicted ability 
for some S-PAC-1 to cross the BBB we postulate that these symptoms represent a 
neurosuppressive phenotype.  Given the structural similarities of PAC-1 and S-PAC-1 it 
is interesting that these compounds exhibit toxicity with distinct patterns of symptoms. 
Maximum Tolerated Dose 
 Mice treated with S-PAC-1 exhibited life-limiting toxicity at doses over 500 
mg/kg i.p.  At 1000 mg/kg mice exhibited severe neurosuppression resulting in severely 
depressed breathing for a prolonged period of time.  These mice deteriorated 
progressively over the course of a 24 hour period to complete non-responsiveness. 
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Repeat Dose Toxicity 
 Mice treated with S-PAC-1 at 350 mg/kg daily for 21 consecutive days 
exhibited no adverse effects.  At 500 mg/kg mice treated daily began to show significant 
toxicity after three days and 1/3 mice died after 5 days of treatment. 
Pharmacokinetics 
Given the dramatically reduced neurotoxic effect of S-PAC-1, pharmacokinectic 
analysis was performed to compare the plasma concentrations achievable with PAC-1 
and S-PAC-1.  Together with Dr. Tim Fan and Dr. Diana Thomas, mice were treated 
with 350 mg/kg S-PAC-1 via tail vein injection.  Serum was analyzed by HPLC to 
provide the pharmacokinetic profiles for S-PAC-1 and were compared to the 
pharmacokinetic profiles for PAC-1 described in section 3.2.1 (Figure 3.16A).  At the 
PAC-1 dosage that induced mild neurotoxicity (20 mg/kg), peak plasma concentrations 
were ~50 µM.  In contrast, a 350 mg/kg dose of S-PAC-1 provided peak plasma levels of 
~3500 µM without any signs of neurotoxicity. 
 154 
  
Figure 3.16. A)  Serum concentrations of PAC-1 and S-PAC-1 in mice.  C57/BL6 mice were treated with 
20 and 50 mg/kg PAC-1 and 350 mg/kg S-PAC-1 solubilized in HPβCD via tail vein injection.  Mice were 
sacrificed at the times indicated and blood was drawn.  The concentration of drug was determined by 
HPLC.  For PAC-1 error bars represent range, n=2.  For S-PAC-1 error bars represent SEM, n=3.  B) 
Serum concentrations of S-PAC-1 administered i.p. in mice.  C57/BL6 mice were treated with 125 mg/kg 
of S-PAC-1 solubilized in HPβCD via i.p. administration.  Mice were sacrificed at the times indicated and 
blood was drawn.  The concentration of S-PAC-1 in the serum was determined by HPLC.  Administration 
of 125 mg/kg S-PAC-1 provides a peak plasma concentration of ~170 µM and a half-life of ~1 hour.  Error 
bars represent SEM, n = 3.  Taken with permission from Cancer Res.  2010, 70 (18), 7232-7241. 
 
S-PAC-1 has a short half-life in mice.  S-PAC-1 (125 mg/kg) was administered to 
mice via i.p. injection and found to have a short half-life (~1 hour, Figure 3.16B); it was 
predicted that the mice would need to be treated with a 85 mg/kg dose of S-PAC-1 every 
two hours to achieve and maintain a minimum plasma concentration of 10 µM over a 
course of 24 hours.  Evaluation of S-PAC-1 administered at 30 mg/kg i.p. shown in 
Figure 3.17 further confirmed the short half life of S-PAC-1 in mice and the necessity for 
repeat dosing at short intervals. 
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Figure 3.17.  Pharmacokinetic profile of S-PAC-1 in mice.  C57/BL6 mice were treated with 30 mg/kg 
PAC-1 solubilized in HPβCD via i.p. injection.  Mice were sacrificed at the times indicated and blood was 
drawn.  The concentration of drug was determined by HPLC.  Error bars represent SEM (n=3). 
 
 
In an attempt to identify a route of administration with improved 
pharmacokinetics subcutaneous administration was investigated.  It was anticipated that 
slower absorption of the drug would allow for plasma levels to remain elevated for a 
longer period of time.  S-PAC-1 formulated in 2HPβCD was administered 
subcutaneously to mice at 150 mg/kg.  Mice were sacrificed at various time points over a 
6 hours period after drug administration with three mice per time point.  Serum was 
collected and drug concentration was analyzed by HPLC (Figure 3.18).    
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Figure 3.18.  Subcutaneous pharmacokinetic profile of S-PAC-1 in mice.  C57/BL6 mice were treated with 
150 mg/kg PAC-1 solubilized in HPβCD via s.c. injection.  Mice were sacrificed at the times indicated and 
blood was drawn.  The concentration of drug was determined by HPLC.  Error bars represent SEM (n=3). 
 
 As expected plasma concentrations of S-PAC-1 remained elevated above 20 
µM for 200 minutes with subcutaneous injection where plasma concentrations remained 
above 20 µM for 120 minutes in the i.p. administered mice.  This increase is likely due to 
the absorption rate of the compound as the formulation of chemical composition of the 
drug has not changed.  As such the elimination rate and metabolic degradation rate are 
not likely to have changed.  Indeed the half-life for S-PAC-1 administered via s.c. 
injections is 1.3 hours compared to ~1 hour for i.p. administration.  This modest increase 
in half-life is not sufficiently improved to significantly change the predicted dosing 
regimen described above (85 mg/kg of S-PAC-1 every 2 hours for 24 hours).   
Additionally, the slow rate of adsorption results in a lower peak plasma concentration and 
a lower bioavailability.  As such further studies were performed with i.p. drug 
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administration due to the ease of administration.  Additionally, i.p. drug administration is 
frequently used in animal studies allowing for direct comparison of our results with those 
found in literature studies. 
3.3.2 S-PAC-1 Efficacy in Murine Tumor Models 
 
 
Efficacy in EL4 syngeneic subcutaneous tumor model 
 In an effort to investigate the efficacy of S-PAC-1 treatment in mice we evaluated 
S-PAC-1 in a syngeneic EL4 subcutaneous tumor model.  The EL4 murine lymphoma 
cells were injected subcutaneously and allowed to establish tumors.  Mice were then 
separated into three treatment groups with 12 mice in each treatment group.  One 
treatment group received 85 mg/kg of drug every 2 hours for 24 hours (12 total 
injections) on days 1, 7 and 14.  A second group received 500 mg/kg of drug every 12 
hours for 24 hours (2 injections total) on day 1, 7 and 14.  The final group of mice 
received only vehicle. 
 As shown in Figure 3.19, this study design did not show efficacy as a result of 
treatment.  As this study was performed prior to the discovery of mycoplasma 
contamination described in section 3.2.1, it is possible that the cells implanted in this 
study were also contaminated.  Indeed the large variation seen in the tumor growth rate 
for these mice are consistent with the idea that some tumors were rejected by the host.  
Further, the large error associated with the tumor volumes results in no statistical 
difference in the tumor volumes for any of the treatment groups.  It is possible that the 
lack of statistical effect observed is the result of the poor pharmacokinetics of the drug or 
insufficient drug exposure.  Although predicted to achieve a plasma concentration above 
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10 µM for 24 hours, it is unclear if this dosing regimen is sufficient drug exposure for 
efficacy to be observed.  It is possible that the predicted pharmacokinetics do not match 
the actual pharmacokinetics observed in tumor bearing mice and that the predictive 
model was inaccurate.  Further our prediction that efficacy would be observed with 
exposures above 10 µM for 24 hours is based on cell culture data that does not take into 
account the level of exposure to the tumor site due to vasculature, metabolism or 
biological barriers.  It is unclear how well cell culture cytotoxicity data translates into 
more complex in vivo models. 
 
Figure 3.19. Tumor growth curves for PAC-1 syngeneic subcutaneous tumor model.  EL4 murine 
lymphoma cells were implanted subcutaneously in the right flank of C57BL6. Mice received 85 mg/kg S-
PAC-1 every 2 hours for 24 hours or 500 mg/kg S-PAC-1 BID on days 1, 8 and 15 via i.p. administration. 
Control mice received an equivalent dose of 2HPβCD.  
 
 Although efficacy could not be evaluated from this study, we were able to 
evaluate the tolerability of this treatment strategy.  Prior to this study, the highest dose of 
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S-PAC-1 shown to be safe in mice by i.p. administration was 500 mg/kg.  In this study, 
mice received this same dose (500 mg/kg of S-PAC-1) two times per day with treatments 
separated by one week.  This treatment was well tolerated with mice exhibiting mild 
lethargy but recovering to normal activity prior to the next dose administration twelve 
hours later.  Additionally, as shown in Figure 3.20 there was no significant difference in 
weight of any of the treatment groups. 
 Mice in the 12 injections/day group also tolerated treatment well.  These mice 
exhibited no symptoms upon the first 6 injections and developed only mild lethargy by 
the end of treatment (injections 10-12).  It is possible that this lethargy was a result of the 
excessive manipulation and handling required to administer this dosing regimen. 
 
Figure 3.20.  Weight of mice at day 21 in subcutaneous EL4 syngeneic tumor model. 
 To maximize the opportunity to observe efficacy with this tumor model a second 
efficacy study was initiated that sought to evaluate the S-PAC-1 at the maximum 
tolerated dose.  In this study, mice were administered S-PAC-1 in 2HPβCD at 350 mg/kg 
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BID (bis in die or twice daily) for 21 days.  As shown in Figure 3.21, there was not a 
significant difference in the tumor volumes of mice in this dosing strategy.   
 
 
Figure 3.21. Tumor growth curves for PAC-1 syngeneic subcutaneous tumor model.  EL4 murine 
lymphoma cells were implanted subcutaneously in the right flank of C57BL6. Mice received 350 mg/kg S-
PAC-1 BID or 500 mg/kg PAC-1 BID for 21 days via i.p. administration. Control mice received an 
equivalent dose of 2HPβCD.  
 
 At the end of this study mice from both treatment groups were administered S-
PAC-1 and pharmacokinetic data was collected from mice in each treatment group.  As 
shown in Figure 3.22 the peak plasma concentration for mice that had received 350 
mg/kg S-PAC-1 BID for 21 days was significantly lower than mice that had received 
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only vehicle.  Additionally, the half-life for mice that had received chronic treatment of 
S-PAC-1 was much shorter than for mice who had received only vehicle.  These results 
suggest that chronic exposure to S-PAC-1 results in a sensitization to S-PAC-1.  It is 
possible that metabolic enzymes are upregulated in response to S-PAC-1 or that the 
clearance rate was elevated for the drug.  This may contribute to the lack of efficacy 
observed in this strategy.  In total the results from our murine efficacy studies suggest 
that improved dosing strategies are required to see antitumor activity. 
 
Figure 3.22.  Intraperitoneal pharmacokinetic profile of S-PAC-1 in chronically treated mice and naïve 
mice.  C57/BL6 mice were treated with 350 mg/kg PAC-1 solubilized in HPβCD BID or vehicle via i.p. 
injection for 21 days.  All mice were then treated with 350 mg/kg of PAC-1.  Mice were sacrificed at the 
times indicated and blood was drawn.  The concentration of drug was determined by HPLC.  Error bars 
represent SEM (n=3). 
 
3.3.3 Canine Preclinical Studies 
Although this frequent dosing regimen for S-PAC-1 in mice (i.p. every 2 hours 
for 24 hours) was technically feasible, our initial murine studies did not show significant 
efficacy and further evaluation of S-PAC-1 as a novel therapeutic agent using murine 
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tumor models was not methodologically practical.  As such collaborator Dr. Tim Fan and 
coworkers sought to further investigate S-PAC-1 in a larger mammalian experimental 
system, specifically healthy and spontaneous cancer-bearing dogs, which conferred 
greater practicality for the maintenance of S-PAC-1 steady state concentrations for 
prolonged periods of time (Figure 3.23).  
 
Figure 3.23.  Drugs can be administered to dogs in both a bolus regimen (left) or a continuous infusion 
(right) that results in a steady state level of drug in the plasma. 
 
IV pharmacokinetics 
 
 Assessment of S-PAC-1 in research dogs.  Healthy research hound dogs were 
utilized for pharmacokinetic and toxicity investigations of S-PAC-1.  First, four research 
hound dogs were treated with 25 mg/kg S-PAC-1 (solublized in HPβCD) via IV injection 
over 10 minutes. In addition to pharmacokinetic analysis, the hematologic and non-
hematologic tolerability of single-dose, intravenous S-PAC-1 administration was 
monitored  
in research dogs weekly for 4 consecutive weeks (Table 3.7).  As shown in Figure 3.24, 
the peak plasma concentration resulting from this 25 mg/kg i.v. bolus dose was ~150 µM.  
From analysis of the pharmacokinetic profile, the half-life of S-PAC-1 in dogs was 
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calculated to be 1.09±0.02 hours (Table 3.8). Additionally, single-dose, intravenous S-
PAC-1 treatment was well-tolerated by all 4 research dogs and no short or long term 
adverse events were observed with these animals as a result of treatment.   
 
Figure 3.24. A) Serum concentrations of a single-dose of S-PAC-1 in research hound dogs.  Four hound 
dogs were administered a single intravenous dose of S-PAC-1 (25 mg/kg in HPβCD), blood was drawn at 
the times indicated, and S-PAC-1 concentration from serum was determined by HPLC.  S-PAC-1 has a 
peak plasma concentration of ~150 µM and a half-life of ~1 hour in dogs.  B)  Three healthy hound dogs 
were administered a continuous infusion of S-PAC-1.  Dogs received an initial loading dose over the 
course of 10 minutes followed by a constant rate infusion over the next 24 hours.  Blood was drawn at the 
times indicated and S-PAC-1 concentration in the plasma was determined by HPLC analysis.  Continuous 
infusion of S-PAC-1 was well-tolerated and successful in establishing a steady state serum concentration of 
S-PAC-1 in dogs.  Taken with permission from Cancer Res.  2010, 70 (18), 7232-7241. 
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A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B) 
 
Parameter Reference Range Day 0 Day 7 Day 14 Day 21 
WBC 6-17.0 x 103 8.6 ± 0.9 9.1 ± 1.4 9.7 ± 1.0 9.7 ± 0.8 
Neutrophil 3-11.5 x 103 5.4 ± 0.8 6.1 ± 0.3 6.5 ± 0.7 6.1 ± 0.6 
Platelet 2-9 x 105 2.0 ± 0.7 2.3 ± 0.3 2.2 ± 0.6 2.0 ± 0.6 
Creatinine 0.5-1.6 mg/dl 0.8 ± 0.1 0.9 ± 0.1 0.8 ± 0.1 0.9 ± 0.1 
ALT 17-87 U/L 31.3 ± 1.7 31.5 ± 3.0 31.5± 4.2 32.0 ± 3.7 
BUN 7.0-31.0 mg/dl 15.0 ± 3.7 15.5 ± 1.8 17.1 ± 4.6 18.4 ± 3.9 
Sodium 141-161 mEq/L 147.8 ± 0.5 149.5 ± 3.1 148.3 ± 2.1 149.3 ± 1.7 
Potassium 3.9-5.7 mEq/L 4.6 ± 0.2 4.7 ± 0.3 4.7 ± 0.2 4.8 ± 0.3 
Chloride 104-125 mEq/L 113.8 ± 3.5 111.5 ± 2.6 111.5 ± 1.7 112.8 ± 2.4 
Calcium 7.9-11.5 mg/dl 10.4 ± 0.1 10.6 ± 0.3 10.7 ± 0.4 10.6 ± 0.3 
Phosphorous 2.4-6.5 mg/dl 3.6 ± 0.2 4.1 ± 0.7 4.3 ± 0.3 4.3 ± 0.2 
ALP 12-110 U/L 24.0 ± 3.6 31.5 ± 6.2 27.3 ± 3.3 25.3 ± 3.3 
Bilirubin 0.08-0.5 mg/dl 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 
 
Table 3.7. Select hematologic and non-hematologic parameters of A, healthy research dogs treated with 
single dose (25 mg/kg) of S-PAC-1 (n=4);  B, Healthy research dogs treated with a continuous rate 
infusion (see chapter text) of S-PAC-1 for 24 hours (n=3);  C, Dogs with lymphoma treated with S-PAC-1 
in a 24 hour continuous rate infusion every week for 4 consecutive treatments (n=3); and D, Dogs with 
lymphoma treated with S-PAC-1 in a 72 hour constant rate infusion every other week for 2 consecutive 
treatments (n=3).  Day zero represents the pre-treatment values.  Treatments began on day zero after blood 
collection and proceeded as described above.  For all values the error represents the SEM.  Taken with 
permission from Cancer Res.  2010, 70 (18), 7232-7241. 
Parameter Reference Range Day 0 Day 7 Day 14 Day 21 
WBC 6-17.0 x 103 8.5 ± 1.0 8.6 ± 1.8 8.9 ± 1.2  9.6 ± 1.9 
Neutrophil 3-11.5 x 103 4.7 ± 1.1 5.7 ± 0.3 5.5 ± 0.7 5.7 ± 1.5 
Platelet 2-9 x 105 2.0 ± 0.5 2.0 ± 0.7 2.2 ± 0.5 2.2 ± 0.8 
Creatinine 0.5-1.6 mg/dl 0.9 ± 0.1 0.9 ± 0.0 0.8 ± 0.1 1.0 ± 0.2 
ALT 17-87 U/L 34.7 ± 1.5 32.3 ± 1.2 35.7 ± 2.1 40.3 ± 6.5 
BUN 7.0-31.0 mg/dl 14.8 ± 2.1 17.0 ± 0.4 14.4 ± 6.1 16.4 ± 3.8 
Sodium 141-161 mEq/L 148.0 ± 3.0 147.3 ± 4.5 147.7 ± 2.1 149.3 ± 1.5 
Potassium 3.9-5.7 mEq/L 4.9 ± 0.3 4.7 ± 0.3 5.1 ± 0.2 5.0 ± 0.3 
Chloride 104-125 mEq/L 115.3 ± 2.3 112.7 ± 2.1 113.0 ± 1.7 112.3 ± 2.3 
Calcium 7.9-11.5 mg/dl 10.4 ± 0.1 10.7 ± 0.4 10.8 ± 0.4 10.9 ± 0.4 
Phosphorous 2.4-6.5 mg/dl 4.0 ± 0.5 4.0 ± 0.8 4.1 ± 0.5 3.9 ± 0.3 
ALP 12-110 U/L 26.0 ± 4.6 29.7 ± 5.5 28.7 ± 4.7 27.7 ± 4.2 
Bilirubin 0.08-0.5 mg/dl 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 
 165 
C) 
Parameter Reference Range Day 0 Day 7 Day 14 Day 21 Day 28 
WBC 6-17.0 x 103 8.8 ± 3.3 11.1 ± 4.2 9.7 ± 3.1 11.0 ± 3.9 10.1 ± 2.4 
Neutrophil 3-11.5 x 103 6.7 ± 0.6 8.7 ± 0.8 7.2 ± 0.5 8.8 ± 1.1 7.6 ± 0.4 
Platelet 2-9 x 105 2.6 ± 0.5 2.6 ± 0.8 2.7 ± 0.7 2.7 ± 1.0 2.4 ± 1.0 
Creatinine 0.5-1.6 mg/dl 1.2 ± 0.1 1.1 ± 0.1 1.2 ± 0.1 1.2 ± 0.2 1.6 ± 0.9 
ALT 17-87 U/L 50.7 ± 19.9 46.3 ± 11.0 41.0 ± 13.2 43.0 ± 15.5 53.0 ± 30.5 
BUN 7.0-31.0 mg/dl 17.2 ± 2.6 14.0 ± 1.6 14.6 ± 1.1 15.5 ± 2.8 24.5 ± 16.7 
Sodium 141-161 mEq/L 148.7 ± 2.1 145.3 ± 2.1 147.0 ± 1.7 149.3 ± 1.2 149.7 ± 1.5 
Potassium 3.9-5.7 mEq/L 4.4 ± 0.3 4.3 ± 0.2 4.4 ± 0.3 4.4 ± 0.4 4.0 ± 0.6 
Chloride 104-125 mEq/L 117.0 ± 1.0 111.3 ± 3.1 113.3 ± 1.5 118.0 ± 1.7 113.7 ± 4.9 
Calcium 7.9-11.5 mg/dl 11.3 ± 1.9 11.7 ± 2.1 11.4 ± 2.5 11.0 ± 1.1 12.0 ± 2.7 
Phosphorous 2.4-6.5 mg/dl 3.6 ± 1.0 3.5 ± 0.3 3.2 ± 0.3 3.2 ± 0.6 3.8 ± 0.8 
ALP 12-110 U/L 26.7 ± 11.2 37.3 ± 18.4 45.7 ± 16.5 45.0 ± 18.5 49.0 ± 20.7 
Bilirubin 0.08-0.5 mg/dl 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.0 0.1 ± 0.1 
 
 
D) 
Parameter Range Day 0 Day 14 Day 28 
WBC 6-17.0 x 103 14.3 ± 8.1 9.6 ± 4.2 14.1 ± 11.2 
Neutrophil 3-11.5 x 103 10.3 ± 5.6 6.6 ± 2.2 9.8 ± 7.9 
Platelet 2-9 x 105 2.7 ± 0.6 2.9 ± 0.7 2.8 ± 0.7 
Creatinine 0.5-1.6 mg/dl 0.8 ± 0.2 0.8 ± 0.2 0.8 ± 0.3 
ALT 17-87 U/L 63.3 ± 34.4 69.7 ± 45.5 58.7 ± 32.6 
BUN 7.0-31.0 mg/dl 15.3 ± 4.9 14.1 ± 3.3 13.5 ± 1.7 
Sodium 141-161 mEq/L 148.0 ± 4.0 147.7 ± 0.6 148.7 ± 1.5 
Potassium 3.9-5.7 mEq/L 4.5 ± 0.2 4.3 ± 0.2 4.5 ± 0.1 
Chloride 104-125 mEq/L 116.0 ± 2.6 115.7 ± 2.9 116.0 ± 2.0 
Calcium 7.9-11.5 mg/dl 10.0 ± 0.6 9.8 ± 0.3 10.1 ± 0.4 
Phosphorous 2.4-6.5 mg/dl 4.2 ± 0.1 3.6 ± 0.3 3.2 ± 0.9 
ALP 12-110 U/L 72.7 ± 63.6 46.0 ± 54.6 68.7 ± 57.9 
Bilirubin 0.08-0.5 mg/dl 0.2 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 
WBC-white blood cell, ALT- alanine transferase, BUN- blood urea nitrogen, ALP- alkaline 
phosphatase 
 
Table 3.7 (Cont.). Select hematologic and non-hematologic parameters of A, healthy research dogs treated 
with single dose (25 mg/kg) of S-PAC-1 (n=4);  B, Healthy research dogs treated with a continuous rate 
infusion (see chapter text) of S-PAC-1 for 24 hours (n=3);  C, Dogs with lymphoma treated with S-PAC-1 
in a 24 hour continuous rate infusion every week for 4 consecutive treatments (n=3); and D, Dogs with 
lymphoma treated with S-PAC-1 in a 72 hour constant rate infusion every other week for 2 consecutive 
treatments (n=3).  Day zero represents the pre-treatment values.  Treatments began on day zero after blood 
collection and proceeded as described above.  For all values the error represents the SEM.  Taken with 
permission from Cancer Res.  2010, 70 (18), 7232-7241. 
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Table 3.8.  Non-compartmental pharmacokinetic analysis of S-PAC-1 (25 mg/kg) in four healthy research 
dogs.  Taken with permission from Cancer Res.  2010, 70 (18), 7232-7241. 
 
Parameters Hound A Hound B Hound C Hound D 
Body weight (kg) 33.2 34.1 34.2 32.5 
Lambda_z half-life (h)  1.05 1.11 1.11 1.09 
Tmax (h) 0.17 0.17 0.17 0.17 
Cmax (ug/ml) 69.86 63.71 80.07 69.83 
AUC0-inf h*ug/ml 73.56 74.60 82.19 78.81 
AUMC0-inf h*h*ug/ml 93.63 104.77 90.48 101.78 
Cls (ml/h/kg) 340 335 304 317 
Vss (ml/kg) 432.5 470.8 334.8 410 
MRT (h) 1.27 1.40 1.10 1.29 
 
Constant Rate Infusion 
 
Based on the half-life of 1.09±0.02 hours in dogs, continuous-rate infusion was 
explored by Dr. Tim Fan in an attempt to maintain a steady-state serum concentration of 
S-PAC-1 during the course of the treatment.  Three healthy research dogs were utilized 
to determine if S-PAC-1 could be safely administered via a continuous-rate infusion 
regimen, and to determine appropriate dosing levels to maintain plasma concentrations 
above ~10 µM.  Each dog received a different dose of S-PAC-1 (Figure 3.24B) with an 
initial loading dose via IV infusion over the course of 10 minutes followed by a 
maintenance dose delivered by an infusion pump for an additional 24 hours.  Each dog 
was observed throughout the course of their 24-hour infusions for adverse reactions and 
blood was drawn by Dr. Tim Fan and coworkers at intervals to assess the 
pharmacokinetic profile of S-PAC-1 treatment.  In addition, following completion of S-
PAC-1 infusion, research dogs were evaluated for hematologic and non-hematologic 
toxicity weekly for 4 consecutive weeks.  During this period, no dogs exhibited 
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hematological parameters outside of normal ranges (Table 3.7) and no adverse events 
were reported by animal care staff.  
 
CRI pharmacokinetics 
 
S-PAC-1 administered as a 24-hour continuous-rate infusion can be safely given 
to research dogs and easily reaches micromolar steady-state plasma concentrations that 
correlate with dose escalation (Figure 3.24B).   Based on these results it was predicted 
that a 7 mg/kg loading dose and 3 mg/kg/h constant rate infusion would be sufficient to 
achieve a steady state plasma concentration of ~10 µM.   
 
Tolerability in research dogs 
 All research dogs treated by Dr. Tim Fan and coworkers with S-PAC-1 were 
observed by animal care staff and researchers for signs of toxicity.  No adverse effects 
were observed in response to treatement with S-PAC-1 in the constant rate infusion 
dosing regimen.  Additionally, blood biochemistry panels were performed before and 
after treatment to observe any physiological changes.  These results are shown in Table 
3.7.  All parameters were within control levels further supporting the observations of 
animal care staff.  In all measurements, S-PAC-1 treatment was well tolerated in these 
animals. 
Tolerability and efficacy in canine patients 
 
Assessment of S-PAC-1 in dogs with lymphoma.  Having confirmed the in vitro 
activity of S-PAC-1, shown that the compound can be safely administered via 
continuous-rate infusion, and that steady state plasma concentrations of S-PAC-1 of >10 
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µM may be achieved for a 24 hour duration, a small (n=6) clinical trial of client-owned 
pet dogs with spontaneous lymphoma was conducted by Dr. Tim Fan and coworkers.  
The aim of this trial was to demonstrate the feasibility of dosing S-PAC-1 in dogs with 
lymphoma, and to determine if therapeutic serum levels of compound could be achieved 
via this dosing regimen.  Pet dogs presented or referred to the Small Animal Clinic at the 
UIUC College of Veterinary Medicine were considered for enrollment in the clinical trial 
(see supplementary data for inclusion criteria).  Dogs that entered the study received 
treatment with S-PAC-1 as a single entity drug for 4 weeks and were followed for an 
additional 2 weeks after drug withdrawal. 
Toxicity and pharmacokinetics of S-PAC-1 in canine lymphoma patients.   
 
Six patient dogs received treatment with S-PAC-1 via one of two treatment regimens 
(summarized in Table 3.9).  Patients enrolled in the first treatment regimen (n=3) 
received a once-a-week 24 hour continuous infusion of S-PAC-1 for 4 weekly cycles.  
Patients enrolled in the second treatment regimen (n=3) received a 72 hour continuous 
infusion of S-PAC-1 every other week for 2 treatment cycles.   
 
Table 3.9.  Characteristics of the six pet dogs with lymphoma treated with S-PAC-1. Taken with 
permission from Cancer Res.  2010, 70 (18), 7232-7241. 
 
PD, Progressive Disease; PR, Partial Response; SD, Stable Disease 
Patient Breed Male/ Female Age 
Weight 
(lb) 
Immuno-
phenotype 
Prior 
Therapy Treatment Outcome 
1-Zombie Mixed Breed Castrated Male 7 79 
B-Cell 
Lymphoma CHOP 24 h PR 
2-Sophie Labrador Retriever 
Spayed 
Female 7 89 
T-Cell 
Lymphoma Naïve 24 h SD 
3-TJ Newfoundland 
Intact 
Male 4 160 
T-Cell 
Lymphoma Naïve 24 h SD 
4-Cinnamon Welch Corgi Spayed Female 8 30 
B-Cell 
Lymphoma Naïve 72 h SD 
5-Shelby Golden Retriever 
Spayed 
Female 7 80 
B-Cell 
Lymphoma Naïve 72 h PD 
6-Scooby 
Doo MC Boxer 
Castrated 
Male 6 59 
T-cell 
Lymphoma Naïve 72 h PD 
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Blood was collected during each S-PAC-1 treatment cycle for pharmacokinetic 
analysis.  In addition, blood was collected from all pet dogs at each scheduled follow up 
visit to characterize hematologic and non-hematologic toxicity.  Between administrations, 
patients were monitored by pet owners for gastrointestinal toxicity observational scores 
adhering the Veterinary Co-operative Oncology Group Common Terminology and 
Criteria for Adverse Events (VCOG_CTCAE)146.  All patients enrolled in either 
treatment regimen did not demonstrate any clinically significant hematologic or non-
hematologic toxicity (Table 3.7C and D).  Only minor adverse events were reported by 
pet owners such as self-limiting and localized irritation at the infusion site (n=4), 
transient loss of appetite (n=1), and mild diarrhea (n=3).  All adverse reactions subsided 
within 48 hours of the end of each treatment cycle.  Serum analysis indicated that all 
patients had measurable serum concentrations of S-PAC-1, as shown in Figure 3.25.  In 
accordance with our prediction from the healthy research dogs, an infusion with a loading 
dose of 7 mg/kg and a constant rate infusion of 3 mg/kg/h was sufficient to achieve 
steady-state plasma concentrations of  >10 µM in the majority of treatments. 
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Figure 3.25.  Serum concentrations of S-PAC-1 in lymphoma-bearing dogs.  Dogs enrolled in the clinical trial were 
typically administered S-PAC-1 at 7 mg/kg loading dose and 3 mg/kg/hr constant rate infusion for either 24 (A) or 72 
(B) hours.  Blood was drawn at the times indicated and the serum concentration of S-PAC-1 was determined by HPLC 
analysis. Zombie (top left), Sophie (top middle), TJ (top right), Cinnamon (bottom left), Shelby (bottom middle), 
Scooby Doo (bottom right).  Taken with permission from Cancer Res.  2010, 70 (18), 7232-7241. 
 
 Antitumor activity of S-PAC-1.  Given the small number of patients included in 
this clinical study, antitumor activity of S-PAC-1 cannot be conclusively determined.  
However, of the 6 patients treated, one patient (patient 1) showed a partial response with 
a ~30% reduction in both caliper RECIST score and the mandibular lymph node 
measurements by CT scan over the course of the 4-week treatment (Figures 3.26A and 
B).  During treatment, this dog received a 24-hour continuous intravenous infusion of S-
PAC-1 once-a-week (total of 4 treatments).  Following the four treatment cycles, drug 
administration was withdrawn and the dog was monitored by RECIST for 2 subsequent 
weeks.  After discontinuation of S-PAC-1 treatment, the RECIST scores for this dog 
increased dramatically (day 36 and 42). In addition to this partial response, three patients 
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showed stable disease (patients 2-4) while two patients showed disease progression 
(patients 5 and 6), (Figure3.27).  
 
 
 
 
Figure 3.26.  Anti-tumor effect of S-PAC-1 treatment.  A)  RECIST scores for patient 1 over the course of 
7 weeks.  Arrows indicate treatment days.  During the course of treatment patient 1 experienced a 27% 
decrease in RECIST score.  After treatment ended, tumor size increased rapidly (day 42).  B)  CT scans of 
the mandibular lymph nodes (outlined in yellow) demonstrate a clinically measurable  decrease in tumor 
size prior to treatment (day 0) and one week after S-PAC-1 administration (Day 7).  Taken with permission 
from Cancer Res.  2010, 70 (18), 7232-7241. 
 
 
 
A) B)
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Figure 3.27.  Anti-tumor effect of S-PAC-1 treatment.   RECIST scores for all six patients over the course 
of 4 weeks.  Treatment occurred on days 0, 7, 14 and 21 (top) or days 0 and 14 (bottom). Percent increase 
or decrease in RECIST score is noted for each patient.  
 
 
Although inconclusive in this study design, it is highly encouraging that four out 
of six patients achieved partial response or stable disease for 4 weeks in duration, as 
canine lymphoma is generally a rapidly progressive malignancy with dramatic 
enlargement of peripheral lymph nodes within weeks of disease diagnosis.  As shown in 
Table 3.9, one dog enrolled in the current study (patient 1) was in remission for 5 months 
after CHOP therapy, and was recently diagnosed with recurrent lymphoma.  Upon 
enrollment in the study, this dog showed a ~30% reduction in tumor size in response to 
S-PAC-1 treatment.  This partial response is significant given the comparatively short 
treatment duration (4 weeks for S-PAC-1 vs. 19 weeks for CHOP), and that the dose of 
S-PAC-1 administered does not appear to be near the maximum tolerated dose. 
Indeed, 8 additional dogs were enrolled in a dose escalation study by Dr. Tim Fan 
and coworkers to determine the maximum tolerated dose of S-PAC-1 in canine patients.  
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Given the response rate of dogs in the 24 hour treatment vs. the 72 hour treatment, further 
studies were carried out using a 24 hour continuous infusion once a week for four weeks.  
Table 3.10 summarizes the data for these patients and the dose administered. 
 
Table 3.10 Dose escalation of S-PAC-1 in dogs with lymphoma treated in 24-hour constant rate infusion.  
Treatment at 1x is 7mg/kg loading dose and 3 mg/kg/hr maintenance dose. 
 
 
 Blood was collected for each dog during treatment for pharmacokinetic analysis.  
Blood serum concentrations for dogs receiving a 2x dose of S-PAC-1 are shown in 
Figure 3.28.  As expected these dogs exhibited higher plasma concentrations than the 
dogs shown in Figure 3.25.  Generally, this dose was well tolerated by the three dogs that 
received the 2x dose.  Max exhibited no adverse events during the first administration of 
S-PAC-1 however, severe toxicity was observed during the final 3 hours of the second 
treatment.  It is notable that the plasma concentrations during this period and this 
treatment were significantly higher than during the first treatment reaching a plasma 
concentration of ~140 µM.  Max was euthanized following treatment.  As a result, it is 
unknown if the toxicity observed was transient in nature or if Max would have recovered 
from treatment. 
  
Dog Breed Weight 
(lbs) 
Treatment Adverse 
Events 
Response 
Gizmo Mixed 52 2x None Stable 
Max Labrador 98 2x Severe Stable 
Sport Mixed 48 2x None Stable 
Beaner Australian Shep 56 2.25x Death ND 
Ellie Mae Mixed 38 3.3x Severe Response 
CoCo Poodle 80 3.3x Slight Progression 
Thane Doberman 116 3.3x Death Response 
Serena German Shep 78 3.3x Severe Progression 
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Figure 3.28.  Serum concentrations of S-PAC-1 in lymphoma-bearing dogs receiving 2x treatment.   
Gizmo (left), Max (middle) and Sport (right) received a constant rate infusion for 24 hours.  Blood was 
drawn at the times indicated and the serum concentration of S-PAC-1 was determined by HPLC analysis. 
 
 
 Given the limited toxicity observed with Max, four dogs were enrolled at a 3.3x 
concentration.  The serum concentration for these dogs is shown in Figure 3.29.  These 
dogs received one dose at the 3.3x dose.  The drug plasma levels for Ellie Mae exceeded 
140 µM.  As was seen with Max, Ellie Mae exhibited significant toxicity during the final 
6 hours of her treatment corresponding with the most elevated plasma levels.  
Intriguingly, Ellie Mae has shown significant antitumor activity with disease regression.  
She has remained in remission for over 8 months with no further anticancer treatment.  
As of the writing of this dissertation, Ellie Mae remains stable. 
 Serena exhibited significant toxicity despite relatively low serum concentration of 
the drug while CoCo tolerated the treatment well despite serum levels higher than 
observed with Serena.  Several hours after treatment, Thane experienced severe toxicity 
and ultimately died.  Although conclusive evidence in not available, it is thought that 
Thane’s death was the result of S-PAC-1 toxicity. Given these results, it is difficult to 
draw any one-to-one correlation between serum levels of the drug and the toxicity 
observed; however, it serum concentrations above 80 µM have the potential to induce 
severe toxicity. 
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Figure 3.29. Serum concentrations of S-PAC-1 in lymphoma-bearing dogs receiving 3.3x treatment.   
Blood was drawn at the times indicated and the serum concentration of S-PAC-1 was determined by HPLC 
analysis. 
 
 
 Given the toxicity observed in two dogs at the 3.3x treatment dose, doses between 
2x and 3.3x were investigated.  Beaner received 2.25x S-PAC-1 formulated in 2HPβCD.  
During treatment Beaner died.  It is thought that his death was due to severe toxicity 
observed during treatment.  Death occurred 22 hours into treatment preventing serum 
samples from being collected at the 24 hour time point (see Figure 3.30).  As a result, it is 
unknown what the serum concentration of S-PAC-1 was at the time of death, but given 
the serum levels during the first 12 hours of treatment, it is not expected that the serum 
concentration at death was elevated. 
 
 
Figure 3.30. Serum concentrations of S-PAC-1 in Beaner receiving 2.25x treatment.   Beaner died before 
the completion of the study.  Blood was drawn at the times indicated and the serum concentration of S-
PAC-1 was determined by HPLC analysis. 
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3.4 Evaluation of other PAC-1 derivatives in vivo 
 Results from PAC-1 and S-PAC-1 efficacy studies suggest that these compounds 
are capable of exerting an anticancer effect in spontaneously arisen cancer in pet dogs.  
The extent of this effect is limited by the hyperexcitation and neurosuppressive toxicity 
observed in response to these compounds.  Additionally, the instability of these 
compounds as exhibited by the short half-life prevents conventional administration of 
these drugs.  It is possible that the toxicity observed as a result of these compounds is due 
to the cumulative effects of the constant rate infusion of drug.  Indeed, in instances where 
PAC-1 and S-PAC-1 resulted in severe adverse events in pet dogs, the toxicity occurred 
after 18-24 hours of treatment.  The available pharmacokinetics data suggest that this 
toxicity does not absolutely correlate with plasma concentration of the drug.  Thus we 
sought to identify additional compounds that might further inform our understanding of 
the toxicity of PAC-1 and S-PAC-1 as well as present new candidate compounds that 
overcome some of these challenges. 
 Given the limited efficacy that was observed in dogs and mice with S-PAC-1 it is 
likely that the therapeutic window is small.  The minimum effective dose (MED) and the 
maximum tolerated dose (MTD) are very close to each other (see Figure 3.31).  It was 
hoped that new compounds would be able to either increase the MTD or reduce the MED 
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thus increasing the therapeutic window and enhancing the opportunity for efficacious 
treatment. 
 
Figure 3.31.  Improving the therapeutic window.  The distance between the MTD and MED determine the 
therapeutic window.  For compounds with narrow therapeutic windows (right) the MTD must be raised or 
the MED lowered (left). 
 
3.4.1 Murine Toxicity Studies 
 Several compounds have been evaluated in murine studies to determine their 
toxicity and pharmacokinetic profile.  These compounds have been chosen from PAC-1 
libraries and rationally designed compounds with the hope of identifying compounds 
with improved therapeutic windows and enhanced stability, solubility and potency.  
Compounds requiring shorter exposure time for activity. 
 One of the limitations of S-PAC-1 treatment is the long exposure time required 
for cytotoxic activity.  As described in Chapter 2, S-PAC-1 exposures of less than 24 
hours in cell culture exhibited reduced cytotoxicity.  Due to the short half life of the drug, 
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this requires constant rate infusion of the drug in vivo to maintain elevated serum 
concentrations.  It is during the final hours of these 24 hour treatments that toxicity is 
observed.  As such, a compound that is capable of inducing cancer cell death with a 
shorter exposure time would be advantageous.  Such a compound would eliminate the 
need for long constant rate infusions and may reduce the toxicity observed.   This would 
have the result of simultaneously increasing the MTD and reducing the MED. 
 To the end of indentifying compounds capable of inducing cell death with short 
exposures to drugs we began by investigating the ability of the compounds from chapter 
2 to induce cell death with a 1 hour exposure time in EL4 cells.  Cells were treated with 
100 µM for 1 hour after which the cells were washed with fresh media and cultured for an 
additional 23 hours.  Cell death was assessed by PI exclusion using flow cytometry.  
Figure 3.32 shows the viable cells as a function of logBB with each data point 
representing a compound described in chapter 2. 
 Generally, compounds with logBB near zero induce significant amounts of cell 
death even with this short exposure time.  Compounds with negative logBB such as S-
PAC-1 (PAC-1-II-9) do not induce cell death with this short exposure time.  Although a 
number of compouds were identified that are capable of inducing cell death with a short 
exposure time, many of these compounds have unfavorable logBB (near zero or positive) 
that would be predicted to cause neurotoxicity in vivo.  Although the trend toward 
enhanced cytotoxic activity with increasing logBB, a few compounds fall outside this 
trend.  Of note is PAC-1-II-12 (azido-PAC-1) which has a predicted logBB of -0.7 and 
potently induces cell death in cell culture with a 1 hour exposure to 100 µM compound.  
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Figure 3.32.  Cytotoxicity and LogBB of PAC-1 derivatives.  Compounds discussed in Chapter 2 were 
evaluated for their ability to induce cell death after a 1 hour exposure in EL4 cells.  Cell death is plotted as 
a function of LogBB. 
 
Evaluation of PAC-1-II-12 
 Given the properties for PAC-1-II-12 described above, the toxicity in mice was 
determined by Dr. Tim Fan.  Mice were treated with PAC-1-II-12 at 12.5 mg/kg, 25 
mg/kg and 50 mg/kg via i.v. administration.  No toxicity was observed at 12.5 mg/kg or 
25 mg/kg.  At 50 mg/kg only slight toxicity was observed with mild ataxia and lethargy.  
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Given the predicted logBB of this compound it is not surprising that toxicity is observed 
at higher doses than observed with PAC-1. 
 Pharmacokinetic analysis of PAC-1-II-12 is shown in Figure 3.33.  Mice were 
treated with 90 mg/kg PAC-1-II-12 via i.p. administration.  Mice were sacrificed and 
blood collected at various time points.  Plasma concentration of PAC-1-II-12 was 
determined by HPLC analysis.  The peak plasma concentration for PAC-1-II-12 was 8.8 
µM and the half-life of elimination was ~1 hour.  Given the relatively high dose of PAC-
1-II-12 administered, this pharmacokinetic profile suggests a very low bioavailability.  
Despite the promising characteristics of PAC-1-II-12 it is unlikely that a significant 
concentration of the drug could be achieved in the plasma to observe efficacy.  As such, 
PAC-1-II-12 was not further evaluated in tumor bearing mice. 
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Figure 3.33. Intraperitoneal pharmacokinetic profile of PAC-1-II-12 in mice.  C57/BL6 mice were treated 
with 90 mg/kg PAC-1-II-12 solubilized in HPβCD via i.p. injection.  Mice were sacrificed at the times 
indicated and blood was drawn.  The concentration of drug was determined by HPLC.  Error bars represent 
SEM (n=3). Peak plasma concentration of 8.8 µM, half-life of ~1 hour.   
 
Evaluation of PAC-1-II-24 
 Given the promising results with PAC-1-II-12 we sought to identify other 
compounds with highly negative logBB that induce cell death with short exposure with 
the hope of identifying a compound that will not only have an improved toxicity profile, 
but will also be bioavailable.  The cyclohexalamine derivative of PAC-1 (PAC-1-II-24) 
has a predicted logBB (-0.87) and was also shown to induce cell death in EL4 cells as 
described for PAC-1-II-12. 
 The toxicity profile of PAC-1-II-24 as assessed by Dr. Tim Fan is very similar to 
PAC-1-II-12.   At 50 mg/kg, mice administered PAC-1-II-24 formulated in 2HPβCD via 
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tail vein injection exhibited ataxia and lethargy that persisted for 5-10 minutes before 
completely resolving.  At 100 mg/kg, PAC-1-II-24 treatment resulted in death in 3 of 3 
mice tested. 
 Given the similar toxicity profile to PAC-1-II-12, the pharmacokinetics of PAC-
1-II-24 was evaluated to determine if PAC-1-II-24 is bioavailable.  Figure 3.34 shows the 
pharmacokinetic profile for PAC-1-II-24.  The peak plasma concentration of 4.3 µM and 
half-life of ~1 hour are similar to that obtained with PAC-1-II-12 and do not support the 
further evaluation of PAC-1-II-24. 
 
Figure 3.34.  Intraperitoneal pharmacokinetic profile of PAC-1-II-24 in mice.  C57/BL6 mice were treated 
with 25 mg/kg PAC-1-II-24 solubilized in HPβCD via i.p. injection.  Mice were sacrificed at the times 
indicated and blood was drawn.  The concentration of drug was determined by HPLC.  Error bars represent 
SEM (n=3).  
 
 L28R8 (Figure 3.35) was identified from a library of 868 PAC-1 compounds as a 
compound that induces cell death as a result of short exposures to compound.  L28R8 
was shown to be similar to PAC-1 in many ways (see Diana C. West dissertation for 
comprehensive discussion).   Of note, L28R8 has a logBB of -0.86 and as such is an 
attractive candidate for in vivo studies. 
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Figure 3.35.  Structure and LogBB of L28R8. 
 L28R8 formulated in 2HPβCD was administered to mice at 150 mg/kg and 200 
mg/kg via i.p. administration.  Both of these doses were well tolerated with only mild 
lethargy observed and resolving after 30 minutes after administration.  Further repeat 
dose toxicity was performed at 200 mg/kg daily for 10 days.  Mice tolerated this 10-day 
treatment well with transient, mild lethargy observed after each treatment but significant 
toxicity was not observed.  In further studies performed by Tim Fan, L28R8 administered 
at 180 mg/kg daily for 10 days resulted in significant weight loss and death in some 
animals.  The difference in these results may be explained by the age of the mice treated.  
Tim Fan utilized mice that were 8-12 weeks old while the mice used in my study were 6 
months old.  Although doses were adjusted to account for differences in weight, it is 
likely that older mice that weigh more would be more resilient in response to a drug that 
causes weight loss. 
 In a separate screen three additional compounds were identified from the 868-
member PAC-1 library as compounds that are significantly more potent than PAC-1 and 
S-PAC-1 (Table 3.11).  Compounds were screened at 20 µM for 24 hours (the 24 hour 
IC50 value for PAC-1 and S-PAC-1) in an attempt to identify compounds that were more 
L28R8 
LogBB: –0.86 
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potent at exposures as short as 24 hours.  Compounds L14R8, L27R8 and L5R8 were 
identified as derivatives that induce greater than 80% cell death in the screening 
conditions.  These compounds also exhibit 72 hour IC50 values that are significantly more 
potent than PAC-1 and S-PAC-1.   
Table 3.11.  Compounds identified from 868-member PAC-1 library with associated toxicity in mice when 
formulated in 2HPβCD and administered by a single i.p. injection. 
 
 
 Although these compounds do not have exhibit a highly negative logBB as the 
compounds described above, they are significantly more potent than PAC-1 which has 
been shown to be safely administered at low levels in both mice and dogs.  Given the 
enhanced potency of these compounds it was envisioned that these compounds may elicit 
a lower MED while maintaining the same MTD thus expanding the therapeutic window.  
As such we sought to evaluate and compare the toxicity of these three compounds in 
mice with the MTD of PAC-1. 
 Mice were treated with PAC-1, L14R8, L27R8 or L5R8 formulated in 2HPβCD 
at 150 mg/kg via i.p. administration and observed for toxicity (n=1 for each compound).  
Compound Structure 72h IC50 value 
(!M) 
LogBB 
value 
Mouse toxicity 
(150 mg/kg) 
L5R8 
 
 
 
 
0.7 ± 0.04 + 0.14 Severe 
L14R8 1.4  ± 0.6  + 0.42 Severe 
L27R8 
 
 
 
 
 
1.4  ± 0.6 + 0.02 Severe 
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As expected, PAC-1 elicited significant neurotoxicity as has been previously described.  
L14R8, L27R8 and L5R8 all exhibited more mild neurotoxicity during the first hour after 
drug administration including ataxia and tremors.  These symptoms subsided by one hour 
after administration and mice exhibited lethargy for the next 6-18 hours.  The mouse that 
received L14R8 died 6 hours after treatment.  Mice that received L5R8 or L27R8 began 
to express more severe neurological symptoms including shaking and continued ataxia.  
At 18 hours, these mice experienced shallow breathing and severe unresponsiveness 
followed by death.  Mice that received PAC-1 recovered fully.  These results suggest that 
the MTD for these compounds lies below the MTD for PAC-1 
 In order to confirm that the prolonged neurotoxicity observed in comparison to 
PAC-1 was not the result of enhanced stability of these compounds, we evaluated the 
pharmacokinetic properties of the most promising compound.  Due to poor solubility of 
L27R8 and the earlier death of the mouse treated with L14R8, we performed 
pharmacokinetic analysis of L5R8 administered at 30 mg/kg via i.p. injection (Figure 
3.36).  The peak plasma concentration observed for L5R8 was 2.5 µM and a half-life of 
elimination of ~3 hours.  This bioavailability is significantly lower than that of PAC-1 
and S-PAC-1 although the stability of the compound appears to be significantly 
improved, however, these results do not explain the prolonged toxicity and it is unlikely 
that a dosing strategy could be developed that would achieve sufficiently elevated plasma 
concentrations without inducing toxicity. 
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Figure 3.36. Intraperitoneal pharmacokinetic profile of L5R8 in mice.  C57/BL6 mice were treated with 30 
mg/kg L5R8 solubilized in HPβCD via i.p. injection.  Mice were sacrificed at the times indicated and blood 
was drawn.  The concentration of drug was determined by HPLC  
 
Evaluation of Glucose PAC-1 
 Glucose conjugation is a strategy to improve solubility and enhance selectivity of 
a drug for cancer cells.  Dr. Isak Im synthesized a PAC-1 derivative with glucose 
conjugated through the hydroxyl required for activity (Figure 3.37).  As such this 
compound is predicted to be inactive until it enters a cell and is cleaved by glycosidases 
in the cell.  In this way G-PAC-1 acts as a prodrug minimizing off target side effects. 
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Figure 3.37.  Structure, LogBB and cytotoxicity of G-PAC-1. 
 G-PAC-1 and PAC-1 formulated in 2HPβCD were administered to mice via i.p. 
injection.  PAC-1 was administered at 150 mg/kg and G-PAC-1 was administerd at 150 
mg/kg, 200 mg/kg, 250 mg/kg, 300 mg/kg and 350 mg/kg.  As anticipated, PAC-1 
exhibited severe neurotoxicity as previously described.  Encouragingly, G-PAC-1 did not 
exhibit any neurotoxicity at any dose tested.  No symptoms were observed for treatments 
as high as 250 mg/kg.  At 300 mg/kg and 350 mg/kg G-PAC-1, mice exhibited mild 
lethargy for 2 hours after treatment that was self-limiting. 
 Given the encouraging results with G-PAC-1, repeat dose toxicity studies were 
undertaken.  Mice were administered 350 mg/kg of G-PAC-1 daily for 5 days.  During 
this time no significant toxicity was observed in mice.  Taken together these results 
demonstrate the safety advantage provided by glucose conjugation.  Further studies are 
underway to evaluate the efficacy of treatment with G-PAC-1. 
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3.5 Summary 
As the first procaspase-activating compound, experiments with PAC-1 can begin 
to define the potential of procaspase-3 activation as a viable anticancer strategy.  To 
further develop PAC-1 as an experimental therapeutic for the treatment of cancer in 
humans, we sought to characterize the effect of this compound when administered 
intravenously and in more sophisticated in vivo tumor model systems, specifically, 
canines with spontaneous cancer.  The evaluation of experimental therapeutics in pet 
dogs with cancer offers many advantages over murine xenograft models.143 
Second, we characterized the pharmacokinetics of intravenous and oral PAC-1 in 
a large mammalian model, the dog, which closely resembles the physiology and 
metabolism of human beings.  Last, we assessed the feasibility and safety of a 
pharmacokinetically-derived dosing regimen which achieved and maintained steady-state 
concentrations of PAC-1 in dogs predicted to correlate with in vitro cytotoxic 
concentrations. 
Using dogs greater than 30 kilograms in weight, we were able to demonstrate the 
feasibility and safety of PAC-1 IV therapy in an experimental system which more closely 
approximates the anatomic size, physiology, and metabolism of human beings when 
compared to conventional rodent models.   As such, this investigation provides pertinent 
and valuable information for future plausible PAC-1 dosing strategies which may be 
well-tolerated and effective in human cancer patients.  
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We discovered S-PAC-1 as a procaspase-activating compound that can be safely 
administered in vivo, and have identified pet dogs with lymphoma as a tractable model 
for the assessment of small molecule procaspase-3 activation as an anticancer strategy.  
Use of this large animal model allows drug administration via continuous rate IV 
infusion, something necessary with S-PAC-1 (due to its short half-life in vivo) and not 
practical in murine tumor models.  S-PAC-1 induces apoptotic death in cultured cancer 
cells, with similar activity to the parent compound PAC-1.  While high doses of PAC-1 
(when administered in HPβCD) induce neurotoxicity in vivo, S-PAC-1 does not cause 
this effect at serum concentration ~70-fold higher.  S-PAC-1 can be safely administered 
to mice, research dogs, and dogs with lymphoma, and shows encouraging clinical effect 
in this preliminary evaluation.  Given the absence of neurotoxicity with S-PAC-1 and the 
large safety window observed in mice, we evaluated the tolerability of S-PAC-1 at 
escalated doses, and identified the dose limiting toxicities observed at these elevated 
doses.   
S-PAC-1 is the first compound in the PAC-1 class (and the first small molecule 
activator of procaspase-3) to be evaluated in a clinical trial of cancer patients.  As such, 
the evaluation of S-PAC-1 in a clinical setting is proof-of-concept for the strategy of 
direct procaspase-3 activation as an anticancer therapy.  Compounds in the PAC-1 class 
activate procaspase-3 via chelation of inhibitory zinc ions.61  Intracellular zinc is found 
principally in tightly-bound complexes in metalloproteases, zinc-finger domains, and 
other metal binding proteins; however, approximately 10% of cellular zinc is believed to 
exist in a loosely-bound, labile pool.147  A number of studies implicate labile zinc as an 
endogenous antiapoptotic regulator,33,34,69 and chelation of the loosely-bound pool of zinc 
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is an emerging anticancer strategy.60,61,148  Thus, the evaluation of S-PAC-1 is also proof-
of-concept for the chelation of the labile zinc pool as an anticancer therapy.   
3.6 Materials and Methods 
Cell lines and reagents 
 Two canine B-cell lymphoma lines (17-71 and GL-1) were provided by Dr. Steve Suter, 
North Carolina State University.  These cells were maintained in Dulbecco's Modified 
Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), penicillin 
and streptomycin (P/S).  A human B-cell lymphoma line, CA46, was purchased from 
American Tissue Culture Collection (Manassas, VA) and maintained in DMEM 
supplemented with 20% FBS and P/S.  All three lymphoma cell lines grew as free 
suspensions in cell culture flasks (Corning, Inc., Corning, NY) when incubated at 37 oC 
in 5% CO2, and cultures were passaged 2-3 times a week to maintain high cell viability.  
As necessary, cells were harvested and a trypan blue dye exclusion test was performed to 
assess viability ≥ 95% prior to any experimentation. 
 PAC-1 and deuterated PAC-1 were synthesized as described.45  For all in vitro 
experiments, PAC-1 was reconstituted with 99.5% DMSO (Sigma-Aldrich, St. Louis, 
MO) to produce a 10 mM stock solution, which then was aliquoted and kept frozen at -
20oC until needed.  For all in vivo experiments, PAC-1was freshly reconstituted to a 
concentration of 15 mg/ml immediately prior to infusion by solubilizing in 2-
hydoxypropyl-β-cyclodextrin (Sigma-Aldrich, St. Louis, MO) and sterile water for 
injection. 
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Cell Lines and Reagents—U-937 and EL4 cells were obtained from ATCC, 
maintained at low passage number and used without further authentication. All cultures 
were maintained in RPMI-1640 media supplemented with 10% FBS and 1% Pen-Strep 
and grown at 37 °C and 5% CO2.  PAC-1 was synthesized as previously described.45  S-
PAC-1 was synthesized as described in the supplementary data.  
 
Animals and sample collection 
Six healthy, intact male hound dogs weighing at least 30 kg were used for all 
pharmacokinetic studies.  All procedures involving care and handling of the dogs 
followed guidelines set forth by the University of Illinois Animal Care and Use 
Committee.  Pharmacokinetic analyses were derived from PAC-1 dissolved in 2-
hydoxypropyl-β-cyclodextrin and sterile water, and dosed at 1.0 mg/kg body weight as 
either a 10-minute intravenous (IV) bolus or 5-minute oral slurry.  All dogs received a 
single dose of PAC-1 via both IV and oral routes, with a two-week washout period 
between dosing.  Blood was drawn from the jugular vein, centrifuged, and plasma stored 
at -80oC until analysis.  Sample collection times for dogs receiving IV PAC-1 were 0, 10, 
20, 30, 40, 60, 120, 240, 480, 720 minutes, and 24 hours post administration.  Sample 
collection times for dogs administered oral PAC-1 were 0, 15, 30, 45, 60, 120, 240, 480, 
720 minutes, and 24 hours post administration.   
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Pharmacokinetic-derived dosing regimen and toxicity assessment of constant rate 
infusion PAC-1   
Following the pharmacokinetic characterization of IV PAC-1, a dosing regimen 
predicted to achieve and maintain a steady state plasma concentration of 10 µM or 
greater was derived and tested in 4 of the original 6 hound dogs.  These 4 dogs were 
treated with IV PAC-1 delivered as a constant rate infusion (CRI), comprising of a10-
minute loading dose (LD), and followed by a constant maintenance dose (MD) for 48 
hours.  Blood samples were collected at 0, 1, 6, 12, 24, 36 and 48 hours to determine 
PAC-1 plasma concentrations.  Following PAC-1 infusion, dogs were assessed for any 
potential hematologic, non-hematologic, or gastrointestinal side effects weekly for 4 
consecutive weeks.   
Liquid chromatography-Mass Spectrometry (LC/MS) Analysis of PAC-1  
A Waters Alliance 2795 Separation Module (Waters Co., Milford, MA) was used 
at a flow rate of 200 ml/min to deliver an isocratic mobile phase consisting of 32% (v:v) 
acetonitrile in aqueous 0.1% formic acid (v:v).  Separations were conducted using a Luna 
C18 (2) column (2 x 150 mm, 3 µ particle size (Phenomenex, Torrance CA) maintained 
at ambient temperature.  An AD20 detector (Dionex Co., Sunnyvale, CA) was used to 
assess chemical purity and to quantify the internal standard (254 nm detection). 
A Micromass Quattro Ultima (Waters Co.) triple quadrupole mass spectrometer 
equipped with an electrospray probe was used in multiple reactions monitoring (MRM) 
mode for analysis of positive ions.  The optimal MRM transitions (i.e., those giving the 
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maximal responses) for PAC-1 and deuterated PAC-1 were determined to be m/z 393 --
>189 and 400 -->196, respectively (i.e., [M+H]+ -->benzyl-piperazine=CH2+).  Other MS 
parameters included dwell times of 0.2 sec, argon collision gas at 2.2 x 10-3 bar, nitrogen 
as both cone gas (100 L/hr) and desolvation gas (750 L/hr), and source and desolvation 
temperatures of 100 °C and 350 °C, respectively.  An optimized sampling cone-skimmer 
potential of 50 V and a collision energy of 25 eV were used was used throughout.  
Resolution was set to give peak widths at half-height of 0.9 Th for product and precursor 
ions. 
Characterization of labeled internal standard 
The solution concentration of deuterated PAC-1 was determined by comparing 
LC-UV response (254 nm) with that from a solution of the authentic unlabeled analog 
prepared by accurate weighing.  No unlabeled PAC-1 was observed using full scan MS 
or MRM monitoring (<0.1%).  The plot of response ratios for labeled versus unlabeled 
PAC-1 was linear over the concentration range of 2.5-250 fmol unlabeled plus 100 fmol 
deuterated PAC-1 with a slope of 0.97 and a correlation coefficient of 0.999.  Seven 
different concentration ratios, analyzed in duplicate, were used for the plot and all back-
calculated concentrations were within 10% of the nominal value. 
Solid phase extraction 
 Thawed serum samples (10 µl) and 100 fmol deuterated PAC-1 internal 
standards (in 10 µl acetonitrile) were added to a total of 500 µl of 50 mM ammonium 
acetate (pH 7.2).  Solid phase extraction was performed in the 96-well format using an 
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Oasis HLB plate (Waters Corp., 10 mg wells).  The wells were activated by sequential 
application of 1 ml methanol and 1 ml 50 mM ammonium acetate (pH 7.2).   The samples 
were applied and the cartridges were washed with 0.5 ml of 50 mM ammonium acetate 
(pH 7.2) and then eluted with 2 x 0.5 ml methanol containing 0.1% formic acid (v/v).  
The samples were concentrated to approximately 30 ml using a centrifugal vacuum 
concentrator (SpeedVac, Savant, Farmingdale, NY) and 50 µl methanol containing 0.1% 
formic acid (v/v) and then 50 µl water were added.  Aliquots of 10 ml were analyzed 
using LC-ES/MS/MS. 
Pharmacokinetic determinations  
  Pharmacokinetic analyses were performed, using a non-linear regression program 
(Winnonlin, version 5.1) (Pharsight Corporation, Cary, NC).  Area under the curve 
(AUC) following intravenous administration was measured by use of a linear trapezoidal 
approximation with extrapolation to infinity, and slope of the terminal portion (β) of the 
log plasma drug concentrations versus time curve was determined by the method of least-
squares regression. 
  The compartmental model used is represented by general equation a where Cp is 
plasma concentration of compound at any time (t), A and B are the Y intercepts 
associated with distribution and elimination phase, respectively, and α and β represent 
the rate constant of distribution and terminal elimination phase, respectively.  The rate 
constant of distribution (α), and distribution half-life (t1/2 α) were determined using the 
method of residuals.  The terminal half-life (t1/2 β)149,150 was calculated according to 
Equation 1. 
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 Cp = A×e-α.t + B×e-β.t        (a) 
t1/2β = ln2/β         (1) 
 Total body clearance (Cls) was calculated by use of Equation 2. 
 Cls = IV Dose/AUC0-inf (IV).       (2) 
  
  The absolute bioavailability (F) was calculated from the AUC0-inf ratio obtained 
following oral and IV administration according to Equation 3. 
F = AUC0-inf (Oral)/AUC0-inf (IV) × IV Dose/Oral Dose    (3) 
  The volume of distribution in central compartment (Vdc), volume of distribution 
in terminal elimination phase (Vdβ) and volume of distribution at steady state (Vdss) were 
calculated according to Equations 4, 5 and 6, respectively.149,150 
 Vdc = Dose (IV)/A+B        (4) 
 Vdβ = IV Dose / AUC0-inf × β       (5) 
 Vdss = IV Dose × AUMC0-inf / (AUC0-inf )2     (6) 
 AUMC is area under the first moment curve and calculated by the trapezoidal method 
and extrapolated to infinity.  
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  The compartmental model used following oral administration is represented by 
general equation b where A is Y intercept associated with terminal elimination phase, K01 
is the apparent rate constant of absorption, and K10 is the apparent rate constant of 
elimination (Shargel, 1993).  The rate constant of absorption (K01) and the absorption 
half-life (t1/2 K01) were determined, using the method of residuals.  The linear terminal 
slope (K10) was calculated from the log plasma drug concentrations versus time curve by 
using the method of least-squares regression.  The terminal elimination half-life (t1/2 K10) 
was calculated according to equation 7.  
 Cp = A×e-K10.t - A×e-K01.t        (b) 
 t1/2K10= ln2/K10         (7) 
  Total oral clearance (Clo) will be calculated by use of Equation 8 
 Clo = Dose (Oral)/AUC0-inf       (8) 
  The maximum drug concentration after oral administration (Cmax) and the time at 
which Cmax was achieved (Tmax)149,150 were determined by use of equations 9 and 10, 
respectively. 
 Cmax = A.e-K10.Tmax – A.e-K01.Tmax       (9) 
      Tmax = 1/K01-K10 × (Ln (K01/K10)      (10) 
Statistical analysis  
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The effect of two variables, being incubation time (time-dependent) and PAC-1 
concentration (dose-dependent), on cytotoxicity in the 17-71, GL-1, and CA46 cell lines 
were compared with a 2-way ANOVA test.  Significance was evaluated with either 
Tukey or Dunnett’s post hoc tests for time-dependent or concentration-dependent 
variables, respectively.  Differences in caspase-3 activation following incubation with 
PAC-1 (10 or 20 µM) for varying exposure durations were analyzed with one-way 
ANOVA and post-hoc Dunnett’s test.  Significance was defined as p < 0.05. 
Toxicity determinations of PAC-1 and S-PAC-1.  PAC-1 and S-PAC-1 were 
formulated in 2-hydroxypropyl-β-cyclodextrin (HPβCD)127 as described in the 
supplementary data.  C57/BL6 mice were administered varying doses of either PAC-1 or 
S-PAC-1 via tail vein injection.  Mice were monitored by observation for a period of 24 
hours for signs of toxicity including sensitivity to touch, hypothermia, hunched posture, 
agitation, and rapid or depressed breathing. 
Pharmacokinetics of S-PAC-1 in healthy research dogs and dogs with lymphoma.  
Four healthy male hound dogs weighing at least 30 kg were used for all preclinical 
pharmacokinetic studies.  All dogs received a single dose of S-PAC-1 via IV injection. 
After a two week washout period three dogs received a dosing regimen predicted to 
achieve and maintain a steady state plasma concentration of 10 µM, that is, IV S-PAC-1 
delivered as a constant rate infusion comprising a 10-minute loading dose, followed by a 
constant maintenance dose for 24 hours.  Dogs with lymphoma were treated with IV S-
PAC-1 in a constant rate infusion for either 24 hours or 72 hours.  For all dogs and 
dosing strategies, blood was drawn from the femoral vein, centrifuged, and plasma stored 
at -80oC until analysis.     
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Toxicological Assessment of S-PAC-1 in healthy research dogs.  Toxicity of S-
PAC-1 administration was determined by serial weekly complete blood counts, serum 
biochemistry panels, and animal caregiver gastrointestinal toxicity observational scores 
adhering to the Veterinary co-operative oncology group common terminology criteria for 
adverse events (VCOG-CTCAE).   
Antitumor assessment of S-PAC-1 in dogs with lymphoma.  Caliper measurement 
was performed according to the RECIST method151.  Briefly, the longest linear length 
measurement was recorded for 4 pairs of peripheral lymph nodes (mandibular, 
prescapular, inguinal, and popliteal), with the summation of these values giving a 
RECIST score.  In addition to caliper measurements for all four sets of peripheral lymph 
nodes, computed tomography (CT) scans were performed of the mandibular lymph nodes 
in every patient, allowing for accurate and objective measurement of maximal lymph 
node linear length. 
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Chapter 4:  Zinc chelation in procaspase activation 
 Zinc is known to exert an antiapoptotic role in cells.33,69,113  Numerous studies 
have sought to understand the role of zinc in exerting this antiapoptotic effect.34,36,82,91,152  
It has been shown that zinc inhibits caspase-3 activity in vitro.35,83  Contained in chapter 2 
are results showing that zinc also inhibits procaspase-3 activity and processing in vitro.  It 
has been suggested that one way in which zinc exhibits antiapoptotic activity is through 
the inhibition of cellular caspases.33,69  It has also been reported that zinc and procaspase-
3 are colocalized in the cell.36 Several of the studies contained in this body of work 
support this hypothesis and further show that removal of this inhibitory zinc is capable of 
activating procaspase-3 to caspase-3 in cells.  
 Although zinc has been shown to exhibit antiapoptotic activity when added to 
cells exogenously33, the role of endogenous zinc in the regulation of apoptosis is not 
clear.  Zinc levels in cells are tightly regulated by a system of zinc import and export 
proteins that respond to environmental levels of zinc.82  Studies suggest that 90% of 
intracellular zinc maintained by this system is bound in tight protein complexes and 10% 
of zinc existing in a loosely-bound pool.36 
 Zinc levels have been shown to be elevated in many cancers.94,115,147  These 
elevated zinc levels have been suggested to be partially responsible for the ability of these 
cells to evade apoptosis,115 however, the exact mechanism of this antiapoptotic effect and 
its role in cancer has not been extensively studied.   In this chapter we report studies 
evaluating the mode by which zinc inhibits procaspase-3.  Efforts to identify the zinc-
binding site are described and implications on the regulation of apoptosis are discussed. 
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4.1 Zinc mode of inhibition of Procaspase-3 
 Studies in the literature suggest that caspase-3 is inhibited by zinc as a result of 
the affinity of zinc for free thiols,35 and thus by anology the same could be true for 
procaspase-3.  It should be noted that there is little definitive proof tha zinc inhibits 
caspase-3 through a zinc-thiol interaction.  Procaspase-3 and caspase-3 contain a reactive 
thiol in their active site that is required for catalytic activity of the enzyme.153  Some 
studies have reported to observe competitive inhibiton, but these studies evaluate IC50 
values at fixed substrate concentrations rather than complete Michaelis-Menton kinetic 
parameters.35 
Our initial enzymatic studies on procaspase-3 indicate that the mode of inhibition 
of zinc is not compatible with a competitive inhibition model.  Procaspase-3 D3A and 
caspase-3 activity were evaluated at a range of substrate concentrations to determine the 
Michaelis-Menton kinetic parameters of the enzyme (Table 4.1 and 4.2).  The enzyme 
was then evaluated in the presence of increasing concentrations of zinc.  The Michaelis-
Menton curves for these studies are shown in Figure 4.1 and 4.2.  In the presence of zinc, 
a decrease in the Vmax and Km is observed, suggesting mixed inhibition.   
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Figure 4.1.  Enzymatic inhibition of procaspase-3 D3A with zinc.  10 µM procaspase-3 was incubated with 
various concentrations of ZnSO4.  Activity was assessed using various concentrations of Ac-DEVD-pNA 
substrate.  Data was fit the Michaelis-Menton equations and kinetic parameters were calculated. 
 
 
Table 4.1  Michaelis-Menten parameters for procaspase-3 D3A 
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Figure 4.2. Enzymatic inhibition of caspase-3 with zinc.  500 nM caspase-3 was incubated with various 
concentrations of ZnSO4.  Activity was assessed using various concentrations of Ac-DEVD-pNA substrate.  
Data was fit the Michaelis-Menton equations and kinetic parameters were calculated. 
 
Table 4.2.  Michaelis-Menten parameters for caspase-3 
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4.2 Zinc inhibition of C163A mutant 
 To further investigate zinc inhibition of procaspase-3 independent of the active 
site thiol, we evaluated the activity of an active site mutant of procaspase-3 where the 
active site cysteine (C163A) had been mutated to alanine.  Consistent similar studies 
looking at the mutation of active site cysteines in other proteases, we observe a 6000-fold 
decrease in catalytic activity of this enzyme compared to a protein with the intact active 
site.  The residual activity observed is thought to occur as a result of the histidine partner 
in the active site his-cys diad and the coordination of the substrate with water. 
 When evaluated at high concentrations, procaspase-3 C163A protein has 
sufficient activity to turn over the synthetic Ac-DEVD-pNA substrate.  The progress 
curve for 50 µM procaspase-3 C163A is shown in Figure 4.3.  In the presence of 50 µM 
zinc, this activity is inhibited by 80% suggesting that procaspase-3 can be inhibited 
independent of binding to the active site.   
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Figure 4.3. Enzymatic activity of procaspase-3 C163A active site mutant in the presence and absence of 
zinc.  Procaspase-3 C163A (50 µM) was incubated with and without 50 µM zinc for 5 minutes before 
addition of 200 µM Ac-DEVD-pNA to assess the enzymatic activity of the enzyme 
 
Isothermal titration calorimetry (ITC) has been used to evaluate the metal-protein 
complexes.154,155  ITC is has many advantages when evaluated this type of interaction.  
Because ITC measures the heat evolved upon binding, there is no requirement for tags or 
special reagents to evaluate the interaction.  This is particularly helpful when evaluating a 
metal-protein interaction as there is usually no way to modify the metal being evaluated.  
In the analysis of zinc-protein interactions this is especially true as zinc is 
spectroscopically invisible.   
In addition to the logistical benefits of evaluating this interaction through ITC, the 
data generated by this technique has many advantages over other techniques.  ITC is the 
only technique that provides access to all of the thermodynamic parameters (ΔG, ΔH, and 
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ΔS) in addition to assessing the strength of interaction and stoichiometry.  Several studies 
in the literature have successfully characterized zinc-protein interactions.156,157 
Further, evaluation of C163A by ITC supports the idea that zinc directly binds to 
procaspase-3 with or without an intact active site.  The active site mutant procaspase-3 
C163A was titrated with zinc to produce the binding isotherm shown in Figure 4.4.  
Analysis of this data indicates that this protein binds zinc with a Kd of 1.7 µM.  
Compared with the binding of zinc to procaspase-3 (Kd of 1.2 µM) shown in Figure 4.5, 
there does not appear to be a significant difference in the affinity of these proteins for 
zinc.  As such, it is unlikely that the active site cysteine of procaspase-3 plays an 
important role in the binding and inhibition of procaspase-3 by inhibitory zinc. 
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Figure 4.4. ITC data for procaspase-3 C163A and zinc.  Procaspase-3 C163A (50 µM) was titrated with 1 
mM ZnSO4.  Heats were measured and plotted to create the binding isotherm.  The disassociation constants 
were calculated form the data. 
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Figure 4.5.  ITC data for procaspase-3 D3A and zinc.  Procaspase-3 D3A (50 µM) was titrated with 1 mM 
ZnSO4.  Heats were measured and plotted to create the binding isotherm.  The disassociation constants 
were calculated from the data. 
 
4.3 Procaspase-3 cysteine mutants 
Given the results described above, we sought to identify the residues responsible 
for zinc binding on procaspase-3.  Due to the known interaction of zinc and thiols, our 
first approach was to investigate other cysteines on procaspase-3 as potential members of 
a zinc binding site.  Procaspase-3 contains eight cysteines (C47, C116, C148, C163, 
C170, C184, C220, C264) including the active site cysteine (Figure 4.6).  Using 
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quickchange mutagenesis we developed constructs for the expression of procaspase-3 
single mutants where each of these cysteine residues have been individually mutated to 
alanine in order to test this hypothesis (Figure 4.6).  
 
Figure 4.6.  Sites of cysteine residues in procaspase-3 primary sequence and caspase-3 crystal structure.  
Cysteines that were mutated to alanine in procapsase-3 sequence are highlighted in orange in the crystal 
strucuture of caspase-3.  Additional putative binding residues that are conserved and surface exposed are 
shown below. 
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4.4 Conserved sequences in procaspase-3 
 In addition to this screening approach, we have employed a bioinformatics 
approach to identify putative zinc binding pockets on procaspase-3.  To do this, we did a 
number of sequence alignments to identify conserved residues.  First, we aligned all the 
sequence of each member of the caspase family to identify residues that are conserved 
among this family (Figure 4.7).  A number of residues were conserved among all of these 
caspases.  Based on homology modeling the majority of these conserved residues are near 
the active site and are involved in the catalytic activity or structure of the active site.  Of 
interest is a set of residues that are distal from the active site that are conserved.  These 
residues include one of the eight cysteines in the caspase-3 sequence and a histadine that 
is surface exposed. 
 The second alignment we produced was the alignment of caspase-3 among 15 
different species (Figure 4.8).  Again the cysteine-histadine pair indentified above was 
absolutely conserved in these sequences.  Through this approach we identified a putative 
binding pocket that is distal from the active site of procaspase-3 and contains these 
cysteine and histidine residues.  There is also a conserved leucine that is in proximity of 
this pair.  These surface exposed residues may constitute an allosteric regulatory site 
(Figure 4.6). We hypothesize that this pocket is capable of binding zinc and affecting the 
active site through a beta sheet that runs through the core of the enzyme between the 
active site and this putative allosteric site.  We have developed constructs in which each 
of these three conserved residues in this pocket are mutated to alanines. 
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Figure 4.7.  Partial sequence alignment of each caspase family member.  Conserved residues are shown in 
yellow. 
 
 
Figure 4.8.  Partial sequence alignment of caspase-3 in 15 species.  Conserved residues are shown in 
yellow. 
 
4.4.1 Evaluation of kinetic parameters 
Having designed and generated constructs for alanine mutants of each of the 
residues described above, we expressed and purified each mutant.  In an effort to evaluate 
the effect of these mutations on the activity of the enzyme we evaluated the enzyme 
kinetics of each mutant.  The results of these experiments are summarized in Table 4.3.  
Some mutations effect the ability of the protein to be processed.  For example, mutation 
352 506360 370 380 390 400 410 420 430 440 450 460 470 480 490(352)
--SRSGTDVDAANLRETFRNLKYEVRNKNDLTREEIVELMRDVS---KEDHSKRSSFVCVLLSHGEEG-------IIFGTNG------PVDLKKITNFFRGDRCRSLTGKPKLFIIQACRGTELDCGIETDSG----------------------CASP3 Human (63)
--VRNGTDKDAEALFKCFRSLGFDVIVYNDCSCAKMQDLLKKAS---EEDHTNAACFACILLSHGEEN-------VIYGKDG------VTPIKDLTAHFRGDRCKTLLEKPKLFFIQACRGTELDDGIQADSGP-----I---------------CASP7 Human (86)
IRDRNGTHLDAGALTTTFEELHFEIKPHDDCTVEQIYEILKIYQ---LMDHSNMDCFICCILSHGDKG-------IIYGTDG-----QEAPIYELTSQFTGLKCPSLAGKPKVFFIQACQGDNYQKGIPVETDSEEQ------P---------YLCASP8 Human Isoform G(316)
--TRTGSNIDCEKLRRRFSSLHFMVEVKGDLTAKKMVLALLELA---QQDHGALDCCVVVILSHGCQASHLQFPGAVYGTDG-----CPVSVEKIVNIFNGTSCPSLGGKPKLFFIQACGGEQKDHGFEVASTSPEDESPGSNPEPDATPFQEGLCASP9 Human(179)
--ERRGTCADRDNLTRRFSDLGFEVKCFNDLKAEELLLKIHEVS---TVSHADADCFVCVFLSHGEGN-------HIYAYDAK------IEIQTLTGLFKGDKCHSLVGKPKIFIIQACRGNQHDVPVIPLDVVDNQTEKLDTN-----------CASP6 Human (63)
LEFRSGGDVDHSTLVTLFKLLGYDVHVLCDQTAQEMQEKLQNFAQ--LPAHRVTDSCIVALLSHGVEG-------AIYGVDG-----KLLQLQEVFQLFDNANCPSLQNKPKMFFIQACRGGAIGSLGHLLLFTAATASLAL-------------CASP2 Human(185)
--DRQGTHKDAEILSHVFQWLGFTVHIHNNVTKVEMEMVLQKQKC--NPAHADGDCFVFCILTHGRFG-------AVYSSDEA-----LIPIREIMSHFTALQCPRLAEKPKLFFIQACQGEEIQPSVSIEADALNP------------------CASP10 Human(299)
--PRNGAALDILGMKQLLEGLGYTVEVEEKLTARDMESVLWKFAA--REEHKSSDSTFLVFMSHGILD-------GICGTMHSEEEPDVLPYDTIFRTFNNRNCLSLKDKPKVIIVQACRGANRGELWVSDSP--PALADSFSQS----------CASP13 Cow(151)
--PRNGADFDITGMKELLEGLDYSVDVEENLTARDMESALRAFAT--RPEHKSSDSTFLVLMSHGILE-------GICGTVHDEKKPDVLLYDTIFQIFNNRNCLSLKDKPKVIIVQACRGANRGELWVRDSP--ASLEVASSQS----------CASP4 Human (95)
--ARNGAHYDIVGMKRLLQGLGYTVVDEKNLTARDMESVLRAFAA--RPEHKSSDSTFLVLMSHGILE-------GICGTAHKKKKPDVLLYDTIFQIFNNRNCLSLKDKPKVIIVQACRGEKHGELWVRDSP--ASLAVISSQS----------CASP5 Human(192)
--LRYGANIDISGMKGLLEELGYDVVVKEELTAEGMESEMKDFAA--LSEHQTSDSTFLVVMSHGTLQ-------GLCGTMHSEATPDVLLYDTIYQIFNNCHCPGLRDKPKVIIVQACRGGNSGEVWIRESS--GAHSYRAVDL----------CASP11 Rat(147)
--NRNGSELDLLGMQDLLENLGYSVVIEENLTAQEMETALRQFAA--RPEHQSSDSTFLVFMSHGILN-------GICGTKHWDQEPDVLHDDTIFEIFNNRNCRSLRDKPKVIIMQACRGSGAGIVWFTTDSGKASADTHGQLL----------CASP12 Rhesus Monkey(193)
--RRTGAEVDITGMTMLLQNLGYSVDVKKNLTASDMTTELEAFAH--RPEHKTSDSTFLVFMSHGIRE-------GICGKKHSEQVPDILQLNAIFNMLNTKNCPSLKDKPKVIIIQACRGDSPGVVWFKDSV--GVSGNLSLPT----------CASP1 Human(154)
-KAREGSEEDLDALEHMFRQLRFESTMKRDPTAEQFQEELEKFQQAIDSREDPVSCAFVVLMAHGREG-------FLKGEDG-----EMVKLENLFEALNNKNCQALRAKPKVYIIQACRGEQRDPGETVGGD---------------------ECASP14 Human (27)
61 21470 80 90 100 110 120 130 140 150 160 170 180 190 200(61)
IIINNKNFHKSTGMT-----SRSGTDVDAANLRETFRNLKYEVRNKNDLTREEIVELMRDVS-KEDHSKRSSFVCVLLSHGEEGIIFGTNGPVDLKKITNFFRGDRCRSLTGKPKLFIIQACRGTELDCGIETDSG-------------VDDDMCASP3 Human (48)
IIINNKNFHKSTGMT-----SRSGTDVDAANLRETFRNLKYEVRNKNDLTREEIVELMRDVSK-EDHSKRSSFVCVLLSHGEEGIIFGTNGPVDLKKITNFFRGDRCRSLTGKPKLFIIQACRGTELDCGIETDSG-------------VDDDMCASP3  Chimp (48)
IIINNKNFHENTGMA-----CRSGTDVDAANLRETFMNLKYEVRIKNDLTCKEMLELMSNVSK-EDHSKRSSFICVLLSHGEEGIIFGTNGPVNLKKLASFFRGDYCRSLTGKPKLFIIQACRGTELDCGIETDSG-------------AEDDMCASP3 Cow (48)
IIINNKNFDKNTGMA-----CRSGTDVDAANLRETFTNLKYEVRNKNDLTREEILELMHSVSK-EDHSKRSSFICVLLSHGEEGKIFGTNGPVDLKKLTSFFRGDCCRTLTGKPKLFIIQACRGTELDCGIETDSG-------------TEDDMCASP3 Pig (48)
IIINNKNFHKSTGMA-----PRSGTDVDAANLRETFTNLKYEVRNKNDLTCEEILELMNSVSK-EDHSKRSSFVCVLLSHGDEGIIFGTNGPVDLRKVTGFFRGDYCRSLTGKPKLFIIQACRGTELDCGIETDSG-------------IEDDMCASP3 Dog (48)
IIINNKNFHESTXXX-----XRSGTDVDAANLRETFTNLKYEVRNKNDLTREQIXXXXXXXSR-EDHSKRSSFICVLLSHGDEGIIYGTNGPVDLKKLTGFFRGDYCRSLTGKPKLFIIQACRGTELDCGIETDSG-------------TEDDICASP3 Cat (48)
IIVNNKNFHKSTGMT-----SRSGTDVDAANLRETFRNLKYGVRNKNDLTREGIVELMRDVSK-EDHSKRSSFVCVLLSHGEEGIIFGTNGPVDLKKITNFFRGDRCRSLTGKPKLFIIQACRGTELDCGIETDSG-------------VGDDMCASP3 Hamster (48)
IIINNKNFHKSTGMS-----ARNGTDVDAANLRETFMALKYEVRNKNDLTREEIMELMDSVSK-EDHSKRSSFVCVILSHGDEGVIFGTNGPVDLKKLTSFFRGDYCRSLTGKPKLFIIQACRGTELDCGIETDSG-------------TDDDMCASP3 Rat (48)
IIINNKNFHKSTGMS-----SRSGTDVDAANLRETFMGLKYQVRNKNDLTREDILELMDSVSK-EDHSKRSSFVCVILSHGDEGVIYGTNGPVELKKLTSFFRGDYCRSLTGKPKLFIIQACRGTELDCGIETDSG-------------TDEEMCASP3 Mouse (48)
VIINNKNFHRDTGLS-----SRSGTDADAASVREVFMKLGYKVKLNNDLSSRDIFKLLKNVSE-EDHSKRSSFVCVLLSHGDEGLFYGTDGPLELKVLTSLFRGDKCRSLAGKPKLFFIQACRGTELDSGIEADSG--------------PDETCASP3 Chicken (56)
IIINNKNFDRRTGMN-----PRNGTDVDAGNVMNVFRKLGYIVKVYNDQTVAQIMQVLTTVAH-DDHSRCASLVCVLLSHGDEGVFFGTDTSVDLKSLTSLFRGDRCPSLVGKPKLFFIQACRGTELDPGVETDHT---D--------HPDIPDCASP3 Danio Rerio (51)
IIINNKNFDRRTGMN-----TRNGTDVDAANAMKVFLSLGYKVKVHNDQTVKQMKQLLVSAAE-EDHSACASFVCVLLSHGDEGVFFGTDGSVELKYLTSLFRGDRCKSLVGKPKLFFIQACRGNDLDGGIETDSA---------------ADSCASP3 Takifugu (54)
IIINNKNFDRRTGMN-----QRNGTDVDAGNAMKVFTKLGYKTKIYNDQTVEQMKQVLISVSK-EDHSCNASFICVLLSHGDEGVFFGTDGSVELKYLTSLFRGNHCISLVGKPKLFFIQACRGTDLDPGIETDSG----------------EDEuropean Sea Bass (54)
LILNHKDVKGQK--------QRVGTERDRDDMEATLQGFGFDVRTFDDLTFSEINDTLKEVAR-EDHSQNDCFVLAVMSHGTEGKVYAKDMSYPVERLWNPFLGDNCKTLKNKPKLFFIQACRGANLEKAVEFSSFAVMTRELVPEPA-AAVQPPutative CASP3 Drosophila (59)
IIFNHYTFKKTKYFQYKQPSTRNGTFEDVKSLKDLFEGLSYNVTTYTDLIYEDILNRVAEFCK-RDHSKTSCVIVTILTHGDSGEVFAADQ-PYKISDLTNMIENAHHTLVGKPKIFFIQACRGPFMDEGRTVVLD--------------GESRCASP3 Silkworm (52)
IIINNKNFHK TGM       RSGTDVDAANLRETF  LKY VRNKNDLT E I ELM  VSK EDHSKRSSFVCVLLSHGDEG IFGTNGPVDLKKLTSFFRGD CRSLTGKPKLFIIQACRGTELDCGIETDSG               DDMConsensus (61)
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the active site cysteine to alanine (C163A) results in a protein that has dramatically 
reduced activity.  As such, this protein is not able to process itself.  The standard method 
for generating activated caspase-3 is through autoprocessing of procaspase-3.  Given this 
method, a protein that does not possess significant activity will not be able to autoprocess 
and the mature protein form cannot be generated.  As such, procaspase-3 C163A is 
expressed in the proenzyme form.  The form of the protein expressed is noted in Table 
4.3.  All proteins maintained enzymatic activity commensurate with level of maturation 
and the state of the active site.  All proteins maintained a similar Km to the WT (C3) and 
Procaspase-3 D3A.  Values for Km for the mutants ranged from 50 to 150 µM.  This 
suggests that mutations have not significantly effected the active site of the proteins. 
 
Table 4.3.  Kinetic parameters and disassociation constants for procaspase-3 mutants.   The kinetic 
parameters were evaluated using the chromogenic substrate Ac-DEVD-pNA.  Kds were determined by ITC.  
NA = value could not be generated from data.  ND = this has not yet been evaluated. 
 
 
Enzyme  
Average 
Km  
Average 
Vmax  
Average 
Kcat  
Inhibited by 
Zinc?  
Kd for Zinc 
(µM) 
WT(C3) 52.7 0.0445 222,250 Yes  1.9 
D3A (PC3) 77 0.0001 125,000 Yes 1.2 
C116A (C3) 71.28 0.0516 258,166 Yes  ND 
C170A (C3)  78.54 0.0476 238,000 Yes  2.5 
C220A (C3) 52.4 0.02432 121,600 Yes  ND 
C148A (C3)   NA NA NA NA ND 
C184A (C3) 151.054 0.11938 501,040 Yes  ND 
C163A (PC3) NA   NA NA Yes 1.7 
C264A (C3)  120.85 0.10242 512,100 Yes  ND 
 212 
4.4.2 Evaluation of zinc binding by ITC 
A number of these mutants have been evaluated by ITC to determine the binding 
affinity of these mutants for zinc.  The disassociation constant for these interactions are 
shown in Table 4.3.  The disassociation constant for caspase-3 and zinc is reported as 1.9 
µM.  This method of direct detection of binding suggests an association of greater affinity 
than the indirect literature value of 15 µM.  To our knowledge this is the first direct 
analysis of the caspase-3:zinc interaction.  Further we report a disassociation constant for 
procaspase-3 (D3A) and for the active site mutant (C163A) that are not significantly 
different from caspase-3 (1.2 µM and 1.7 µM respectively).  It is important to note that 
the affinity suggested by these numbers is much weaker than most bimolecular 
interactions reported in the literature; however, other metal:protein interactions have been 
reported with similar affinities.158,159  Of the data available at this time, there is no clear 
indication that any of the residues evaluated to date are responsible for zinc binding. 
 
4.5 Summary 
 Taken together, the evidence presented in this dissertation highlights the complex 
system of regulation involved in the apoptotic pathway.  The traditional view of apoptosis 
as described in Chapter 1, involves the activation of procaspase-3 as the “point of no 
return”.  In this view, activation of procaspase-3 to caspase-3 is a committed step that 
supposes that active caspase-3 is available to cleave its cellular substrates.  Although 
generally true, this view minimizes the complexities involved in the cellular environment 
to a linear pathway.  In reality there are many considerations that influence the ability of 
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procaspase-3 to become activated and for caspase-3 to carry out the apoptotic program.  
Once activated to caspase-3 (that is processed from the full-length form to the cleaved 
form) the activity of caspase-3 is regulated by several additional players.  Inhibitors of 
apoptosis such as XIAP and CIAP may prevent full processing or activity of caspase-3.  
Inhibitory zinc may prevent the activation of procaspase-3 to caspase-3 and once 
activated may inhibit the enzymatic activity of caspase-3.   
4.6 Materials and Methods 
Materials.  All reagents were obtained from Fisher unless otherwise indicated.  
All buffer solutions were made with Milli-Q purified water. Ac-DEVD-pNA was 
synthesized as described.120  Luria Broth (LB) was obtained from EMD. Ni NTA Binding 
Buffer contains 50 mM Tris pH 8.0, 300 mM NaCl, 10 mM imidazole.  Ni NTA Wash 
Buffer contains 50 mM Tris pH 8.0, 300 mM NaCl, 20 mM imidazole.  Ni NTA Elution 
Buffer contains 50 mM Tris pH 8.0, 300 mM NaCl, 500 mM imidazole. The C-terminal 
6xHis-tagged procaspase-3 proteins were expressed and purified as described below.   
 Strains and Plasmids.  Procaspase-3 D3A and caspase-3 were expressed using the 
pHC332 expression plasmid.  The cysteine mutants of procaspase-3 was created by 
successive quick change mutations on pHC332 using the following primers. H108 was 
mutated to alanine using the forward primer (5’- CGT GAT GTT TCT AAA GAA GAT CAC 
AGC AAA AGG AGC -3’) and the reverse primer (5’- GCT CCT TTT GCT GTG ATC TTC 
TTT AGA AAC ATC ACG 3’).  L151 was mutated to alanine using the forward primer (5’-GGG 
GAT CGT TGT AGA AGT CTA ACT GGA AAA CCC-3’) and the reverse primer (5’-GGG 
TTT TCC AGT TAG ACT TCT ACA ACG ATC CCC-3’).  C148 was mutated to alanine using 
the forward primer (5’ CAA ACT TTT TCA GAG GGG ATC GTG CTA GAA GTC TAA CTG 
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G-3’) and the reverse primer (5’-CCA GTT AGA CTT CTA GCA CGA TCC CCT CTG AAA 
AAG TTT G-3’).  C163 was mutated to alanine using the forward primer (5’-CCC AAA CTT 
TTC ATT ATT CAG GCC GC 3’) and the reverse primer (5’-GTC CAG TTC TGT ACC ACG 
GGC GGC CT 3’).  C170 was mutated to alanine using the forward primer (5’-GGC CTG CCG 
TGG TAC AGA ACT GGA CGC TGG CAT TGA GAC AGA CAG TGG-3’) and the reverse 
primer (5-CCA CTG TCT GTC TCA ATG CCA GCG TCC AGT TCT GTA CCA CGG CAG 
GCC-3’).  C184 was mutated to alanine using the forward primer (5’-GAC ATG GCG GCT CAT 
AAA ATA CCA GTG GAG GCC -3’) and the reverse primer (5’- GGC CTC CAC TGG TAT 
TTT ATG AGC CGC CAT GTC -3’).  C220 was mutated to alanine using the forward primer 
(5’- 5' - CAT CCA GTC GCT TGC TGC CAT GCT GAA ACA G - 3' -3’) and the reverse 
primer (5’ CTG TTT CAG CAT GGC AGC AAG CGA CTG GAT G 3’).  C264 was mutated to 
alanine using the forward primer (5’-CAG ATT CCA GCT ATT GTT TCC ATG CTC ACA 
AAA G-3’) and the reverse primer (5’-CTT TTG TGA GCA TGG AAA CAA TAG CTG GAA 
TCT G- 3’).  All mutations were confirmed by sequence analysis of both strands.   
Recombinant expression and purification of procaspase-3/-7.  Expression of 
procaspase-3 was preformed in the BL21(DE3) strain of Escherichia coli (Novagen) 
similar to that previously described.45  Briefly, plasmids encoding for the C-terminally 
6xHis-tagged procaspase-3/-7 protein were transformed into electrocompetent BL21.  
The transformants were selected for by growth in ampicillin.  Individual colonies were 
picked and used to inoculate 10 mL seed cultures of LB with ampicillin (100 µg/mL) for 
expression.  Seed cultures were used to inoculate 2 L cultures of LB which were grown at 
37oC to an OD600 = 0.6.  Protein expression was induced via the addition of IPTG to a 
final concentration of 0.5 mM; after addition of IPTG the culture was incubated at 37oC 
with shaking for 20 additional minutes.  Bacterial cultures were then pelleted by 
centrifugation (at 5000 x g, 5 min, 4oC) and lysed by pulse sonication on ice for five 
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minutes in the presence of 30 mL Ni NTA binding Buffer.  Bacterial debris was removed 
by centrifugation (at 35,000 x g, 30 min, 4oC) and the 6xHis-tagged protein was purified 
from the supernatant with 1 mL 50% slurry Ni NTA resin (Qiagen).  Protein was batch 
loaded onto the resin for 1 hr at 4°C.  The bound resin was applied to a disposable 
column and the resin was washed with 15 mL of Ni NTA Wash Buffer.  The protein was 
then eluted from the column with 10 mL of Ni NTA Elution Buffer.  Fractions (~1 mL) 
were collected and the presence of protein was determined by reaction with the Bradford 
reagent (BioRad).  Fractions containing protein were pooled and flash frozen in liquid 
nitrogen.  Protein was stored at -80 °C.  
Zinc-Free Preparation.  Protein was expressed and purified as above until 
fractions were pooled.  Protein was not flash frozen at this point, but fractions containing 
protein were pooled and applied to a PD-10 column (GE Healthcare) charged with 
HEPES buffer that had been treated with Chelex® resin.  The HEPES buffer consisted of 
50 mM HEPES, 300 mM NaCl, pH = 7.4.  The pH was monitored after treatment with 
the chelex resin and was found to have not changed.  The protein was eluted using an 
additional 3.5 mL of Chelex®-treated HEPES buffer and the concentration was 
determined using the Edelhoch method for protein quantitation by absorbance at 280 nm.  
Protein isolated directly from the column typically had a concentration of ~50 µM; for 
experiments described herein requiring zinc-free conditions, the protein was typically 
diluted to the desired concentration in HEPES Buffer that had been treated with Chelex® 
resin.  Protein was flash frozen in 500 µL aliquots in liquid nitrogen and stored at -80°C.   
Kinetic analysis of procaspase-3—Zinc-free stocks (2X) of caspase-3 (1 µM) 
were prepared in Caspase Activity Buffer. A stock (10X) of ZnSO4 (25 µM) in Caspase 
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Activity Buffer was prepared.  To each well of 384 well plate was added 25 µL of the 
appropriate protein (500 nM final) and 25 µL of ZnSO4 (appropriate concentration) or 
buffer. The plates were incubated at room temperature for 30 minutes.  Then, to each well 
of the plate was added 5 µL of a stock of Ac-DEVD-pNA substrate to achieve the final 
substrate concentration and the absorbance at 405 nm was immediately monitored every 
1 minute for 60 minutes on a spectramax plate reader (Molecular Devices, Sunny Vale, 
CA).  The slope of each well was used to determine the activity.  The data for each 
condition (4 wells) was averaged and plotted as a function of substrate concentration.  
The data was analyzed using Table Curve 2D and fitted to a Michaelis-Menton equation. 
Isothermal Titration Calorimetry—Protein was diluted in HEPES buffer to 50 
µM.  Zinc stocks were made in HEPES buffer.  ITC experiments were performed on a 
Microcal VP-ITC thermostated at °25 C.  The sample cell was loaded with 1.8 µL of 
protein stock.  The buret was filled with a ZnSO4 solution.  35 injections of 5 µL were 
performed with a 300 second interval.  Data was analyzed with the Microcal ITC add-in 
for Origin. 
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